ID,Name,CAS #,CAS,SMILES ,InChiKeys,VDss (L/kg),Reference,Comments
1,Abacavir,136470-78-5,136470-78-5,c12n(cnc1c(nc(n2)N)NC1CC1)[C@@H]1C[C@@H](CC1)CO,TYPRESGPNUCUCA-SCZZXKLOSA-N,0.84,"Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, and Stein DS. (1999) Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.    Pharmacotherapy 19: 932-942.  Ziagen Product Label.",
2,Abanoquil,90402-40-7,90402-40-7,CCC(C1NC(=O)C(NC(=O)CC(C)(C)SSCC(NC(=O)C(NC(=O)C(NC1=O)C(O)C)CC(=O)N)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)N)CC(C)C)Cc1ccc(cc1)OC)C,ZXHAQJSRGRIXJY-UHFFFAOYSA-N,6.3,"Schafers RF, Elliott HL, Meredith PA, Miller SHK, and Reid JL (1991) Studies with abanoquil (UK-52,046) a novel quinoline α1-adrenoceptor antagonist:  II.  Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects.  Br. J. Clin. Pharmacol. 32: 605-610.",
3,Acarbose,56180-94-0,56180-94-0,O([C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]1CO)O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]1CO)O)[C@H]1O[C@@H]([C@@H](N[C@@H]2[C@H](O)[C@@H](O)[C@H](O)C(=C2)CO)[C@H](O)[C@H]1O)C,XUFXOAAUWZOOIT-SXARVLRPSA-N,0.32,"Putter J, Keup U, Krause HP, Muller L, and Weber H (1982) Pharmacokinetics of acarbose.  Int. Congr. Ser. 594: 38-48. ",
4,Acebutolol,37517-30-9,37517-30-9,O(CC(O)CNC(C)C)c1c(cc(NC(=O)CCC)cc1)C(=O)C,GOEMGAFJFRBGGG-UHFFFAOYSA-N,1.7,"Kaye CM, Kumana CR, Leighton M, Hamer J, and Turner P (1976) Observations on the pharmacokinetics of acebutolol.  Clin. Pharmacol. Ther.  19: 416-420.  Meffin PJ, Winkle RA, Peters FA, and Harrison DC (1977) Acebutolol disposition after intravenous administration.  Clin. Pharmacol. Ther. 22: 557-567.  Roux A, Flouvat B, Chau NP, Letac B, and Lucsko M (1980) Pharmacokinetics of acebutalol after intravenous bolus administration.  Br. J. Clin. Pharmacol. 9: 215-217.","Vss calculated from digitized plots from Kaye, et al, and from reported microconstants from Roux, et al."
5,Acecainide (N-acetylprocainamide),32795-44-1,32795-44-1,c1cc(ccc1C(=O)NCCN(CC)CC)NC(=O)C,KEECCEWTUVWFCV-UHFFFAOYSA-N,1.9,"Coyle JD, Boudoulas H, and Lima JJ (1991) Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.  Biopharm. Drug Dispos. 12: 599-612.   Connolly SJ and Kates RE (1982)  Clinical pharmacokinetics of N-acetylprocainamide.    Clin. Pharmacokinet. 7: 206-220.",
6,Acetaminophen,103-90-2,103-90-2,CC(=O)Nc1ccc(cc1)O,RZVAJINKPMORJF-UHFFFAOYSA-N,1.0,"Rowlins MD, Henderson DB, Hijab AR (1977) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 11: 283-286.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss calculated from micro rate constants provided in Rowlins et al.
7,Acetazolamide,59-66-5,59-66-5,CC(=O)c1cc[nH]c1C(=O)N,CDSATVVADOLVOV-UHFFFAOYSA-N,0.37,"Chapron DJ, Sweeney KR, Feig PU, and Kramer PA (1985) Influence of advanced age on the disposition of acetazolamide.  Br. J. Clin. Pharmacol. 19: 363-371.",VDss and t1/2 were calculated from C vs t data obtained by digitization of plots included in the reference.
8,"Acetylcysteine, N-",616-91-1,616-91-1,SC[C@H](NC(=O)C)C(=O)[O-],PWKSKIMOESPYIA-BYPYZUCNSA-M,0.55,"Prescott LF, Donovan JW, Jarvie DR, and Proudfoot AT (1989) The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage.  Eur. J. Clin. Pharmacol. 37: 501-506.  Acetadote Product Label.",
9,"Acetylmethadol, L-",1477-40-3,1477-40-3,O([C@H](C(c1ccccc1)(c1ccccc1)C[C@@H](N(C)C)C)CC)C(=O)C,XBMIVRRWGCYBTQ-AVRDEDQJSA-N,8.3,"Walsh SL, Johnson RE, Cone EJ, and Bigelow GE (1998) Intravenous and oral l-.alpha.-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.  J. Pharmacol. Exp. Ther.  285: 71-82.  Toro-Goyco E, Martin BR, and Harris LS (1980) Binding of 1-alpha-acetylmethadol and its metabolites to blood constituents.  Biochem. Pharmacol. 29: 1897-1902.",
10,Acetylsalicylic Acid,50-78-2,50-78-2,CC(=O)Oc1ccccc1C(=O)O,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,0.22,"Aarons L, Hopkins K, Rowland M, Brossel S, and Thiercelin JF (1989) Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt.   Pharm. Res. 6: 660-666.  Lee S, Johnson D, Klein J, and Eppler J (1995) Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum.  Vet. Human Toxicol. 37: 224-225",
11,Acivicin,42228-92-2,42228-92-2,ClC1=NO[C@H]([C@H](N)C(=O)O)C1,QAWIHIJWNYOLBE-OKKQSCSOSA-N,0.50,"McGovern JP, Pratt EA, Belt RJ, Taylor SA, Benjamin RS, Ardalan B, and Ohnuma T (1985) Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.  Canc. Res.  45: 4460-4463.",VDss was calculated from C vs t data obtained by digitization of a plot for one subjected that was included in the reference.  Plasma concentrations were determined by bioassay.
12,Acyclovir,59277-89-3,59277-89-3,n1c(nc2c(c1O)ncn2COC(C(O)([2H])[2H])([2H])[2H])N,MKUXAQIIEYXACX-LNLMKGTHSA-N,0.71,De Miranda P and Blum MR (1983) Pharmacokinetics of acyclovir after intravenous and oral administration.  J. Antimic. Chemother. 12(Suppl B): 29-37.,
13,Adefovir,106941-25-7,106941-25-7,Nc1ncnc2c1ncn2CCOCP(=O)(O)O,SUPKOOSCJHTBAH-UHFFFAOYSA-N,0.42,"Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, and Jaffe HS. (1995) Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.  Antimic. Ag. Chemother. 39: 2401-2405.   Hepsera Product Label.",
14,Adinazolam,37115-32-5,37115-32-5,Clc1cc2c(n3c(nnc3CN(C)C)CN=C2c2ccccc2)cc1,GJSLOMWRLALDCT-UHFFFAOYSA-N,0.98,"Fleishaker JC, Friedman H, and Pollock SR (1991)  Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.  Pharm. Res.  8: 162-167.",
15,Albuterol (salbutamol),18559-94-9,18559-94-9,OC(CNC(C)(C)C)c1cc(c(O)cc1)CO,NDAUXUAQIAJITI-UHFFFAOYSA-N,1.9,"Boulton DW and Fawcett JP (1996) Enantioselective disposition of salbutamol in man following oral and intravenous administration.  Br. J. Clin. Pharmacol. 1996, 41, 35-40.  Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, and Ziccone SP (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.  Br. J. Clin. Pharmacol.  22: 587-593.",Data for enantiomers were averaged.
16,Alcuronium,23214-96-2,23214-96-2,N12[C@@H]3[C@]4(c5c1cccc5)[C@@H]1C[C@H](C3=CN3[C@@H]5[C@]6(c7c3cccc7)[C@@H]3C[C@H](C5=C2)/C(=C\CO)/C[N@+]3(CC=C)CC6)/C(=C\CO)/C[N@+]1(CC=C)CC4,MUQUYTSLDVKIOF-CHJKCJHBSA-N,0.32,"Walker J, Shanks CA, and Triggs EJ (1980)  Clinical pharmacokinetics of alcuronium chloride in man.  Eur. J. Clin. Pharmacol. 17: 449-457. ",
17,Alfentanil,71195-58-9,71195-58-9,CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCn3c(=O)n(nn3)CC)COC,IDBPHNDTYPBSNI-UHFFFAOYSA-N,0.45,"Bower S and Hull CJ (1982) Comparative pharmacokinetics of fentanyl and alfentanil.  Br. J. Anaesth. 54: 871-877.  McDonnell CG, Malkan D, Van Pelt FD, and Shorten GD (2003) Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.    Eur. J. Anaesth. 20: 662-667.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.    Arch. Int. Pharmacodyn. Ther.  257: 4-19.  Lemmens HJ, Burm AG, Bovill JG, Hennis PJ, and Gladines MP (1992)  Pharmacodynamics of alfentanil. The role of plasma protein binding.    Anesthesiol.  76: 65-70.",
18,Alfuzosin,81403-80-7,81403-80-7,O=C(C1OCCC1)NCCCN(c1nc(N)c2cc(OC)c(OC)cc2n1)C,WNMJYKCGWZFFKR-UHFFFAOYSA-N,1.5,"Guinebault P, Colafranceschi C, Bianchetti G, Thenot JP, Maillard D, Thiercelin JF, Larribaud J, and Morselli PL (1984) Absolute bioavailability of alfluzocine, a new alpha1 postsynaptic receptor antagonist, after oral and intravenous administration.  Biopharm. Pharmacokinet. 2nd European Congress 2: 578-583.",VDss calculated from C vs t data obtained by digitization of the plots included in the reference.
19,Alizapride,59338-93-1,59338-93-1,C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC,KSEYRUGYKHXGFW-UHFFFAOYSA-N,1.6,"Houin G, Barre J, and Tillement JP (1984) Absolute intramuscular, oral, and rectal bioavailability of alizapride.  J. Pharm. Sci. 73: 1450-1453.",VDss calculated from C vs t data obtained by digitization of the plots included in the reference.
20,Allopurinol,315-30-0,315-30-0,O=c1nc[nH]c2[nH]ncc12,OFCNXPDARWKPPY-UHFFFAOYSA-N,0.58,"Breithaupt H and Tittel M (1982) Kinetics of allopurinol after sinlge intravenous and oral doses.  Eur. J. Clin. Pharmacol. 22: 77-84.  Elion GB, Kovensky A, Hitchings GH, Metz E, and Rundles RW (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.    Biochem. Pharmacol. 15: 863-889.",
21,Almotriptan,154323-57-6,154323-57-6,S(=O)(=O)(N1CCCC1)Cc1cc2c([nH]cc2CCN(C)C)cc1,WKEMJKQOLOHJLZ-UHFFFAOYSA-N,2.2,"Gras J, Llenas J, Jansat JM, Jáuregui J, Cabarrocas X, Palacios JM (2002) Almotriptan, a New Anti-Migraine Agent: A Review CNS Drug Rev. 8: 217-234.  Jansat, JM, Costa J, Salva P, Fernandez FJ, and Martinez-Tobed A (2002) Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.  J. Clin. Pharmacol. 42: 1303-1310.","VDss calculated from MRT and CL reported in Jansat, et al. "
22,Alosetron,122852-42-0,122852-42-0,O=C1N(CCc2n(c3c(c12)cccc3)C)Cc1nc[nH]c1C,JSWZEAMFRNKZNL-UHFFFAOYSA-N,1.1,"Kock KM, Palmer JL, Noordin N, Tomlinson JJ, and Baidoo C (2002) Sex and age differences in the pharmacokinetics of alosetron.  Br. J. Clin. Pharmacol. 53: 238-242.  Lotronex Product Label",
23,Alprazolam,28981-97-7,28981-97-7,Clc1cc2c(n3c(nnc3C)CN=C2c2ccccc2)cc1,VREFGVBLTWBCJP-UHFFFAOYSA-N,0.80,"Smith RB, Kroboth PD, Vanderligt JT, Phillips JP, and Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.  Psychopharmacology 84: 452-456.  Greenblatt DJ and Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications.    Clin. pharmacokinet. 24: 453-471.  ",VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.
24,Alprenolol,13655-52-2,13655-52-2,O(CC(O)CNC(C)C)c1c(CC=C)cccc1,PAZJSJFMUHDSTF-UHFFFAOYSA-N,3.2,"Bodin NO, Borg KO, Johansson R, Obianwu H, Svensson R (1974) The absorption, distribution, and excretion of alprenolol in man, dog, and rat.  Acta Pharmacol. Toxicol. 35: 261-269.   Imamura H, Komori T, Ismail A, Suenaga A, and Otagiri M (2002)  Stereoselective protein binding of alprenolol in the renal diseased state.  Chirality 14: 599-603.",VDss and CL calculated from C vs t data obtained by digitization of the plot provided in the reference.
25,Amantadine,768-94-5,768-94-5,[C@@H]12C[C@@H]3C[C@@H](C1)CC(C2)(C3)N,DKNWSYNQZKUICI-LXZMWDSTSA-N,6.6,Aoki FY and Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride.  Clin. Pharmacokinet. 14: 35-51.,
26,Amdinocillin,32887-01-7,32887-01-7,S1[C@H]2N(C(C1(C)C)C(=O)OCOC(=O)C(C)(C)C)C(=O)[C@H]2/N=C/N1CCCCCC1,NPGNOVNWUSPMDP-LRKSUFLFSA-N,0.37,"Patel IH, Bornemann LD, Brocks VM, Fang LS, Tolkoff-Rubin NE, and Rubin RH (1985) Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.  Antimic. Ag. Chemother. 28: 46-50.",VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.
27,Amikacin,37517-28-5,37517-28-5,NCCC(O)C(=O)N[C@@H]1C[C@H](N)C(O[C@H]2O[C@H](CN)[C@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O[C@H]1OC(CO)[C@@H](O)[C@H](N)[C@H]1O,LKCWBDHBTVXHDL-HAUVRSHRSA-N,0.16,"Lanao JM, Dominguez-Gil A, Tabernero JM, and De Castro S (1979)  Pharmacokinetics of amikacin (BB-K8) in patients with normal or impaired renal function.  Int. J. Clin. Pharmacol. Biopharm. 17: 171-175.  Clarke JT, Libke RD, Regamey C, and Kirby WMM (1974) Comparative pharmacokinetics of amikacin and kanamycin.  Clin. Pharmacol. Ther.  15: 610-616.  Brunnemann SR and Segal JR (1991) Amikacin serum protein binding in spinal cord injury.  Life Sci. 49: PL1-PL5.",CL calculated from reported compartmental model parameters. Protein binding data averaged from two papers.
28,"Aminocamptothecin, 9-",91421-43-1,91421-43-1,O1Cc2c(C(O)(CC)C1=O)cc1n(Cc3c1nc1c(c3)c(N)ccc1)c2=O,FUXVKZWTXQUGMW-UHFFFAOYSA-N,2.2,"Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, and ten Bokkel Huinink WW (1999)  Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.  J. Clin. Oncol.17: 1906-1914.  Masubuchi N, May RD, and Atsumi R (2004)  A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.  Clin. Cancer Res. 10: 6722-6731.",
29,"Aminohexanoic acid, 6-",60-32-2,60-32-2,NCCCCCC(=O)O,SLXKOJJOQWFEFD-UHFFFAOYSA-N,0.39,"Frederiksen  MC, Bowsher DJ, Ruo TI, Henthorn TK, Ts'ao CH, Green D, and Atkinson AJ (1984) Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects.  Clin. Pharmacol. Ther. 35: 387-393.  McNicol GP, Fletcher AP, Alkjaersig N, and Sherry S (1962) The absorption, distribution, and excretion of e-aminocaproic acid following oral or intravenous administration to man.  J. Lab Clin. Med. 59: 15-24.",
30,"Aminosalicylic acid, 5-",89-57-6,89-57-6,[O-][N+](=O)c1c(C(N(/N=C/c2c([N+](=O)[O-])cccc2)C)N(/N=C/c2c([N+](=O)[O-])cccc2)C)cccc1,LLMRAEGWKAYSSZ-FEZYOMQXSA-N,0.33,"Bondesen S, Hegnhoj J, Larsen F, Hansen H, Hansen CP, and Rasmussen SN (1991) Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.  Digest. Dis. Sci.  12: 1735-1740.  Way EL, Smith PK, Howie DL, Weiss R, and Swanson R (1948) The absorption, distribution, excretion, and fate of para-aminosalicylic acid.  J. Pharmacol. Exp. Ther. 93: 368-382.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss and t1/2 calculated from data obtained by digitization of C vs t plots provided in the references.
31,Amiodarone ,1951-25-3,1951-25-3,C(=O)(c1c(c(c(c(c1)I)OCCN(CC)CC)I)c1c(oc2c1cccc2)CCCC)c1c(c(c(c(c1)I)OCCN(CC)CC)I)c1c(oc2c1cccc2)CCCC,ISBICGJCBZOIOL-UHFFFAOYSA-N,60,"Ujhelyi MR, Klamerus KJ, Vadiei K, O'Rangers E, Izard M, Neefe DL, Zimmerman JJ, and Chow MSS (1996) Disposition of intravenous amiodarone in subjects with normal and impaired renal function.  J. Clin. Pharmacol. 36: 122-130.  Veronese ME, McLean S, and Hendriks R (1988) Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.  Br. J. Clin. Pharmacol 26: 721-731.",
32,Amitriptyline,50-48-6,50-48-6,N(CC/C=C\1/c2c(CCc3c1cccc3)cccc2)(C)C,KRMDCWKBEZIMAB-UHFFFAOYSA-N,8.7,Jorgensen A and Hansen V (1976) Pharmacokinetics of amitriptyline infused intravenously in man.  Eur. J. Clin. Pharmacol.  10: 337-341.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.    Naunyn-Sch Arch. Pharmacol. 327: 260-265.,
33,Amlodipine,88150-42-9,88150-42-9,C1(=C(NC(=C(C1c1c(Cl)cccc1)C(=O)OC)C)COC(C([2H])([2H])N)([2H])[2H])C(=O)OCC.C(=O)(/C=C/C(=O)O)O,TZNOWAJJWCGILX-CIPKXTDXSA-N,17,"Faulkner JK, McGibney D, Chasseaud LF, Perry JL, and Taylor IW (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 22: 21-25.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",VDss calculated from C vs t data obtained by digitization of the plot in Faulkner et al.
34,Amoxicillin,26787-78-0,26787-78-0,S1[C@H]2N([C@H](C1(C)C)C(=O)O)C(=O)[C@H]2NC(=O)[C@H](N)c1ccc(O)cc1,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,0.25,"Arancibia A, Guttmann J, Gonzalez G, and Gonzalez C (1980) Absorption and disposition kinetics of amoxicillin in normal human subjects.  Antimic. Ag. Chemother. 17: 199-202.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",
35,Amphetamine,300-62-9,300-62-9,N[C@H](Cc1ccccc1)C,KWTSXDURSIMDCE-QMMMGPOBSA-N,6.1,"Angagard E, Gunne LM, Jonsson LE and Niklasson F (1970) Pharmacokinetics and clinical studies on amphetamine dependent subjects.  Eur. J. Clin. Pharmacol. 3: 3-11.  Busto U, Bendayan R, and Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs.  Clin. Pharmacokinet. 16: 1-26.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",PK reported as monoexponential decline so reported VD was used as VDss.  CL calculated from VD and t1/2.
36,Ampicillin,69-53-4,69-53-4,c1c(cccc1)[C@@H](C(=O)N[C@H]1C(=O)N2[C@H]1SC([C@H]2C(=O)O)(C)C)N,AVKUERGKIZMTKX-DYNIEEOBSA-N,0.22,"Blum RA, Kohli RK, Harrison NJ, and Schentag JJ (1989) Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.    Antimic. Ag. Chemother. 33: 1470-1476.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",
37,Amrinone,60719-84-8,60719-84-8,CCOC(=O)C(N)C(=O)OCC,WLTCKEHCTUYJGI-UHFFFAOYSA-N,1.3,"Hamilton RA, Kowalsky SF, Wright EM, Cernak P, Benziger DP, Stroshane RM, and Edelson J (1986)  Effect of the acetylator phenotype on amrinone pharmacokinetics.  Clin. Pharmacol. Ther. 40: 615-619.  Koprda V, Trnovec T, and Landmann H (1986) The binding of amrinone to plasma proteins.  Pharmazie 41: 300-301.",CL value from rapid acetylators only.
38,Amsacrine,51264-14-3,51264-14-3,Cl.S(=O)(=O)(Nc1cc(OC)c(Cc2c3c(nc4c2cccc4)cccc3)cc1)C,BVCVPWKWOSOVKB-UHFFFAOYSA-N,1.6,"Jurlina JL, Varcoe AR, and Paxton JW (1985) Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.  Canc. Chemother. Pharmacol.  14: 21-25.  Paxton JW, Kim SN, and Whitfield LR (1990) Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.  Cancer Res.  50: 2692-2697.","VDss reported in Paxton, et al, and cites Jurlina, et al.,  references which has only Vdbeta at 1.7 L/kg.  Used value from Paxton report."
39,Amsalog,80841-47-0,80841-47-0,S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4C(=O)NC)c(ccc3)C)cc1)C,TWHSQQYCDVSBRK-UHFFFAOYSA-N,0.30,"Paxton JW, Hardy JR, Evans PC, Harvey VJ, and Baguley BC (1988) The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial.  Canc. Chemother. Pharmacol. 22: 235-240.  Fyfe D, Prce C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, and Carmichael J (2001) A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.  Canc. Chemoher. Pharmacol. 47: 333-337.  Paxton JW, Kim SN, and Whitfield LR (1990) Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.  Cancer Res.  50: 2692-2697.",
40,Anhydrovinblastine,38390-45-3,38390-45-3,O([C@@H]1[C@]2([C@@H]3N(CC[C@@]43C(N(c3c4cc(c(OC)c3)[C@]3(CC4CN(CCc5c3[nH]c3c5cccc3)CC(=C4)CC)C(=O)OC)C)[C@@]1(O)C(=O)OC)CC=C2)CC)C(=O)C,FFRFGVHNKJYNOV-YQQWXOIBSA-N,12,"Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, and Creaven PJ (2003) Phase I and pharmacokinetic study of anhydrovinblastine every three weeks in patients with refractory solid tumors.  Canc. Chemother. Pharmacol. 51: 227-230.",VDss was calculated from C vs t data obtained by digitization of the plots provided in the reference.  Median values for CL and t1/2 were reported.
41,Anidulafungin,166663-25-8,166663-25-8,C1N2[C@@H]([C@H]([C@H]1C)O)C(=O)N[C@@H]([C@@H](C[C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H]([C@@H]([C@H](c1ccc(cc1)O)O)O)C(=O)N[C@H](C2=O)[C@@H](C)O)O)NC(=O)c1ccc(cc1)c1ccc(cc1)c1ccc(cc1)OCCCCC)O)O,JHVAMHSQVVQIOT-MFAJLEFUSA-N,0.57,"Dowell JA, Schranz J, Baruch A, and Foster G (2005) Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.  J. Clin. Pharmacol. 45: 1373-1382.  Eraxis Product Label.",
42,Antipyrine,60-80-0,60-80-0,O=c1cc(C)n(C)n1c1ccccc1,VEQOALNAAJBPNY-UHFFFAOYSA-N,0.77,"Andreasen PB and Vesell ES (1974) Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.  Clin. Pharmacol. Ther. 16: 1059-1065.  Danhof M, vanZuilen A, Boeijinga JK, and Breimer DD (1982) Studies of the different metabolic pathways of antipyrine in man.  Eur. J. Clin. Pharmacol.  21: 433-441.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003)  Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",Danhof reference not included for VDss (would require digitization); Andreason reference used a one-compartment model so VDc = VDss.
43,Aprepitant,170729-80-3,170729-80-3,c1(cc(cc(c1)[C@@H](O[C@@H]1OCCN([C@@H]1c1ccc(cc1)F)Cc1nc(=C)[nH][nH]1)C)C(F)(F)F)C(F)(F)F,VSEBZPDGARNVML-QYDGOFIISA-N,0.94,"Majumdar AK, Howard L, Goldberg, MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K,  Knops A, De Lepeleire I, Michiels N, and Petty KJ (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.  J. Clin. Pharmacol. 46: 291-300.  Emend Product Label.",
44,Argatroban,74863-84-6,74863-84-6,S(=O)(=O)(N[C@H](C(=O)N1[C@H](C[C@@H](CC1)C)C(=O)O)CCCN=C(N)N)c1c2NC[C@@H](Cc2ccc1)C,KXNPVXPOPUZYGB-XYVMCAHJSA-N,0.17,"Hauptmann, J. (2002) Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs A review of small-molecule thrombin inhibitors.    Eur J Clin Pharmacol  57:  751-758. ",
45,Aripiprazole,129722-12-9,129722-12-9,O=C1Nc2c(ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2)CC1,CEUORZQYGODEFX-UHFFFAOYSA-N,4.9,Abilify Product Label.,CL value in FDA documents on-line.
46,Artesunate,88495-63-0,88495-63-0,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)[O-])O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,FIHJKUPKCHIPAT-AHIGJZGOSA-M,15,"Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul, W, Ruangveerayuth R, and WhiteNJ (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.    Eur. J. Clin. Pharmacol.  62: 1003-1009.  Li Q, Xie LH, Haeberle A, Zhang J, and Weina P (2006) The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans.  Am. J. Trop. Med. Hyg. 75: 817-826.",
47,Atenolol,29122-68-7,29122-68-7,OC(COc1ccc(cc1)CC(=O)N)CNC(C)C,METKIMKYRPQLGS-UHFFFAOYSA-N,0.95,"Mason WD, Winer N, Kochak G, Cohen I, and Bell R (1979) Kinetics and absolute bioavailability of atenolol.  Clin. Pharmacol. Ther.  25: 408-415.  Henry JA and Mitchell SN (1981)  Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. ",VDss calculated from reported micro constants. 
48,Atomoxetine,83015-26-3,83015-26-3,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,VHGCDTVCOLNTBX-QGZVFWFLSA-N,0.85,Strattera Product Label,CYP2D6 EM data MRT is calculated as VD/CL; CL was calculated as CLpo/F (F=63%)
49,Atovaquone,95233-18-4,95233-18-4,O=C1C(=O)C(=C(O)c2ccccc12)C1CCC(c2ccc(Cl)cc2)CC1,BSJMWHQBCZFXBR-UHFFFAOYSA-N,0.60,Mepron Product Label,
50,Atracurium,64228-79-1,64228-79-1,c12C([N+](CCc1cc(c(c2)OC)OC)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C(c2c(CC1)cc(c(c2)OC)OC)Cc1cc(c(cc1)OC)OC)C)C)Cc1cc(c(cc1)OC)OC,YXSLJKQTIDHPOT-UHFFFAOYSA-N,0.10,"Cameron M, Donati F, and Varin F (1995) In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients.    Anesth. Analg. 81: 1019-1025.   deBros FM, Lai A, Scott R, deBros J, Batson AG, Goudsouzian N, Ali HH, Cosimi AB, and Savarese JJ (1986) Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients.    Anesth. Analg. 65: 743-746.  Ward S, Neill EAM, Weatherly BC, and Corall IM (1983) Pharmacokinetics of atricurium besylate in healthy patients after a single i.v. bolus dose.  Br. J. Anaesth. 55: 113-118.","VDss calculated from estimated C vs t data from Cameron, et al, and from reprted microconstants from Ward, et al."
51,Atropine,51-55-8,51-55-8,O([C@@H]1C[C@H]2N([C@@H](C1)CC2)C)C(=O)C(c1ccccc1)CO,RKUNBYITZUJHSG-SPUOUPEWSA-N,3.3,"Adams RG, Verma P, Jackson AJ, and Miller RL (1982) Plasma pharmacokinetics of intravenously administered atropine in normal human subjects.  J. Clin. Pharmacol. 22: 477-481.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",
52,Azacitidine,320-67-2,320-67-2,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,NMUSYJAQQFHJEW-KVTDHHQDSA-N,0.47,"Marcucci G, Silverman L, Eller M, Lintz L, and Beach CL (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.  J. Clin. Pharmacol. 45:  597-602. ",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.
53,Azapropazone,13539-59-8,13539-59-8,O=C1n2n(C(=O)C1CCC)c(nc1c2cc(cc1)C)N(C)C,MPHPHYZQRGLTBO-UHFFFAOYSA-N,0.12,"Gikalov I, Kaufmann R, and Schuster O (1982) Humanpharmakokinetik verschiedener i.v. dosen von azapropazon (HPLC-bestimmung).    Arzn. Forsch. 32: 423-426.",VDss was calculated from C vs t data provided in the reference.
54,Azelastine,58581-89-8,58581-89-8,CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)c([2H])c(c(c2[2H])[2H])[2H],MBUVEWMHONZEQD-USSMZTJJSA-N,15,"Weliky I, Howard JR, and Wichmann JK (1990) Absolute bioavailability and pharmacokinetics of azelastine.  Pharm. Res. 7: S-247.  Estelle F, Simons R, and Simons KJ (1999) Clinical pharmacology of new histamine H1 receptor antagonists.  Clin. Pharmacokinet. 36: 329-352.",
55,Azimilide,149908-53-2,149908-53-2,Clc1ccc(c2oc(/C=N/N3C(=O)N(C(=O)C3)CCCCN3CCN(CC3)C)cc2)cc1,MREBEPTUUMTTIA-PCLIKHOPSA-N,13,"Corey AE, Agnew JR, Valentine SN, Nesbitt JD, Wagner DL, Powell JH, and Thompson GA (1999) Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.  J. Clin. Pharmacol. 39: 1272-1276.",
56,Azithromycin,83905-01-5,83905-01-5,N1(C[C@@H](C[C@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O[C@@H]([C@]([C@@H]([C@H]1C)O)(O)C)CC)C)O[C@H]1C[C@@]([C@H]([C@@H](O1)C)O)(C)OC)C)O[C@H]1[C@@H]([C@H](C[C@H](O1)C)N(C)C)O)(O)C)C)C,MQTOSJVFKKJCRP-BICOPXKESA-N,33,"Luke DR, Foulds G, Cohen SF, and Levy B (1996) Safety, toleration, and pharmacokinetics of intravenous azithromycin.  Antimic. Ag. Chemother.  40: 2577-2581.  Foulds G, Shepard RM, and Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues.  J. Antimic. Chemother. 25(Suppl. A):  73-82.",Protein binding is concentration dependent; cited value measured at concentrations observed after IV dosing.
57,Azlocillin,37091-66-0,37091-66-0,CC1(C)SC2C(N(NC(=O)N3CCNC3=O)C(=O)Cc3ccccc3)C(=O)N2C1C(=O)O,LNPZUSALIRFFGM-UHFFFAOYSA-N,0.26,"Haen E, Remien J, Richter E, Frank U, and Adam D (1985) Uber die bedeutung der applikationsgeschwindigkeit fur die pharmakokinetischen parameter von azlocillin und mexlocillin.    Arz. Forsch. 35: 864-868.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",Pharmacokinetic parameters were calculated from C vs t data provided in the reference.
58,Aztreonam,78110-38-0,78110-38-0,S(=O)(=O)(O)N1[C@@H]([C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)/c2nc(sc2)N)C1=O)C,WZPBZJONDBGPKJ-DZIOLEBDSA-N,0.18,"Burgess DS, Summers KK, and HardinTC (1999) Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.  Clin. Ther. 21: 1882-1889.  Swabb EA, Sugerman A, Frantz M, Platt TB, and Stern M (1983) Renal handling of the monobactam azthreonam in healthy subjects.  Clin. Pharmacol. Ther. 33: 609-614.",
59,Bambuterol,81732-65-2,81732-65-2,OC(c1cc(OC(=O)N(C)C)cc(OC(=O)N(C)C)c1)CNC(C)(C)C,ANZXOIAKUNOVQU-UHFFFAOYSA-N,1.6,"Nyberg L, Rosenborg J, Weibull E, Jonsson S, Kennedy BM, and Nilsson M (1998) Pharmacokinetics of bambuterol in healthy subjects.   Br. J. Clin. Pharmacol. 45: 471-478.",
60,BB 83698,325795-25-3,325795-25-3,O=C(N[C@@H](C(C)(C)C)C(=O)C)[C@H](CCCC)CN(O)C=O,VUMMRHDUGBAWSA-CHWSQXEVSA-N,1.1,"Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, and Johnson KW (2004) Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.    Antimic. Ag. Chemother. 48: 4835-4842.",
61,Beclomethasone dipropionate,5534-09-8,5534-09-8,[C@@H]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@]1(Cl)[C@H]2CCC2=CC(=O)C=C[C@]12C,KUVIULQEHSCUHY-AFPZPSHSSA-N,0.29,"Daley-Yates PT, Price AC, Sisson JR, Pereira A, and Dallow N (2001)  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.    Br. J.. Clin. Pharmacol.  51: 400-409.  Beconase AQ Product Label",
62,Benperidol,2062-84-2,2062-84-2,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2,FEBOTPHFXYHVPL-UHFFFAOYSA-N,3.8,"Seiler W, Wetzel H, Hillert A, Schoellnhammer G, Langer M, Barlage U, and Hiemke C (1994) Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.  Psychopharmacology 116: 457-463.",
63,Betamethasone,378-44-9,378-44-9,C1=C[C@]2(C(=CC1=O)CC[C@@H]1[C@]2([C@@H](C[C@]2([C@H]1C[C@@H]([C@]2(C(=O)CO)O)C)C)O)F)C,UREBDLICKHMUKA-AMDXKQBSSA-N,1.3,"Petersen MC, Nation RL, McBride WG, Ashley JJ, and Moore RG (1983) Pharmacokinetics of betamethasone in healthy adults after intravenous administration.  Eur. J. Clin. Pharmacol. 25: 643-650. ",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.
64,Betamipron,3440-28-6,3440-28-6,OC(=O)CCNC(=O)c1ccccc1,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,0.28,"Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy (Tokyo)  39(Suppl. 3): 227-235.  Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, and Kawahara Y (1992) Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data.    Antimic. Ag. Chemother. 36: 1810-1816.",VDss calculated from C vs t data provided in the reference.
65,Betaxolol,63659-18-7,63659-18-7,COC(=O)C[C@@H](CC(=O)C=P(c1ccccc1)(c1ccccc1)c1ccccc1)O[Si](C)(C)C(C)(C)C,LKFANOWXMJEZDI-AREMUKBSSA-N,4.8,"Ludden TM, Boyle DA, Gieseker D, Kennedy GT, Crawford MH, Ludden LK, and Clementi WA (1988) Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects.  J. Pharm. Sci. 77: 779-783.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. ",
66,Bevantolol,59170-23-9,59170-23-9,COc1cc(CCNCC(COc2cccc(c2)C)O)ccc1OC,HXLAFSUPPDYFEO-UHFFFAOYSA-N,0.67,"McNeil JJ, Drummer OH, Anderson AIE, and Louis WJ (1986) Pharmacokinetics and concentration-effect relationships of bevantolol (CI-775) in normal volunteers.  J. Cardiovasc. Pharmacol. 8: 1201-1207.  Ichikawa M, Haruki S, Esumi Y, Takaichi M, Seki H, and Shiina M (1992) Metabolic fate of bevantolol hydrochloride.  Absorption, distribution and excretion in rats and dogs after single oral administration.  Yakuri to Chiryo 20: 1695-1708. ",VDss calculated from reported microconstants.
67,Biapenem,120410-24-4,120410-24-4,N12C(=C([C@@H]([C@@H]2[C@H](C1=O)C(O)C)C)SC1C[n+]2n(C1)cnc2)C(=O)[O-],MRMBZHPJVKCOMA-WAOAVRLKSA-N,0.20,"Shiba K, Maezawa H, Yoshida M, Sakai O, and Saito A (1994) Basic and clinical studies of biapenem.  Chemotherapy 42(Suppl. 4): 322-329.  Yamashita N, Kawashima K, Nomura K, Takeuchi H, Hikida M, and Naruke T (1994) Pharmacokinetics of biapenem in laboratory animals.    Chemotherapy 42(Suppl. 4): 243-250.",
68,Bilobalide,33570-04-6,33570-04-6,[C@H]12OC(=O)[C@@H](O)[C@@]31[C@](O)(C[C@H]1OC(=O)C[C@@]31C(=O)O2)C(C)(C)C,MOLPUWBMSBJXER-ZDXFXCARSA-N,2.5,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144.",
69,Biperiden,514-65-8,514-65-8,O[C@@](CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1,YSXKPIUOCJLQIE-AONDRMHESA-N,12,"Grimaldi R, Perucca E, Ruberto G, Gelmi C, Trimarchi F, Hollmann M, and Crema A (1986) Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.  Eur. J. Clin. Pharmacol.  29: 735-737.  Nakashima E, Yokogawa K, Ichimura F, Kurata K, Kido H, Yamaguchi N, and Yamana T (1987) A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans.  Chem. Pharm. Bull. 35: 718-725.",
70,Bisaramil,89194-77-4,89194-77-4,Clc1ccc(C(=O)OC2[C@H]3CN(C[C@@H]2CN(C3)C)CC)cc1,PMCPYLGCPSNSLS-MZBDJJRSSA-N,9.0,"Gemesi L, Kapas M, Matos L (1993)  Pharmacokinetic study of bisaramil in man.  Acta Pharm. Hungarica  63: 327-333. ",VDss calculated from reported C vs t data table.
71,Bisoprolol,66722-44-9,66722-44-9,OC(=O)/C=C/C(=O)O.CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,RZPZLFIUFMNCLY-WLHGVMLRSA-N,2.4,"Horikiri Y, Suzuki T, and Mizobe M (1998) Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans.  J. Pharm. Sci. 87: 289-294.  Leopold G, Pabst J, Ungethuem W, and Buehring KU (1986) Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist.  J. Clin. Pharmacol. 26: 616-621.  ",VDss calculated from C vs t data obtained by digitization of the plot provided by Leopold et al.
72,BMS-214662,195987-41-8,195987-41-8,c1(ccc2c(c1)CN(S(=O)(=O)c1cccs1)C(CN2Cc1cnc[nH]1)Cc1ccccc1)C#N,OLCWFLWEHWLBTO-UHFFFAOYSA-N,0.84,"Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, and Clark JW (2004) Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1 hour intravenous infusion in patients with advanced solid tumors.  Clin. Canc. Res.  10: 2222-2230.",
73,Bortezomib,179324-69-7,179324-69-7,O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nccnc1)Cc1ccccc1,GXJABQQUPOEUTA-RDJZCZTQSA-N,10,"Papandreou CN, Daliani D, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, and Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.  J. Clin. Oncol. 22: 2108-2121.  Velcade Product Label.",
74,Bosentan,147536-97-8,147536-97-8,S(=O)(=O)(Nc1nc(nc(OCCO)c1Oc1c(OC)cccc1)c1ncccn1)c1ccc(cc1)C(C)(C)C,GJPICJJJRGTNOD-UHFFFAOYSA-N,0.29,"Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, Van Marle S, Viischer HW, and Jonkman JHG (1999)  Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.  J. Clin. Pharmacol. 39:  703-714.  Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Van Marle SP, Peeters PAM, Jonkman JHG, and Jones CR (1996) Pharmacokinetics pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.  Clin. Pharmacol. Ther. 60: 124-137.",
75,Bromazepam,1812-30-2,1812-30-2,Brc1cc2C(=NCC(=O)Nc2cc1)c1ncccc1,VMIYHDSEFNYJSL-UHFFFAOYSA-N,0.85,"Raaflaub VJ and Speiser-Courvoisier J (1974) Zur pharmakokinetik von bromazepam beim menschen.  Arz. Forsch. 24: 1841-1844.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12: 612-619.",Parameters calculated from C vs t data provided in the reference.
76,Bromfenac,91714-94-2,91714-94-2,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,0.11,"Gumbhir-Shah K, Cevallos WH, DeCleene SA, Halstenson CE, and Korth-Bradley JM (1997) Absolute bioavailability of bromfenac in humans.  Ann. Pharmacother. 31: 395-399.",
77,Bromopride,4093-35-0,4093-35-0,Brc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC,GIYAQDDTCWHPPL-UHFFFAOYSA-N,3.1,"Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, and Taylor T (1986) Pharmacokinetics and bioavailability of the anti-emetic agent bromopride.  Biopharm. Drug Dispos.  7: 215-222.",VDss was calculated using C vs t data provided in the reference.
78,Brotizolam,57801-81-7,57801-81-7,Brc1sc2n3c(nnc3C)CN=C(c2c1)c1c(Cl)cccc1,UMSGKTJDUHERQW-UHFFFAOYSA-N,0.75,"Jochemsen R, Wesselman JGJ, Hermans J, Van Boxtel CJ, and Breimer DD (1983) Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.  Br. J. Clin. Pharmacol. 16(Suppl. 2): 285-290.  Jochemsen R, Joeres RP, Wesselman JG, Richter E, and Breimer DD (1983) Pharmacokinetics of oral brotizolam in patients with liver cirrhosis.  Br. J. Clin. Pharmacol.  16(Suppl 2): 315S-322S.",VDss was calculated using data obtained by digitization of the C vs t plot provided in the reference.
79,Budesonide,51333-22-3,51333-22-3,C1=C[C@]2(C(=CC1=O)CC[C@@H]1[C@@H]2[C@H](C[C@]2([C@H]1CC1(C2C(=O)CO)OC(O1)CCC)C)O)C,NTNHWEIEPRBHMJ-WYXCECBBSA-N,3.9,"Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, and Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.  Eur. J. Resp. Dis. 63: 86-95.  Entocort EC Product Label.",VDss was calculated using data obtained by digitization of the C vs t plot provided in the reference.
80,Buflomedil,55837-25-7,55837-25-7,O(c1c(c(OC)cc(OC)c1)C(=O)CCCN1CCCC1)C,OWYLAEYXIQKAOL-UHFFFAOYSA-N,1.3,"Gundert-Remy U, Weber E, Lam G, Chiou WL, Mann W, and Aynilian GH (1981) The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration.  Eur. J.Clin. Pharmacol. 20: 459-63.  Rey E, D'Athis P, Richard MO, Fillastre JP, and Olive G (1984) Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.  Int. J. Clin. Pharmacol. Ther. Toxicol. 12: 648-652.",
81,Bufuralol,54340-62-4,54340-62-4,o1c2c(cc1C(O)CNC(C)(C)C)cccc2CC,SSEBTPPFLLCUMN-UHFFFAOYSA-N,1.7,"Dayer P, Balant L, Kupfer A, Striberni R, and Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.  Eur. J. Clin. Pharmacol. 28: 317-320.  Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and nonspecific binding.  Drug Metab. Dispos. 32: 295-304.",CYP2D6 extensive metabolizers only.  VDss calculated from C vs t data obtained by digitization of the plots included in the reference.
82,Bumetanide,28395-03-1,28395-03-1,O=C(O)c1cc(NCCCC)c(Oc2ccccc2)c(S(=O)(=O)N)c1,MAEIEVLCKWDQJH-UHFFFAOYSA-N,0.16,"Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, and Penttila A (1985) Bumetanide kinetics in renal failure.  Clin. Pharmacol. Ther. 37:  582-528.  Lau HSH, Hyneck ML, Berardi RR, Swartz RD, and Smith DE (1986) Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure.  Clin. Pharmacol. Ther. 39: 635-645.  Cook JA, Smith DE, Cornish LA, Tankanow RM, Nicklas JM, and Hyneck ML (1988) Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.  Clin. Pharmacol. Ther. 44: 487-500.",Data combined from three references.
83,Bunazosin,80755-51-7,80755-51-7,O(c1c(OC)cc2nc(nc(N)c2c1)N1CCN(CCC1)C(=O)CCC)C,RHLJLALHBZGAFM-UHFFFAOYSA-N,0.72,"Morishita N, Tomono Y, Hasegawa J, and Heuer HJ (1993)  Single dose crossover study to evaluate the absolute bioavailability of a sustained-release formulation of bunazosin (E1015) in healthy male volunteers.  Drug Invest.  6:  5-9.  Yamato C, Takahashi T, Tadano K, Kinoshita K, and Fujita T (1985)  The metabolic fate of bunazosin hydrochloride (2). Studies on the transfer to fetus and milk, plasma protein binding, tissue accumulation and effect on drug-metabolizing enzymes. Oyo Yakuri  30: 257-265.",
84,Bupivacaine,38396-39-3,38396-39-3,O=C(Nc1c(cccc1C)C)C1N(CCCC1)CCCC,LEBVLXFERQHONN-UHFFFAOYSA-N,0.84,"Burm AGL, Van der Meer AD, Van Kleef JW, Zeijlmans PWM, and Groen K (1994) Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate.  Br. J. Clin. Pharmacol. 38: 125-129.",Values for enantiomers were averaged.
85,Buprenorphine,52485-79-7,52485-79-7,O1[C@@H]2[C@@]34[C@]5(C[C@@H]([C@]2(OC)CC5)[C@](O)(C(C)(C)C)C)[C@H](N(CC4)CC2CC2)Cc2c3c1c(O)cc2,RMRJXGBAOAMLHD-IHFGGWKQSA-N,4.9,"Kuhlman JJ, Lalani S, Magluilo, J, Levine B, Darwin WD, Johnson RE, and Cone EJ (1996) Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine.  J. Anal. Toxicol. 20: 369-378.   Elkader A and Sproule B (2005)  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.  Clin. pharmacokinet. 44: 661-680.",
86,Busulphan,55-98-1,55-98-1,S(=O)(=O)(OCCCCOS(=O)(=O)C)C,COVZYZSDYWQREU-UHFFFAOYSA-N,0.55,"Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringden O, Eber S, Seger R, and Ljungman P (2002) A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.  Bone Marrow Transplantation  30: 833-841.  Ehrsson H and Hassan M (1984) Binding of busulfan to plasma proteins and blood cells.  J. Pharm. Pharmacol.   36: 694-696.",
87,Butorphanol,42408-82-2,42408-82-2,O[C@@]12[C@@]3(c4c(C[C@H]1N(CC3)CC1CCC1)ccc(O)c4)CCCC2,IFKLAQQSCNILHL-QHAWAJNXSA-N,12,"Vachharajani NN, Shyu WC, Garnett WR, Morgenthien EA and Barbhaiya RH (1996) The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.  Clin. Pharmacol. Ther. 60: 283-294.   Gaver RC, Vasiljev M, Wong H, Monkovic I, Swigor JE, Van Harken DR, and Smyth RD (1980) Disposition of parenteral butorphanol in man.  Drug Metab. Dispos. 8: 230-235.",
88,Caffeine,58-08-2,58-08-2,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,RYYVLZVUVIJVGH-UHFFFAOYSA-N,0.63,Blanchard J and Sawers SJA (1983) Comparative pharmacokinetics of caffeine in young and elderly men.  J. Pharmacokinet. Biopharm. 11: 109-126.,VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  
89,Captopril,62571-86-2,62571-86-2,C(=O)([C@H]1CCCN1C(=O)C(CS)C)O,FAKRSMQSSFJEIM-COBSHVIPSA-N,0.75,"Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DM (1982)  Captopril kinetics. Clin. Pharmacol. Ther. 31: 452-458.  Creasy WA, Morrison RA, Singhvi SM, and Willard DA (1988) Pharmacokinetics of intravenous captopril in healthy men.  Eur. J. Clin. Pharmacol. 35: 367-370.",Combined data from Creasy and Duchin papers.  Note that protein binding also has S-S bond component.
90,Carbenicillin,4697-36-3,4697-36-3,S1[C@H]2N([C@H](C1(C)C)C(=O)O)C(=O)[C@H]2NC(=O)C(c1ccccc1)C(=O)O,FPPNZSSZRUTDAP-UWFZAAFLSA-N,0.17,"Libke RD, Clarke JT, Ralph ED, Luthy RP, and Kirby WMM (1975) Ticarcillin vs carbenicillin: clinical pharmacokinetics.  Clin. Pharmacol. Ther.  17: 441-446.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",
91,Carboplatin,41575-94-4,41575-94-4,[Pt]1(OC(=O)C2(C(=O)O1)CCC2)(N)N,VRENENKIMJXJOK-UHFFFAOYSA-L,0.26,"Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, and Pinedo HM (1987) Pharmacokinetics of carboplatin after i.v. administration.    Cancer Treatment Rep.  71: 1231-1237.  Gaver RC, George AM, and Deeb G (1987) In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.  Cancer Chemother. Pharmacol. 20: 271-276.",Used 1.6 m2 = 60 kg since the study was done in all females.
92,Carmustine (BCNU),154-93-8,154-93-8,ClCCNC(=O)N(CCCl)N=O,DLGOEMSEDOSKAD-UHFFFAOYSA-N,1.2,"Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, and Frei E (1986) Pharmacokinetics and immediate effects of high-dose carmustine in man.  Canc. Treatm. Rep. 70: 877-880. ",Used VD as VDss because PK was first order.
93,Carumonam,87638-04-8,87638-04-8,S(=O)(=O)(O)N1[C@@H]([C@H](NC(=O)/C(=N\OCC(=O)O)/c2nc(sc2)N)C1=O)COC(=O)N,UIMOJFJSJSIGLV-JNHMLNOCSA-N,0.18,"Weidekamm E, Kronenberger D, Portmann R, Stoeckel K, Egger HJ, and Dubach UC (1985) Single dose pharmacokinetics and absolute bioavailability of the new monocyclic .beta.-lactam carumonam (Ro 17-2301, AMA-1080).  Recent Adv. Chemother., Proc. 14th Int. Congr. Chemother. (Antimicrobial Sect. 2),  1335-1336.   Kita Y, Fugono T, and Imada A (1987) Pharmacokinetics of carumonam in experimental animals.  Chemotherapy 35(Suppl. 2): 187-197.","Ro 172301, AMA-1080. "
94,Carvedilol,72956-09-3,72956-09-3,OC(CNCCOc1ccccc1OC)COc1cccc2[nH]c3c(c12)cccc3,OGHNVEJMJSYVRP-UHFFFAOYSA-N,1.3,"Neugebauer G, Akpan W, Mollendorff E, Neubert P, and Reiff K (1987) Pharmacokinetics and disposition of carvedilol in humans.  J. Cardiovasc. Pharmacol. 10(Suppl 11): S85-S88.   Coreg Product Label.",
95,Caspofungin,162808-62-0,162808-62-0,O[C@@H]1[C@@H]2N(CC1)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C[C@H](O)C1)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC(CC(CC)C)C)C[C@@H](O)[C@@H](NC2=O)NCCN)[C@H](O)C)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](O)CCN,JYIKNQVWKBUSNH-IOWAMHHWSA-N,0.13,"Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.  Antimic. Ag. Chemother.  48: 815-823.",VDss was calculated from rate micro-contants provided in the reference.
96,CB 10-277,7203-91-0,7203-91-0,C(=O)(c1ccc(cc1)N=NN(C)C)O,GUAZPUYTLMUTMA-UHFFFAOYSA-N,0.25,"Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, and Calvert AH (1993) Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.  Br. J. Canc. 67: 362-368.",Parameters were calculated using C vs t data obtained by digitzation of the plot provided in the reference.
97,Cefadroxil,50370-12-2,50370-12-2,S1[C@H]2N(C(=O)[C@H]2NC(=O)[C@H](N)c2ccc(O)cc2)C(=C(C1)C)C(=O)O,BOEGTKLJZSQCCD-UEKVPHQBSA-N,0.23,"Marino EL, Dominguez-Gil A, and Muriel C (1982) Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil.  Int. J. Clin. Pharmacol. Ther. Toxicol. 20: 73-77.   Aratani H, Kono S, Tateishi H, Negita S, and Yamanaka Y (1980) Pharmacological studies on cefadroxil.  II.  Pharmacokinetics.  Chemotherapy 28(Suppl. 2): 75-82. ",
98,Cefamandole,34444-01-4,34444-01-4,S1C2N(C(=O)C2NC(=O)C(O)c2ccccc2)C(=C(C1)CSc1n(nnn1)C)C(=O)[O-].[Na+],OJMNTWPPFNMOCJ-UHFFFAOYSA-M,0.16,"Brogard JM, Kopferschmitt J, Spach MO, Grudet O, and Lavillaureix J (1979) Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.  J. Clin. Pharmacol. 19: 366-377.  Leroy A, Fillastre JP, Oksenhendler G, and Humbert G (1977) Pharmacokinetics of cefamandole in normal subjects and in uraemic patients.  Drugs Exptl. Clin. Res. 3: 51-59.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.","VDss and CL calculated from two-compartment terms listed in Brogard, et al. and from a digitized plot in Leroy, et al.."
99,Cefatrizine,51627-14-6,51627-14-6,O=C(C1=C(Sc2c[nH]nn2)C(C)SC2N1C(=O)C2NC(=O)C(c1ccc(O)cc1)N)O,XWQZHNDELUYAKJ-UHFFFAOYSA-N,0.22,"Pfeffer M, Gaver RC, and Ximenez J (1983) Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine. Antimicr. Ag. Chemother. 24: 915-920. Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",Analysis done by bioassay.
100,Cefazolin,25953-19-9,25953-19-9,S1C2N(C(=O)C2NC(=O)Cn2nnnc2)C(=C(C1)CSc1sc(nn1)C)C(=O)O,MLYYVTUWGNIJIB-UHFFFAOYSA-N,0.12,"Chanson P, Joly V, Contrepois A, Garaud JJ, Bauchet J, Mohler J, Nguyen PC, and Carbon C (1987) Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans.  Antimic. Agents Chemother. 31: 645-637.  Decroix MO, Zini R, Chaumeil JC, and Tillement JP (1988) Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs.  Biochem. Pharmacol. 37: 2807-2814.  Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.","VDss assumed to be equal to reported VD in Chanson, et al., because 1st order kinetic model."
101,Cefcanel,41952-52-7,41952-52-7,S1[C@H]2N(C(=O)[C@H]2NC(=O)[C@H](O)c2ccccc2)C(=C(C1)CSc1sc(nn1)C)C(=O)O,VDFFPBOAOLQAJV-SUYBPPKGSA-N,0.13,"Edwall B, Arvidsson A, Lake-Bakaar D, Lanbeck-Vallen K, and Yisak W (1993) Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects.  Drug Metab. Dispos.  21: 171-177. ",
102,Cefepime,88040-23-7,88040-23-7,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(=C(C[N+]3(C)CCCC3)CS[C@H]12)C(=O)[O-])/c1csc(N)n1,HVFLCNVBZFFHBT-ZKDACBOMSA-N,0.28,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, and Martin RR (1992) Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Ag. Chemother. 36: 552-557",
103,Cefetamet,65052-63-3,65052-63-3,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(=C(C)CS[C@H]12)C(=O)O)/c1csc(N)n1,MQLRYUCJDNBWMV-GHXIOONMSA-N,0.28,"Koup JR, Dubach UC, Brandt R, Wyss R, and Stoeckel K (1988) Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.  Antimic. Ag. Chemother. 32: 573-579.",Ro 15-8074. 
104,Cefixime,79350-37-1,79350-37-1,S1[C@H]2N(C(=O)[C@H]2NC(=O)C(=NOCC(=O)O)c2nc(sc2)N)C(=C(C1)C=C)C(=O)O,OKBVVJOGVLARMR-QMTHXVAHSA-N,0.24,"Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, and Silber BM (1988) Absolute bioavailability of cefixime in man.  J. Clin. Pharmacol. 28: 700-706. ",
105,Cefmetazole,56796-20-4,56796-20-4,S1C2N(C(=O)C2(OC)NC(=O)CSCC#N)C(=C(C1)CSc1n(nnn1)C)C(=O)O,SNBUBQHDYVFSQF-UHFFFAOYSA-N,0.13,"Ko H, Cathcart SK, Griffith DL, Peters GR, and Adams WJ (1989) Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.   Antimicr. Agents Chemother. 33: 356-361.  Tan JS, Salstrom SJ, Signs SA, Hoffman HE, and File TM (1989) Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels.  Antimicr. Agents Chemother. 33:  924-927.",
106,Cefodizime,69739-16-8,69739-16-8,S1C2N(C(=O)C2NC(=O)/C(=N/OC)/c2nc(sc2)N)C(=C(C1)CSc1sc(c(n1)C)CC(=O)O)C(=O)O,XDZKBRJLTGRPSS-BRJLIKDPSA-N,0.054,"Bryskier A, Procyk T, Tremblay D, Lenfant B, and Fourtillan JB (1990) The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g.  J. Antimic. Chemother. 26(Suppl C): 59-63.  Scaglione F, Demartini G, Arcidiacono MM, Dugnani S, and Fraschini F (1997) Serum protein binding and extravascular diffusion of cefodizime and ceftriaxone. An in vivo study.  Clin. Drug Inv. 14: 211-216.",VDss calculated from C vs t data provided in the reference.
107,Cefoperazone,62893-19-0,62893-19-0,N12C(=C(CS[C@H]1[C@H](C2=O)NC(=O)C(c1ccc(cc1)O)NC(=O)N1C(=O)C(=O)N(CC1)CC)CSc1n(nnn1)C)C(=O)O,GCFBRXLSHGKWDP-KVUOWAFTSA-N,0.17,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.",
108,Ceforanide,60925-61-3,60925-61-3,S1C2N(C(=O)C2NC(=O)Cc2c(CN)cccc2)C(=C(C1)CSc1n(nnn1)CC(=O)O)C(=O)O,SLAYUXIURFNXPG-UHFFFAOYSA-N,0.17,"Pfeffer M, Gaver RC, and Van Harken DR (1980) Human pharmacokinetics of a new broad-spectrum parenteral cephalosporin antibiotic, ceforanide.  J. Pharm. Sci. 69: 398-403.",
109,Cefotaxime,63527-52-6,63527-52-6,S1[C@H]2N(C(=O)[C@H]2NC(=O)C(=NOC)c2nc(sc2)N)C(=C(C1)COC(=O)C)C(=O)O,GPRBEKHLDVQUJE-QMTHXVAHSA-N,0.19,"Wise R, Baker S, and Livingston R (1980) Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.  Antimic. Ag. Chemother.  18: 369-371.  Esmieu F, Guilbert J, Rosenkilde HC, Ho I, LeGo A (1980) Pharmacokinetics of cefotaxime in normal human volunteers.  J. Antimic. Chemother.  6(suppl A): 83-92.",VDss calculated from C vs t data provided in the reference..
110,Cefotetan,69712-56-7,69712-56-7,CO[C@]1(NC(=O)C2SC(=C(C(=O)N)C(=O)O)S2)[C@H]2SCC(=C(N2C1=O)C(=O)O)CSc1nnnn1C,SRZNHPXWXCNNDU-RHBCBLIFSA-N,0.13,"Zimmerman J, Cohen A, and Thyrum P (1989)  Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.  J. Clin. Pharmacol. 29: 151-157.  Carver PL, Nightingale CH, and Quintiliani R (1989) Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.    J. Antimic. Chemother. 23:  99-106.",
111,Cefoxitin,35607-66-0,35607-66-0,[C@@]1(C(=O)N2C1SCC(=C2C(=O)O)COC(=O)N)(NC(=O)Cc1sccc1)OC,WZOZEZRFJCJXNZ-WMCAAGNKSA-N,0.17,"Ko H, Cathcart SK, Griffith DL, Peters GR, and Adams WJ (1989) Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.   Antimicr. Agents Chemother. 33: 356-361.   ",
112,Cefpirome,84957-29-9,84957-29-9,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(=C(C[n+]3cccc4c3CCC4)CS[C@H]12)C(=O)[O-])/c1csc(N)n1,DKOQGJHPHLTOJR-WHRDSVKCSA-N,0.24,"Nakayama I, Akieda Y, Yamaji E, Nitta Y, Ohishi M, Katagiri K, Imamura N, and Takase K (1992) Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers,  J. Clin. Pharmacol. 32: 256-266.  Tabata S, Shimura T, Maeda T, Hayashi S, Kobayashi I, and Saito A (1991) Protein binding of cefpirome sulfate in man and animals and its displacing effect on bilirubin bound to human serum albumin.    Chemotherapy  39(Suppl. 1):  109-114.",
113,Cefprozil,92665-29-7,92665-29-7,S1[C@H]2N(C(=O)[C@H]2NC(=O)[C@H](N)c2ccc(O)cc2)C(=C(C1)/C=C\C)C(=O)O,WDLWHQDACQUCJR-AGGBKSKLSA-N,0.21,"Shyu WC, Shah VR, Campbell DA, Wilber RB, Pittman KA, and Barbhaiya RH (1992) Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J. Clin. Pharm. 32: 798-803.  Shyu WC, Shukla UA, Shah VR, Papp EA, and Barbhaiya RH (1991)  Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study.  Pharm. Res.  8: 992-996.",Racemate data
114,Ceftazidime,72558-82-8,72558-82-8,S1[C@H]2N(C(=O)[C@H]2NC(=O)C(=NOC(C)(C)C(=O)O)c2nc(sc2)N)C(=C(C1)C[n+]1ccccc1)C(=O)[O-],ORFOPKXBNMVMKC-RDTXWAMCSA-N,0.31,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Wise R, Armstrong GC, Brown RM, and Andrews JM (1981) The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.  J. Antimic. Chemother. 8(SupplB): 277-282.  Lam YWF, Duroux MH, Gambertoglio JG, Barriere SL, and Guglielmo BJ (1988) Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.  Antimic. Ag. Chemother. 32: 298-302.",VDss calculated for Wise et al from C vs t data provided in the reference.  Plasma analysis done by bioassay.
115,Ceftizoxime,68401-81-0,68401-81-0,N12C(=O)[C@H]([C@@H]1SCC=C2C(=O)O)NC(=O)/C(=N\OC)/c1nc(sc1)N,NNULBSISHYWZJU-NNFJCDMRSA-N,0.20,"Yamasaku F and Suzuki Y (1983) Pharmacokinetics of cefotaxime, ceftizoxime and cefmenoxime in healthy volunteers after i.v. constant infusion.  Chemotherapy 31: 842-850.  Peterson LR, Gerding DN, Van Etta, LL, Eckfeldt JH, and Larson TA (1982) Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects.  Antimic. Agents Chemother. 22: 878-881.",VDss calculated from C vs t data provided in the reference.
116,Ceftobiprole,209467-52-7,209467-52-7,C1(=C(N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N/O)/c1nsc(n1)N)C(=O)O)/C=C\1/C(=O)N(CC1)[C@H]1CNCC1,VOAZJEPQLGBXGO-YCGCJULASA-N,0.27,"Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, and Kovacs P (2004) Single dose pharmacokinetics and study of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.  Anitmic. Ag. Chemother.  48: 2570-2575.    Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MGP, Then RL (2001) In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci.  Anitmic. Ag. Chemother.  45: 825-836.",Administered as a prodrg BAL-5788.
117,Ceftriaxone,73384-59-5,73384-59-5,[Na+].CON=C(C(=O)NC1C2SCC(=C(N2C1=O)C(=O)[O-])CSc1nc(=O)c(=O)[nH]n1C)c1csc(N)n1,YOBPSXOHCHDCMU-UHFFFAOYSA-M,0.085,"McNamara PJ, Gibaldi M, and Stoekel K (1983) Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding II.  Physiological significance.  Eur. J. Clin. Pharmacol. 25: 407-412.  Martin C, Ragni J, Lokiec F, Guillen JC, Auge A, Pecking M, and Gouin F (1992) Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery.  Antimic. Agents Chemother.  36: 2804-2807.",Protein binding is concentration dependent; value is the average between doses of 150-3000 mg.
118,Cefuroxime,55268-75-2,55268-75-2,S1[C@H]2N(C(=O)[C@H]2NC(=O)C(=NOC)c2occc2)C(=C(C1)COC(=O)N)C(=O)O,JFPVXVDWJQMJEE-QMTHXVAHSA-N,0.15,"Gower PE and Dash CH (1977) The pharmacokinetics of cefuroxime after intravenous injection.  Eur. J. Clin. Pharmacol. 12: 221-227.  Benson JM, Boudinot FD, Pennell AT, Cunningham FE, and DiPiro JT (1993) In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.  Antimic. Agents Chemother. 37: 1343-1347.",VDss calculated from reported micro rate constants.  Concentration dependent protein binding.
119,Cephalexin,15686-71-2,15686-71-2,N12C(=C(CSC1[C@H](C2=O)NC(=O)[C@@H](c1ccccc1)N)C)C(=O)O,ZAIPMKNFIOOWCQ-SPJRPDJQSA-N,0.21,Kirby WMM and De Maine JB (1971) Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.  Postgrad. Med. J. Suppl. 47(Cephalosporin Antibiotics):  41-46.,Pharamacokinetic parameters calculated from C vs t data obtained by digitization of plots included in the reference.
120,Cephaloridine,50-59-9,50-59-9,O=C([O-])C1=C(C[n+]2ccccc2)CS[C@@H]2[C@H](NC(=O)Cc3cccs3)C(=O)N12,CZTQZXZIADLWOZ-CRAIPNDOSA-N,0.46,"Brogard JM, Brandt C, Dorner M, and Dammron A (1976)  Adjustment of cephaloridine (Keflodin).  Dosage according to its pharmacokinetics.    Chemotherapy 22: 1-11.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated from digitized C vs t plot provided in the report.
121,Cephalothin,153-61-7,153-61-7,s1cccc1CC(=O)NC1C(=O)N2C(=C(COC(=O)C)CSC12)C(=O)[O-].[Na+],VUFGUVLLDPOSBC-UHFFFAOYSA-M,0.070,"Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.  Kuroyama M, Kumano K, Motohashi S, Kimura T, Murase S, and Tomonaga F (1992) Protein binding of 14 cephems in healthy subjects and patients with chronic renal failure.  Chemotherapy 40: 898-908.",
122,Cephapirin,21593-23-7,21593-23-7,S1C2N(C(=O)C2NC(=O)CSc2ccncc2)C(=C(C1)COC(=O)C)C(=O)O,UQLLWWBDSUHNEB-UHFFFAOYSA-N,0.13,"Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.",
123,Cephradine,38821-53-3,38821-53-3,S1[C@H]2N(C(=O)[C@H]2NC(=O)[C@H](N)C2=CCC=CC2)C(=C(C1)C)C(=O)O.O.O,HBKDHIDYMXXJLI-OEDJVVDHSA-N,0.21,"Rattie ES, Bernardo PD, and Ravin LJ (1976) Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans.  Antimic. Ag. Chemother.  10: 283-287.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss estimated from C vs t data obtained by digitzation of plots provided in the reference.
124,Cerivastatin,145599-86-6,145599-86-6,Fc1ccc(c2c(c(nc(c2COC)C(C)C)C(C)C)/C=C/C2OC(=O)CC(O)C2)cc1,MCBZSKZRUIWKPM-ZHACJKMWSA-N,0.33,"Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int. J. Clin. Pharmacol. Ther. 35: 255-260.  Baycol Product Label.",
125,Cetrorelix,120287-85-6,120287-85-6,C(=O)([C@H](N(C(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=O)N)CC(C)C)CCCNC(=N)N)C(=O)[C@H](NC(=O)C)Cc1cc2c(cc1)cccc2)C)N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)Cc1cnccc1)CO)Cc1ccc(O)cc1)C(=O)[C@H](N)Cc1ccc(cc1)Cl,YLUGRSUNOJJSHV-DBPJNJIWSA-N,0.39,"Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, and Derendorf H (2000) Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers.  J. Clin. Pharmacol. 40: 266-274.  Cetrotide Product Label.",VDss calculated from reported micro rate constants.
126,Chlorambucil,305-03-3,305-03-3,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,JCKYGMPEJWAADB-UHFFFAOYSA-N,0.26,"Newell DR, Calvert AH, Harrap KR, and McElwain TJ (1983) Studies on the pharmacokinetics of chlorambucil and prednimustine in man.  Br. J. Clin. Pharmacol. 15: 253-258.   Leukeran Product Label.",VDss calculated from C vs t data obtained by digitization of plots provided in the reference for two subjects administered a 10 mg dose.
127,Chloramphenicol,56-75-7,56-75-7,ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO,WIIZWVCIJKGZOK-RKDXNWHRSA-N,0.94,"Narang APS, Datta DV, Nath N, and Mathur VS (1981) Pharmacokinetic study of chloramphenicol in patients with liver disease.  Eur. J. Clin. Pharmacol. 20: 479-483.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.","One compartment pharmacokinetics, so VDc = VDss."
128,Chlorazepate,23887-31-2,23887-31-2,c1ccc(cc1)C1=NC(C(Nc2c1cc(cc2)Cl)(O)O)C(=O)O,DMKBGLSCDYFSGG-UHFFFAOYSA-N,0.20,"Bertler A, Lindgren S, Magnusson JO, and Malmgren H (1983) Pharmacokinetics of chlorazepate after intravenous and intramuscular administration.  Psychopharmacol.  80: 236-239.",VDss calculated from digitized C vs t plot provided in the report.
129,Chlordiazepoxide,58-25-3,58-25-3,Clc1cc2C(=[N+](O)CC(=Nc2cc1)NC)c1ccccc1,BUCORZSTKDOEKQ-UHFFFAOYSA-O,0.25,"Desmond PV, Patwardhan RV, Schenker S, and Hoyumpa AM (1980) Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man.  Eur. J. Clin. Pharmacol. 18: 275-278.  Boxenbaum HG, Geitner KA, Dixon WR, Spiegel HE, Symington J, Christian R, Moore JD, Weissman L, and Kaplan SA (1977) Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes.  J. Pharmacokinet. Biopharm. 5: 3-23.  Desmond PV, Roberts, RK, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.    Br. J. Clin. Pharmacol.  9: 171-175.  ",
130,Chlormethiazole,533-45-9,533-45-9,s1cnc(c1CCCl)C.Cl,OFXYKSLKNMTBHK-UHFFFAOYSA-N,6.6,"Neuvonen PJ, Pentikainen PJ, Jostell KG, and Syvalahti E (1981) Effect of ethanol on the pharmacokinetics of chlormethiazole in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 552-560.  Jostell KG, Agurell S, Allgen LG, Kuylenstierna B, Lindgren JE, Aberg G, and Osterlot G (1978) Pharmacokinetics of clomethiazole in healthy adults.  Acta Pharmacol. Toxicol. 43: 180-189.  Moore RG, Triggs EJ, Shanks CA, and Thomas J (1975) Pharmacokinetics of chlormethiazole in humans.  Eur. J. Clin. Pharmacol.  8: 353-357.  Pentikainen PJ, Neuvonen PJ, Jostell KG (1980) Pharmacokinetics of clormethiazole in healthy volunteers and patients with cirrhosis of the liver.  Eur. J. Clin. Pharmacol. 17: 275-284. "," VDss calculated from reported micro rate constants in the references by Moore, et al., and Jostell, et al."
131,"Chlorophenylpiperazine, m-",51639-49-7,51639-49-7,Clc1ccccc1N1CCNCC1.Cl.Cl,UBXIECYGXFARTC-UHFFFAOYSA-N,2.5,"Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kuhn KU, and Rao ML (2004) Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implications for the pharmacodynamic profile. Pharmacopsychiatry 37: 180-188.",
132,Chloroquine,54-05-7,54-05-7,N1(c2cc(ccc2CCc2c1cccc2)Cl)CCCN(C)C.[P+](=O)([O-])O,JOKDYASPOHUZMH-UHFFFAOYSA-N,140,"White NJ (1985) Clinical pharmacokinetics of antimalaria drugs.  Clin. Pharmacokinet.  10: 187-215.  Aderounmu AF, Salako LA, Lindstroem B, Walker O, and Ekman L (1986) Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans.  Br. J. Clin. Pharmacol. 22: 559-564.",
133,Chlorpheniramine,132-22-9,132-22-9,Clc1ccc([C@@H](CCN(C)C)c2ncccc2)cc1.OC(=O)/C=C\C(=O)O,DBAKFASWICGISY-HFNHQGOYSA-N,3.3,"Huang SM, Athanikar NK, Sridhar K, Huang YC, and Chiou WL (1982) Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults.  Eur. J. Clin. Pharmacol. 22: 359-365.  Hiep BT, Gimenez F, Khanh V, Hung NK, Thuillier A, Farinotti R, and Fernandez C (1999) Binding of chlorpheniramine enantiomers to human plasma proteins.  Chirality 11: 501-504.",
134,Chlorpromazine,50-53-3,50-53-3,C(N(C)CCOC(c1ccccc1)c1ccc(Br)cc1)Cl,PCHAKXPKGKDBNP-UHFFFAOYSA-N,10,"Yeung PKF, Hubbard JW, Korchinski ED, and Midha KK (1993)  Pharmacokinetics of chlorpromazine and key metabolites.  Eur. J. Clin.Pharmacol. 45: 563-569.  Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Curry SH (1970) Plasma protein binding of chlorpromazine.  J. Pharm. Pharmacol. 22: 193-197.",VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  Protein binding value cited is at a concentration observed in the pharmacokinetic study.
135,Chlorpropamide,94-20-2,94-20-2,ClC(C)C(=O)N,OEZPDHRXGCLGKB-UHFFFAOYSA-N,0.19,Huupponen R and Lammintausta R (1981) Chlorpropamide bioavailability and pharmacokinetics.  Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 331-333.,VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  
136,Chlortetracycline,57-62-5,57-62-5,Clc1c2[C@@](O)(C3C[C@@H]4[C@](O)(C(=O)C3=C(O)c2c(O)cc1)C(=O)/C(=C(\O)/N)/C(=O)[C@H]4N(C)C)C,WKZUQOQLOHMCQC-AQLRPVJISA-N,0.90,"Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest. 38: 1950-1963.",Parameters were calculated from C vs t data obtained by digitization of the plot included in the reference.  
137,Chlorthalidone,77-36-1,77-36-1,O=C1NC(c2c1cccc2)(O)c1ccc(c(c1)S(=O)(=O)N)Cl,JIVPVXMEBJLZRO-UHFFFAOYSA-N,3.9,"Fleuren HLJ, Thien TA, Verwey-van Wissen CPW, and von Rossum JM (1979) Absolute bioavailability of chlorthalidone in man: a cross over study after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 15: 35-50.  Dieterle W, Wagner J, and Faigle JW (1976)  Binding of chlorthalidone (Hygroton) to blood components in man.  Eur. J. Clin. Pharmacol. 10: 37-42.",
138,Cibenzoline,53267-01-9,53267-01-9,c1ccc(cc1)C1(CC1C1=NCCN1)c1ccccc1,IPOBOOXFSRWSHL-UHFFFAOYSA-N,4.1,"Cifenline. Aronoff G, Brier M, Mayer ML, Barbalas M, Aogaichi K, Sloan R, Brazzell R, and Massarella J (1991) Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J. Clin. Pharmacol. 31: 38-44.  Reidenberg MM, Lorenzo BJ, Drayer DE, Kluger J, Nestor T, Regnier JC, Kowal BA, and Bekersky I (1988) A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline.  Ther. Drug Monit. 10: 434-437.",
139,Cicaprost,94079-80-8,94079-80-8,O[C@@H]1C[C@@H]2C/C(=C/COCC(=O)O)/C[C@@H]2[C@H]1C#C[C@@H](O)[C@@H](C)CC#CCC,ARUGKOZUKWAXDS-WPWWXZMJSA-N,0.08,"Hildebrand M, Staks T, Schutt A, and Matthes H (1989) Pharmacokinetics of 3H-cicaprost in healthy volunteers.  Prostaglandins  37: 259-273.",VDss was calculated from MRT from a paper cited in the reference. 
140,Cidofovir,113852-37-2,113852-37-2,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,VWFCHDSQECPREK-LURJTMIESA-N,0.49,"Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJM, and Jaffe HS (1995) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.  Antimic. AgentsChemother. 39: 1274-1282.",
141,Cilastatin,82009-34-5,82009-34-5,S(C[C@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@@H]1C(C1)(C)C)/C(=O)O,DHSUYTOATWAVLW-WFVMDLQDSA-N,0.15,Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy 39(Suppl. 3): 227-235.   Primaxin IV Product Label.  ,VDss calculated from C vs t data provided in the reference.
142,Cilomilast,153259-65-5,153259-65-5,N#CC1(CCC(CC1)C(=O)O)c1ccc(c(c1)OC1C([2H])([2H])C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])OC,CFBUZOUXXHZCFB-UDCOFZOWSA-N,0.23,"Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C, Webber D, Quinlan J, Ritchie SY, and Carr A (2001)  Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.  Pharmacother. 21: 653-660.  Down G, Siederer S, Lim S, and Daley-Yates P (2006) Clinical pharmacology of cilomilast.  Clin. Pharmacokinet. 45: 217-233.",
143,Cimetidine,51481-61-9,51481-61-9,CN/C(=N\C#N)/NCC[S](C)c1[nH]cnc1C,PARMIMWCFHSUGD-UHFFFAOYSA-N,1.2,"Arancibia A, Schindler I, Paccot E, Ruiz I, Gonzalez G, Mella F, and Thambo S (1985) Pharmacicinetique de la cimetidine apres administration d'une dose unique par voie intraveineuse rapide et d'une autre par voie orale.  Therapie  40: 87-92.  Bauer LA, Wareing-Tran C, Edwards WAD, Raisys V, Ferreri L, Jack R, Dellinger EP, and Simonowitz D  (1985) Cimetidine clearance in the obese.  Clin. Pharmacol. Ther. 37: 425-430.  Gugler R, Muller-Liebenau B, and Somogyi A (1982) Altered disposition and availability of cimetdine in liver cirrhotic patients.  Br. J. Clin. Pharmacol. 14: 421-429.  Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, and Bernhard H (1981) Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients.  Clin. Pharmacol. Ther. 29: 737-743.",
144,Ciprofloxacin,85721-33-1,85721-33-1,OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,MYSWGUAQZAJSOK-UHFFFAOYSA-N,2.1,"Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet 41:  741-750.  Jaehde U, Soergel F, Reiter A, Sigl G, Naber KG, and Schunack W (1995)  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.    Clin. Pharmacol. Ther. 58: 532-541.  Lettieri JT, Rogge MC, Kaiser L, Echols RM, and Heller AH (1992) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.  Antimic. Agents Chemother. 36: 993-996.  Ljungborg B and Nilsson-Ehle I (1988) Pharmacokinetics of intravenous ciprofloxacin at three different doses.  J. Antimic. Chemother. 22: 715-720.",
145,Cisatracurium,96946-41-7,96946-41-7,O(c1cc2[C@H]([N@+](CCc2cc1OC)(CCC(=O)OCCCCCOC(=O)CC[N@+]1([C@@H](c2c(CC1)cc(OC)c(OC)c2)Cc1cc(OC)c(OC)cc1)C)C)Cc1cc(OC)c(OC)cc1)C,YXSLJKQTIDHPOT-LGHDNDGLSA-N,0.14,"Bergeron LB, Bevan DR, Berrill A,Kahwaji R, and Varin F (2001) Concentration–Effect Relationship of Cisatracurium at Three Different Dose Levels in the Anesthetized Patient.  Anesthesiology 95: 314-323.  Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",
146,Citalopram,59729-33-8,59729-33-8,N#Cc1ccc2c(c1)COC2(CCCN(C)C)c1ccc(cc1)F,WSEQXVZVJXJVFP-UHFFFAOYSA-N,12,"Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jorgensen T, and Sidhu J (1998) Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.  Eur. J. Clin. Pharmacol. 54: 237-242.  Celexa Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
147,Cladribine,4291-63-8,4291-63-8,n1c(nc2c(c1N)ncn2[C@H]1CC([C@H](O1)CO)O)Cl,PTOAARAWEBMLNO-YSLANXFLSA-N,7.7,"Saven A, Cheung WK, Smith L, Moyer M, Johannsen T, Rose E, Gollard R, Kosty M, Miller WE, and Piro LD (1996) Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.  J. Clin. Oncol. 14: 978-983.    Albertioni F, Herngren L, Juliusson G, and Liliemark J (1994) Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia.    Eur. J. Clin. Pharmacol. 46: 563-564.",
148,Clarithromycin,81103-11-9,81103-11-9,O([C@H]1[C@](OC)(C[C@H](C(=O)[C@@H]([C@@H](O)[C@](O)([C@H](OC(=O)[C@@H]([C@@H](O[C@@H]2O[C@H]([C@H](O)[C@](OC)(C2)C)C)[C@@H]1C)C)CC)C)C)C)C)[C@@H]1O[C@@H](C[C@H](N(C)C)[C@H]1O)C,AGOYDEPGAOXOCK-KCBOHYOISA-N,1.5,"Chu SY, Deaton R, and Cavanaugh J (1992) Absolute bioavailability of clarithromycin after oral administration in humans.  Antimic. Ag. Chemother. 36: 1147-1150.  Kuroyama M, Motohashi S, Kumano K, and Yago K (1996)  Protein binding of clarithromycin in patients with chronic renal failure.  Jap. J. Antibiotics 49: 256-263.  Davey PG (1991) The pharmacokinetics of clarithromycin and its 14-OH metabolite.  J. Hosp. Infec. 19(Suppl A): 29-37.",VDss calculated from C vs t sata obtained by digitization of the plot provided in the reference
149,Clavulanic Acd,58001-44-8,58001-44-8,O1[C@H]2N([C@H](C1=CCO)C(=O)O)C(=O)C2,HZZVJAQRINQKSD-RNFRBKRXSA-N,0.22,"Davies BE, Boon R, Horton R, Reubi FC, and Descoeudres CE (1988) Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin. Br. J. Clin. Pharmacol. 26: 385-390.  de la Pena A and Derendorf H (1999) Pharmacokinetic properties of beta-lactamase inhibitors.  Int. J. Clin. Pharmacol. Ther. 37: 63-75.",
150,Clevidipine,167221-71-8,167221-71-8,CCCC(=O)OCN1C(=C(C(c2cccc(Cl)c2Cl)C(=C1C)C(=O)OC)C(=O)[O-])C,ISHSFMOTCOCUCQ-UHFFFAOYSA-M,0.58,"Ericsson H, Fakt C, Hoglund L, Jolin-Mellgard A, Nordlander M, Sunzel M, and Regardh CG (1999) Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.  Eur. J. Clin. Pharmacol. 55: 61-67.  Ericsson H, Tholander B, and  Regardh CG (1999)  In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man.  Eur. J. Pharm. Sci. 8: 29-37.",Data for the enantiomers are averaged.
151,Clinafloxacin,105956-97-6,105956-97-6,NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1,QGPKADBNRMWEQR-UHFFFAOYSA-N,1.9,"Randinitis EJ, Brodfuehrer JI, Eiseman I, and Vassos AB (2001) Pharmacokinetics of clinafloxacin after single and multiple doses.  Antimic. Agents Chemother. 45: 2529-2535.  Wise R, Ashby JP, and Andrews JM (1988) In vitro activity of PD 127,391, an enhanced-spectrum quinoline.    Antimic. Agents Chemother.  32: 1251-1256.",
152,Clindamycin,18323-44-9,18323-44-9,[C@H]1([C@H]([C@H]([C@H](O[C@H]1SC)[C@H](C(C)Cl)NC(=O)[C@H]1N(C[C@@H](C1)CCC)C)O)O)O,KDLRVYVGXIQJDK-NQQGAZBYSA-N,0.79,"Gatti G, Flaherty J, Bubp J, White J, Borin M, and Gambertoglio J (1993) Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.  Antimic. Agents Chemother. 37: 1137-1143.  Gordon RC, Regamey C, and Kirby WMM (1973)  Serum protein binding of erythromycin, lincomycin, and clindamycin. J. Pharm. Sci. 62: 1074-1077.",
153,Clomipramine,303-49-1,303-49-1,Fc1ccc(cc1)OC(=O)c1ccc(cc1)Cl,QFOOQWZABMLXPS-UHFFFAOYSA-N,13,"Ollagnier M, Pellet J, Gay JP, Lang F, Ouvry MC, and Blanchon Y (1984) Pharmacocinetique d'une dose unique de clomipramine, en intraveneuse, chez le voluntaire sain.  Therapie  39: 237-245.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.",Pharmacokinetic parameters were calculated from C vs t provided in the reference. 
154,Clonazepam,1622-61-3,1622-61-3,OCCN1CCN(CC1)CCCS(=O)(=O)O,OWXMKDGYPWMGEB-UHFFFAOYSA-N,2.9,"Crevoisier C, Delisle MC, Joseph I, and Foletti G (2003) Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers.  Eur. Neurol. 49: 173-177.  Lucek RW and Coutinho CB.  (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-19.",VDss calculated using C vs t data obtained by digitization of the plot included in the reference.
155,Clonidine,4205-90-7,4205-90-7,Clc1c(NC2=NCCN2)c(Cl)ccc1,GJSURZIOUXUGAL-UHFFFAOYSA-N,3.3,"Vanholder R, Van Landschoot N, De Smet R, Schoots A, and Ringoir S (1988) Drug protein binding in chronic renal failure: evaluation of nine drugs.  Kidney Int. 33: 996-1004.  Frisk-Holmberg M, Paalzow L, and Edlund PO (1981) Clonidine kinetics in man-evidence for dose dependency and changed pharmacokinetics during chronic therapy.  Br. J. Clin. Pharmacol. 12: 653-658.",Used 1.27 mg/kg dose level data from Frisk-Holmberg et al.  VDss calculated from reported exponential fit parameters.
156,Clozapine,5786-21-0,5786-21-0,N1c2c(C(=Nc3c1ccc(c3)Cl)N1C(C(N(C(C1([2H])[2H])([2H])[2H])C)([2H])[2H])([2H])[2H])cccc2,QZUDBNBUXVUHMW-JNJBWJDISA-N,1.6,"Cheng YF, Lundberg T, Bondesson U, Lindstrom L, and Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur. J. Clin. Pharmacol. 34: 445-449.   Schaber G, Stevens I, Gaertner HJ, Dietz K, and Breyer-Pfaff U (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.  Br. J. Clin. Pharmacol. 46: 453-459. ",
157,Cocaethylene,529-38-4,529-38-4,O([C@@H]1[C@@H]([C@@H]2N([C@@H](CC2)C1)C)C(=O)OCC)C(=O)c1ccccc1,NMPOSNRHZIWLLL-XUWVNRHRSA-N,1.6,"Perez-Reyes M, Jeffcoat AR, Myers M, Sihler K, and Cook CE (1994) Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine.  Psychopharmacol. 116: 428-432.  Bailey DN (1997) Effect of drugs and cocaine metabolites on cocaine and cocaethylene binding to uman serum in vitro.  Ther. Drug Monit. 19: 427-430.",Parameters were calculated from C vs t data obtained by digitization of plots in the reference.
158,Cocaine,50-36-2,50-36-2,O([C@@H]1[C@@H]([C@@H]2N([C@@H](CC2)C1)C)C(=O)OC)C(=O)c1ccccc1,ZPUCINDJVBIVPJ-LJISPDSOSA-N,2.0,"Chow MJ, Ambre JJ, Ruo TI, Atkinson AJ, Bowsher DJ, and Fischman MW (1985) Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Ther. 38: 318-324.  Javaid JI, Musa MN, Fischman M, Schuster CR, and Davis JM (1983) Kinetics of cocaine in humans after intravenous and intranasal administration.  Biopharm. Drug Dispos. 4: 9-18.  Edwards DJ and Bowles SK (1988) Protein binding of cocaine in human serum.  Pharm. Res.  5: 440-442.  Parker, Robert B.; Williams, Cheri L.; Laizure, S. Casey; Lima, John J.  Factors affecting serum protein binding of cocaine in humans.    Journal of Pharmacology and Experimental Therapeutics  (1995),  275(2),  605-10.","Paper by Javaid, et al. reported one compartment kinetics so VDss = C0/Dose. "
159,Codeine,76-57-3,76-57-3,O1[C@@H]2[C@@]34[C@H]([C@H](N(CC4)C)Cc4c3c1c(OC)cc4)C=C[C@@H]2O,OROGSEYTTFOCAN-DNJOTXNNSA-N,3.5,"Guay DRP, Awni WM, Findlay JWA, Halstenson CE, Abraham PA, Opsahl JA, Jones EC, and Matzke GR (1988) Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.  Clin. Pharmacol. Ther. 43: 63-71.  Mohammed SS, Christopher MM, Mehta P, Kedar A, Gross S, and Derendorf H (1993) Increased erythrocyte and protein binding of codeine in patients with sickle cell disease.  J. Pharm. Sci. 82: 1112-1117.",
160,Colchicine,64-86-8,64-86-8,[C@H]1(c2cc(=O)c(ccc2c2c(c(c(OC)cc2CC1)OC)OC)OC)C(=O)C,UZYVHGGUESXZMN-CQSZACIVSA-N,6.1,"Ferron GM, Rochdi M, Jusko WJ, and Scherrmann JM (1996) Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36: 874-883.  Sabouraud A, Chappey O, Dupin T, and Scherrmann JM (1994)  Binding of colchicine and thiocolchicoside to human serum proteins and blood cells.  Int. J. Clin. Pharmacol. Ther. 32: 429-432.",
161,Conivaptan,210101-16-9,210101-16-9,O=C(N1c2c(c3[nH]c(nc3CC1)C)cccc2)c1ccc(NC(=O)c2c(c3ccccc3)cccc2)cc1,IKENVDNFQMCRTR-UHFFFAOYSA-N,0.76,Vaprisol Product Label,VDss was calculated using C vs t data obtained by digitization of the plot provided in the product label.
162,Cotinine,486-56-6,486-56-6,CN1[C@@H](CCC1=O)c1cnccc1,UIKROCXWUNQSPJ-VIFPVBQESA-N,1.1,"Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.  Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, and Enzell CR (1990) The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 281-287.",VDss calculated from C vs t data obtained by digitization of the plots provided in the references.
163,Cyclophosphamide,50-18-0,50-18-0,ClCCN(P1(=O)OCCCN1)CCCl,CMSMOCZEIVJLDB-UHFFFAOYSA-N,0.73,"Juma FD, Rogers HJ, and Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 8: 209-217.  Juma FD, Rogers HJ, and Trounce JR (1979) The kinetics of salivary elimination of cyclophosphamide in man.  Br. J. Clin. Pharmacol. 8: 455-458.",VDss calculated from microconstants reported in the reference.
164,Cyclosporine,59865-13-3,59865-13-3,[C@H]1(N(C(=O)[C@@H](N(C(=O)[C@@H](N(C(=O)[C@@H](N(C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H](NC1=O)CC)C)C)CC(C)C)C(C)C)C)CC(C)C)C)C)C)CC(C)C)C)CC(C)C)C)C(C)C)C)[C@@H]([C@@H](C/C=C/C)C)O,PMATZTZNYRCHOR-CGLBZJNRSA-N,3.3,"Legg B, Gupta SK, Rowland M, Johnson RWG, and Solomon LR (1988) Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 451-460.  Min DI, Lee M, Ku YM, and Flanigan M (2000) Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers.  Clin. Pharmacol. Ther. 68: 478-486.   ",Reported whole blood parameters converted to plasma parameters using a blood/plasma ratio of 1.3.
165,Dacarbazine,4342-03-4,4342-03-4,O=C(N)C1=NC=NC1=NNN(C)C,OMJKFYKNWZZKTK-UHFFFAOYSA-N,1.2,"Loo TL, Housholder GE, Gerulath AH, Saunders PH, and Farquhar D (1976) Mechanism of action and pharmacology studies with DITC (NSC-45388) Canc. Treatment Rep. 60: 149-152.  DITC-DOME Product Label",Parameters calculated from C vs t data obtained by digitization of a plot provided in the reference.
166,Dalbavancin,171500-79-1,171500-79-1,c12c(c3cc(c1)[C@H](C(=O)N[C@H]1C(=O)N[C@@H]([C@@H](c4cc(c(O3)cc4)Cl)O)C(=O)N[C@H](C(=O)NCCCN(C)C)c3c(c4cc1ccc4O)c(cc(c3)O)O[C@H]1O[C@@H]([C@H]([C@@H]([C@@H]1O)O)O)CO)NC(=O)[C@@H]1c3c(c(cc(c3)Oc3c(cc(cc3)[C@@H](NC)C(=O)N[C@@H](C(=O)N1)Cc1ccc(cc1)O2)O)O)Cl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)C(=O)O)O)O)NC(=O)CCCCCCCCC(C)C,IZJRUXNZMRDQJI-SZUNQUCBSA-N,0.14,"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KCM, and Kelly E (2004) Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.  Antimic. Agents Chemother. 48: 940-945.   Jabés D, Candiani G, Romanó G, Brunati C, Riva S, and Cavaleri M (2004) Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model.  Antimicrob. Agents Chemother. 48: 1118-1123.",
167,Dalfopristin,112362-50-2,112362-50-2,N1C(=O)/C=C/[C@H]([C@H](OC(=O)[C@@H]2N(C(=O)c3nc(CC(=O)C[C@@H](/C=C(/C=C/C1)\C)O)oc3)CC[C@H]2S(=O)(=O)CCN(CC)CC)C(C)C)C,SUYRLXYYZQTJHF-VMBLUXKRSA-N,0.39,"Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, and Montay G (2001) Multiple-dose pharmacokinetics and safety of two regimens of quinupristine/dalfopristin (Synercid) in healthy volunteers.  J. Clin. Pharmacol. 41: 404-414.  Bergeron M and Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.  J. Antimic. Chemother. 39(Supp. A): 129-138.  Bearden DT (2004)  Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin. Pharmacokinet. 43: 239-252.",
168,Dantrolene,7261-97-4,7261-97-4,o1c(c2ccc([N+](=O)[O-])cc2)ccc1C=NN1CC(=O)NC1=O,OZOMQRBLCMDCEG-UHFFFAOYSA-N,0.37,"Podranski T, Boullion T, Schumacher PM, Taguchi A, Sessler DI, and Kurz A (2005) Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth. Analg.  101: 1695-1699. ",
169,Dapsone,80-08-0,80-08-0,Brc1cc2C(=O)CCCOc2cc1,JMIWCASGALGDMJ-UHFFFAOYSA-N,0.83,Pieters FAMJ and Zuidema J (1987) The absolute bioavailability of dapsone in dogs and humans.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 396-400.  Biggs JT and Levy L (1971)  Binding of dapsone and monacetyldapsone by human plasma proteins.  Proc. Soc. Exp. Biol. Med. 137: 692-695.,VDss calculated from C vs t data obtained by digitization of plot provided in the reference.
170,Daptomycin,103060-53-3,103060-53-3,c1(c[nH]c2c1cccc2)C[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@]1([C@H](OC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC1=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@@H](CC(=O)O)C)CC(=O)c1c(cccc1)N)C)C)CC(=O)O)CC(=O)N)NC(=O)CCCCCCCCC,BTOZAHFFZDWCGE-AKVAXVQBSA-N,0.088,"Dvorchik BH, Brazier D, DeBruin MF, and Arbeit RD (2003)  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimic. Agents Chemother. 47: 1318-1323.  Woodworth JR, Nyhart EH, Brier GL, Wolny JD, and Black HR (1992) Single dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.  Antimic. Ag. Chemother. 36: 318-325.  Benvenuto M, Benzinger DP, Yankelev S, and Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.  Antimic. Ag. Chemother. 50: 3245-3249.","VDss calculated from C vs t data obtained by digitization of plot provided in the Benvenuto, et al. references."
171,Darifenacin,133099-04-4,133099-04-4,O=C(N)C([C@H]1CN(CC1)CCc1cc2c(OCC2)cc1)(c1ccccc1)c1ccccc1,HXGBXQDTNZMWGS-RUZDIDTESA-N,2.6,Skerjanec A (2006) The clinical pharmacokinetics of darifenacin.  Clin. Pharmacokinet. 45: 325-350.  Enablex Product Label.,Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
172,Decitabine,2353-33-5,2353-33-5,C1(C[C@@H](O[C@@H]1CO)n1c(=O)nc(nc1)N)O,XAUDJQYHKZQPEU-YSLANXFLSA-N,4.6,"van Groeningen CJ, Leyva A, O'Brien AMP, Gall HE, and Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.  Cancer Res. 46: 4831-4836.  Dacogen Product Label.",
173,Delorazepam (Chlordesmethyldiazepam),2894-67-9,2894-67-9,Clc1ccc2c(c1)c(ncc(=O)n2)c1ccccc1Cl,FJZXDAPDVRRTNM-UHFFFAOYSA-N,2.2,"Bareggi SR, Pirola R, Potvin P, and Devis G (1995) Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam.  Eur. J. Clin. Pharmacol. 48: 265-268.  Sennesael J, Verbeelen D, Vanhaelst L, Pirola R, and Bareggi SR (1991) Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.  Eur. J. Clin. Pharmacol. 41:65-68.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.   Molec. Pharmacol.  12: 612-619.",Parameters were determined from C vs t data obtained by digitization of the C vs t plots for normal subjects provided in the references and averaged (N=2).
174,Demethylchlortetracycline,127-33-3,127-33-3,Clc1c2[C@@H](O)[C@H]3C[C@@H]4[C@](O)(C(=O)C3=C(O)c2c(O)cc1)C(=O)/C(=C(/O)\N)/C(=O)[C@H]4N(C)C,HXPZLYXFFSKHJA-GNCUHUTISA-N,1.3,"Kunin, CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest. 38: 1950-63.",Calculated from digitized plots 
175,Denaverine,3579-62-2,3579-62-2,O(C(c1ccccc1)(c1ccccc1)C(=O)OCCN(C)C)CC(CC)CC,FPTOUQZVCUIPHY-UHFFFAOYSA-N,7.1,"Staab A, Schug BS, Larsimont V, Elze M, Thummler D, Mutschler E, and Blume H (2003) Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral, and rectal single doses.  Eur. J. Pharm. Sci. 18: 121-128.",
176,"Desacetylpaclitaxel, 4-; 4-methyl carbonate",172481-83-3,172481-83-3,O1[C@H]2[C@](OC(=O)OC)([C@@H]3[C@@]([C@@H](O)C2)(C(=O)[C@H](OC(=O)C)C2=C([C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C[C@@](O)([C@H]3OC(=O)c3ccccc3)C2(C)C)C)C)C1,GMJWGJSDPOAZTP-MIDYMNAOSA-N,6.9,"du Bois A, Jung B, Loehr A, Schaller-Kranz T, Cohen M, Frickhofen N (2006) A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.  Br. J. Cancer. 94: 79-84.",
177,Desipramine,50-47-5,50-47-5,Cl.N1(c2c(CCc3c1cccc3)cccc2)CCCNC,XAEWZDYWZHIUCT-UHFFFAOYSA-N,15,"Ciraulo DA, Barnhill JG, and Jaffe JH (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.  Clin. Pharmacol. Ther.  43: 509-518.  Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.  Clin. Pharmacol. Ther.  43: 400-406.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.",VDss calculated from C vs t data obtained by digitization of plots provided in the references.  Data from CYP2D6 poor metabolizers not included.
178,Desmethyldiazepam,1088-11-5,1088-11-5,Clc1cc2C(=NCC(=O)Nc2cc1)c1ccccc1,AKPLHCDWDRPJGD-UHFFFAOYSA-N,0.45,"Klotz U, Antonin KH, Brugel H, and Bieck PR (1977) Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease.  Clin. Pharmacol. Ther. 21: 430-436.  Lucek RW and Coutinho CB. (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12: 612-619.",
179,Desmopressin,16679-58-6,16679-58-6,NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CCSSC1)Cc1ccc(cc1)O)CC(=O)N)CCCNC(=N)N,NFLWUMRGJYTJIN-NXBWRCJVSA-N,0.30,"Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard, JP, and Djurhuus JC (2004) Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur. J. Clin. Pharmacol.  60: 397-402.",
180,Dexamethasone,50-02-2,50-02-2,[C@@]12([C@H]([C@H]3[C@@]([C@@]4(C(=CC(=O)C=C4)CC3)C)([C@H](C2)O)F)C[C@H]([C@@]1(C(=O)CO)O)C)C,UREBDLICKHMUKA-CXSFZGCWSA-N,0.94,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14.  Tsuei SE, Moore RG, Ashley JJ, and McBride WG (1979) Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.  J. Pharmacokinet. Biopharm. 7: 249-264.",
181,Dexfenfluramine,3239-44-9,3239-44-9,FC(F)(F)c1cc(ccc1)C[C@@H](NCC)C,DBGIVFWFUFKIQN-VIFPVBQESA-N,11,"Cheymol G, Weissenburger J., Poirier JM, Gellee C. (1995) The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.  Br. J. Clin. Pharmacol. 39: 684-687.  De la Torre R, Farre M, Navarro M, Pacifici R,  Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",
182,Dexloxiglumide,119817-90-2,119817-90-2,Clc1cc(C(=O)N[C@@H](C(=O)N(CCCCC)CCCOC)CCC(=O)O)ccc1Cl,QNQZBKQEIFTHFZ-GOSISDBHSA-N,0.18,"Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'Amato M, Cybulski, ZR, Chasseaud LF, and Rovati LC (2003) Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.  Xenobiotica  33: 625-641.",Protein binding data for 1 ug/mL concentration is included.
183,Dexmedetomidine,145108-58-3,145108-58-3,c1([C@@H](c2cccc(c2C)C)C)c[nH]cn1.Cl,VPNGEIHDPSLNMU-RFVHGSKJSA-N,1.6,"Anttila A, Penttila J, Helminen A, Vuorilehto L, and  Scheinin H (2003)  Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br. J. Clin. Pharmacol. 56: 691-693.  Precedex Product Label.",
184,Dexniguldipine,120054-86-6,120054-86-6,O(CCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C(=O)C1=C(NC(=C([C@H]1c1cc([N+](=O)[O-])ccc1)C(=O)OC)C)C,SVJMLYUFVDMUHP-MGBGTMOVSA-N,8.4,"Goedhals L, Bezwoda WR, Abratt RP, Rathgeb F, Goebel KJ, and Wurst W (1995) Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug.  Int. J. Clin. Pharmacol. Ther. 33: 664-669.      ",VDss calculated from C vs t data obtained by digitization of plots provided in the reference.
185,Dexrazoxane,24584-09-6,24584-09-6,O=C1NC(=O)CN([C@@H](CN2CC(=O)NC(=O)C2)C)C1,BMKDZUISNHGIBY-SSDOTTSWSA-N,0.55,"Rosing H, Ten Bokkel Huinink WW, Van Gijn R, Rombouts RFM, Bult A, and Beijnen JH (1999) Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).  Eur. J. Drug Metab. Pharmacokinet. 24: 69-77.  Zinecard Product Label.",
186,DHA Paclitaxel,199796-52-6,199796-52-6,O1[C@H]2[C@](OC(=O)C)([C@@H]3[C@@]([C@@H](O)C2)(C(=O)[C@H](OC(=O)C)C2=C([C@@H](OC(=O)[C@H](OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C[C@@](O)([C@H]3OC(=O)c3ccccc3)C2(C)C)C)C)C1,LRCZQSDQZJBHAF-PUBGEWHCSA-N,0.068,"Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, and Baker SD (2003) Disposition of docosahaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.  Clin. Cancer Res. 9: 151-159.",Pharmacokinetic paremeters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
187,Diatrizoic Acid (Amidotrizoate),117-96-4,117-96-4,CC(=O)Nc1c(I)c(NC(=O)C)c(c(c1I)C(=O)O)I,YVPYQUNUQOZFHG-UHFFFAOYSA-N,0.26,"Feldman S, Hayman LA, and Hulse M (1984) Pharmacokinetics of low- and high-dose intravenous diatrizoate contrast media administration.    Invest. Radiol. 19: 54-57.  Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.",
188,Diazepam,439-14-5,439-14-5,Clc1cc2c(N(C(=O)CN=C2c2ccccc2)C)cc1,AAOVKJBEBIDNHE-UHFFFAOYSA-N,1.0,"Klotz U, Avant GR, Hoyumpa A, Schenker S, and Wilkinson (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man.  J. Clin. Invest. 55: 347-359.  Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990) Effect of omeprazole and cimetidine on plasma diazepam levels.  Eur. J. Clin. Pharmacol. 39: 51-54.  Herman RJ and Wilkinson GR (1996) Disposition of diazepam in young and elderky subjects after acute and chronic dosing.  Br. J. Clin. Pharmacol. 42: 147-155.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12:  612-619.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson GR, and Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.",
189,Diazoxide,364-98-7,364-98-7,Clc1cc2=S(=O)(O)N=C(N=c2cc1)C,JEPPHNFUVBTYKM-UHFFFAOYSA-N,0.21,"Oglivie RI, Nadeau JH, and Sitar DS (1982) Diazoxide concentration-response relation in hypertension. Hypertension 4: 167-173.   Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",
190,Dibekacin,34493-98-6,34493-98-6,O([C@@H]1[C@@H](O)[C@H](O[C@H]2O[C@@H](CC[C@H]2N)CN)[C@@H](N)C[C@H]1N)[C@H]1O[C@@H]([C@@H](O)[C@H](N)[C@H]1O)CO,JJCQSGDBDPYCEO-XVZSLQNASA-N,0.13,"Arancibia A, Chavez J, Ibarra R, Ruiz I, Icarte A, Thambo S, and Chavez H (1987) Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.  Int. J. Clin. Pharmacol, Ther. Toxicol. 25: 38-43.  Goto M, Sugiyama M, and Ishizaki T (1980) Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous and intramuscular administration to human volunteers.  Antimic. Agents Chemother. 18: 372-376.",Plasma concentrations measured with a bioassay.
191,Dichloroacetic Acid,79-43-6,79-43-6,ClC(Cl)C(=O)O,JXTHNDFMNIQAHM-UHFFFAOYSA-N,0.19,"Jia M, Coats B, Chadha M, Frentzen B, Perez-Rodriguez J, Chadik PA, Yost RA, Henderson GN, and Stacpoole PW (2006) Human Kinetics of Orally and Intravenously Administered Low-Dose 1,2-13C-Dichloroacetate.  J. Clin. Pharmacol.  46: 1449-1459.",
192,Diclofenac,15307-86-5,15307-86-5,N(c1c(Cl)cccc1Cl)c1c(CC(=O)O)cccc1,DCOPUUMXTXDBNB-UHFFFAOYSA-N,0.22,"Willis JV, Kendall MJ, Flinn RM, Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration.  Eur. J. Clin. Pharmacol. 16: 405-410.  Leucuta SE, Rus V, Bolosiu H, Mocan A, Polinicencu C, and Bojita M (1996) Farmacocinetica diclofenacului sodic administrat in doza unica pe cale intravenosa si orala sub forma de solutie injectabilia experimentala.  Farmacia 43: 43-50.  Chan KKH, Vyas KH, and Brandt KD (1987) In vitro protein binding of diclofenac sodium in plasma and synovial fluid.    J. Pharm. Sci. 76: 105-108.",VDss calculated using micro rate constants and exponential fit parameters reported in the references.  
193,Dicloxacillin,3116-76-5,3116-76-5,Clc1c(c2noc(c2C(=O)NC2C3SC(C(N3C2=O)C(=O)O)(C)C)C)c(Cl)ccc1,YFAGHNZHGGCZAX-UHFFFAOYSA-N,0.11,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 42-48.  Roder BL, Frimodt-Moller, Espersen F, and Rasumussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bacteriocidal titers in healthy subjects after oral administration.  Infection 23: 107-112.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  "
194,Didanosine,69655-05-6,69655-05-6,O1[C@@H](n2c3nc[nH]c(=O)c3nc2)CC[C@H]1CO,BXZVVICBKDXVGW-NKWVEPMBSA-N,0.77,"Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, and Barbhaiya RH (1991) Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.  Clin. Pharmacol. Ther. 49: 523-535.  Videx Product Label.",
195,Diflunisal,22494-42-4,22494-42-4,OC(=O)c1cc(ccc1O)c1ccc(F)cc1F,HUPFGZXOMWLGNK-UHFFFAOYSA-N,0.097,Nuernberg B and Brune K (1989) Buffering the stomach content enhances the absorption of diflunisal in man.  Biopharm. Drug Dispos. 10: 377-387.   Lin JH (1989) Species differences in protein binding of diflunisal.  Drug Metab. Dispos. 17: 221-223.,Parameters calculated from a digitized C vs t plot provided in the report.  Note: N=1
196,Digitoxin,71-63-6,71-63-6,O[C@@]12[C@H]3[C@@H]([C@@]4([C@H](CC3)C[C@@H](O[C@@H]3O[C@@H]([C@@H](O[C@@H]5O[C@@H]([C@@H](O[C@@H]6O[C@@H]([C@@H](O)[C@@H](O)C6)C)[C@@H](O)C5)C)[C@@H](O)C3)C)CC4)C)CC[C@@]1([C@H](CC2)C1=CC(=O)OC1)C,WDJUZGPOPHTGOT-XUDUSOBPSA-N,0.44,"Ochs HR, Grube E, Greenblatt DJ, Arendt R, and Bodem G (1981) Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin.  Klin. Wochenschr. 59: 889-897.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss calculated using C vs t data obtained from digitization of a plot reported in the reference.
197,Digoxin,20830-75-5,20830-75-5,O[C@@]12[C@H]3[C@@H]([C@@]4([C@H](CC3)C[C@@H](O[C@@H]3O[C@@H]([C@@H](O[C@@H]5O[C@@H]([C@@H](O[C@@H]6O[C@@H]([C@@H](O)[C@@H](O)C6)C)[C@@H](O)C5)C)[C@@H](O)C3)C)CC4)C)C[C@@H](O)[C@@]1([C@H](CC2)C1=CC(=O)OC1)C,LTMHDMANZUZIPE-PUGKRICDSA-N,4.1,"Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, and Horgan J (1979) Digoxin in the elderly: pharmacokinetic consequences of old age.  Clin. Pharmacol. Ther. 25: 772-776.  Ohnhaus EE, Spring P, and Dettli L (1972) Protein binding of digoxin in human serum.    Eur. J. Clin. Pharmacol.  5: 34-36.",VDss calculated using C vs t data obtained from digitization of a plot reported in the reference.
198,Dihydroquinidine,1435-55-8,1435-55-8,N12C([C@H](c3c4c(ncc3)ccc(c4)OC)O)CC([C@H](C1)CC)CC2,LJOQGZACKSYWCH-DDWHMBSISA-N,2.8,"Ueda CT, Williamson BJ, and Dzindzio BS (1976) Disposition kinetics of dihydroquinidine following quinidine administration.  Res. Comm. Chem. Path. Pharmacol. 14: 215-225.  Leroyer R, Varoquaux O, Guillebastres R, Jarreau C, Normand JP, Jaillon P, Advenier C, and Pays M (1986) Study on protein binding of 3-(R)- and 3-(S)-hydroxy derivatives of quinidine and dihydroquinidine.  Therapie  41: 159-162.",
199,Dilevalol,75659-07-3,75659-07-3,O[C@H](CN[C@@H](CCc1ccccc1)C)c1cc(c(O)cc1)C(=O)N,SGUAFYQXFOLMHL-FZKQIMNGSA-N,4.8,"Neubeck M, Becker C, Henke D, Roesch W, Spahn-Langguth H, and Mutschler E. (1993) Pharmacokinetics of dilevalol and its conjugates in man: assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.  Arz. Forsch. 43: 953-957.",
200,Diltiazem,42399-41-7,42399-41-7,S1[C@@H]([C@H](OC(=O)C)C(=O)N(CCN(C)C)c2c1cccc2)c1ccc(OC)cc1,HSUGRBWQSSZJOP-LEWJYISDSA-N,4.1,"Hoglund P and Nilsson LG (1988) Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers.  Ther. Drug Monit. 10: 401-409.  Kolle EU, Ochs HR, and Vollmer KO (1983) Pharmacokinetic model of diltiazem.  Arz. Forsch. 33: 972-977.  Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.",Different values reported for terminal phase half-life in the Hoglund and Nillson vs the Kolle et al reports.
201,Diphenhydramine,58-73-1,58-73-1,CN(CCOC(c1ccccc1)c1ccccc1)C,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,6.5,"Meredith CG, Christian CD, Johnson RF, Madhavan SV, and Schenker S (1984) Diphenhydramine disposition in chronic liver disease.  Clin. Pharmacol. Ther. 35: 474-479.  Spector R, Choudhury AK, Chiang CK, Goldberg MJ, and Ghoneim MM (1980) Diphenhydramine in Orientals and Caucasians.  Clin. Pharmacol. Ther. 28: 229-234.",
202,Diprafenone,81447-80-5,81447-80-5,OC(CNC(CC)(C)C)COc1c(C(=O)CCc2ccccc2)cccc1,VDKMYSMWQCFYBQ-UHFFFAOYSA-N,1.2,"Trenk D, Wagner F, Sachs W, and Jaehnchen E (1989) Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.    Eur. J. Clin. Pharmacol. 37: 313-316.",
203,Diprophylline,479-18-5,479-18-5,c12c(c(=O)n(c(=O)n1C)C)n(cn2)C[C@H](O)CO,KSCFJBIXMNOVSH-LURJTMIESA-N,0.42,Zuidema J and Merkus FWHM (1981) Pharmacokinetics and pharmacodynamics of diprophylline.  Pharm. Weekbl. 3: 1320-221.,VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.
204,Disopyramide,3737-09-5,3737-09-5,O=C(N)C(c1ncccc1)(c1ccccc1)CCN(C(C)C)C(C)C,UVTNFZQICZKOEM-UHFFFAOYSA-N,0.52,"Lima JJ, Haughey DB, and Leier CV (1984) Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.  J. Pharmacokinet. Biopharm. 12: 289-313.",
205,Docetaxel,114977-28-5,114977-28-5,O([C@]12[C@@H]3[C@@]([C@@H](O)C[C@H]1OC2)(C(=O)[C@H](O)C1=C([C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c2ccccc2)C[C@@](O)([C@H]3OC(=O)c2ccccc2)C1(C)C)C)C)C(=O)C,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,2.1,"Rosing H, Lustig V, van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Schellens JHM, Rodenhuis S, Bult A, and Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.    Cancer Chemother. Pharmacol. 45: 213-218.  Minami H, Kawada K, Sasaki Y, Igarashi T, Saeki T, Tahara M, Itoh K, and Fujii H (2006) Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.  Cancer Sci.  97: 235-241.",
206,Dofetilide,115256-11-6,115256-11-6,CN(CCOc1ccc(NS(=O)(=O)C)cc1)CCc1ccc(NS(=O)(=O)C)cc1,IXTMWRCNAAVVAI-UHFFFAOYSA-N,3.3,"Gemmill JD, Howie CA, Meredith PA, Kelman AW, Rasmussen HS, Hillis WS, and Elliott HL (1991) A dose ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers.  Br. J. Clin. Phaemacol. 32: 429-432.  Smith DA, Rasmussen HS, Stopher DA, and Walker DK (1992) Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.  Xenobiotica 22: 709-719.",
207,Dolasetron,115956-12-2,115956-12-2,O(C1CC2N3[C@H](CC(C2)C(=O)C3)C1)C(=O)c1c2c([nH]c1)cccc2,UKTAZPQNNNJVKR-DBBXXEFVSA-N,2.0,"Dimmit DC, Choo YS, Martin LA, Arumugham T, Hahne WF, and Weir SJ (1999) Intravenous pharmacokinetcs and absolute oral bioavailability of dolasetron in healthyl volunteers: part 1.  Biopharm. Drug Disp. 20, 29-39.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
208,Domperidone,57808-66-9,57808-66-9,ClCCCn1c(=O)[nH]c2c1cccc2,GUMPYDGUYXOYML-UHFFFAOYSA-N,3.4,"Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, and Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man.  IV.  The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.  Eur. J. Drug Metab. Pharmacokinet.  6: 61-70. ","VD calculated from micro rate constants reported in the paper by Heykants, et al."
209,Doxacurium,133814-18-3,133814-18-3,c12c(cc(c(c1OC)OC)OC)CC[N@+]([C@@H]2Cc1cc(c(c(c1)OC)OC)OC)(CCCOC(=O)CCC(=O)OCCC[N@@+]1([C@H](c2c(CC1)cc(c(c2OC)OC)OC)Cc1cc(c(c(c1)OC)OC)OC)C)C,GBLRQXKSCRCLBZ-IYQFLEDGSA-N,0.22,"Cook DR, Freeman JA, Lai AA, Robertson KA, Kang Y, Stiller RL, Aggarwal S, Abou-Donia MM, and Welch RM (1991) Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. Anesth. Analg. 72: 145-150.   Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",
210,Doxapram,309-29-5,309-29-5,O=C1N(CC(C1(c1ccccc1)c1ccccc1)CCN1CCOCC1)CC,XFDJYSQDBULQSI-UHFFFAOYSA-N,1.2,Robson RH and Prescott LF (1979) A pharmacokinetic study of doxapram in patients and volunteers.  Br. J. Clin. Pharmacol. 7: 81-87.  ,VDss calculated from digitized from plot reported
211,Doxazosin,74191-85-8,74191-85-8,O1C(C(=O)N2CCN(c3nc4c(c(n3)N)cc(OC)c(OC)c4)CC2)COc2c1cccc2,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,1.3,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  Vincent J, Meredith PA, Elliott HL, and Reid JL (1986) The pharmacokinetics of doxazosin in elderly normotensives.  Br. J. Clin. Pharmacol. 21: 521-524.  Kaye B, Cussans NJ Faulkner JK, Stopher DA, and Reid JL (1986) The metabolism and kinetics of doxazosin in man, mouse, rat and dog.    Br. J. Clin. Pharmacol. 21(Suppl. 1): 19S-25S.",
212,Doxepin,1668-19-5,1668-19-5,O1c2c(/C(=C/CCN(C)C)/c3c(C1)cccc3)cccc2,ODQWQRRAPPTVAG-GZTJUZNOSA-N,12,"Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK (2002) Absolute bioavailability and stereoselective pharmacokinetics of doxepin.    Xenobiotica 32: 615-623.  Virtanen R, Iisalo E, and Irjala K (1982) Protein binding of doxepin and desmethyldoxepin.  Acta Pharmacol. Toxicol.  51: 159-164.",Z- and E isomer data were averaged.
213,Doxifluridine,3094-09-5,3094-09-5,O=c1[nH]c(=O)c(F)cn1[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,0.28,"Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1988) The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.  Eur. J. Clin. Pharmacol. 34: 439-443.  Meynial D, Lopez A, Malet-Martino MC, Hoffmann JS, and Martino R (1988) Application of fluorine-19 nuclear magnetic resonance to the determination of plasma-protien binding of 5'-deoxy-5-fluorouridine, a new antineoplastic fluoropyrimidine.  J. Pharm. Biomed. Anal. 6: 47-59.",Concentration dependent; fu data cited is for the lowest concentration.
214,Doxorubicin,23214-92-8,23214-92-8,O(C1CC(O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)c(OC)ccc2)C(=O)CO)C1OC(C(O)C(N)C1)C,AOJJSUZBOXZQNB-UHFFFAOYSA-N,22,"Carmaggi CM, Comparsi R, Strocchi E, Testoni F, Angelli B, and Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics.  Canc. Chemother. Pharmacol. 21: 221-228.  Piscitelli SC, Rodvold KA, Rushing DA, and Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.  Clin. Pharmacol. Ther. 53: 555-561.  Eksborg S, Ehrsson H, and Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin.    Cancer Chemother. Pharmacol. 10: 7-10.",
215,Doxycycline,564-25-0,564-25-0,O[C@@]12[C@@H]([C@@H](O)[C@H]3C(=C1O)C(=O)c1c([C@@H]3C)cccc1O)[C@H](N(C)C)C(=C(C2=O)C(=O)N)O.O,XQTWDDCIUJNLTR-CVHRZJFOSA-N,0.69,"Nguyen VX, Nix DE, Gillikin S, and Schentag JJ (1989)  Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.  Antimic. Agents Chemother. 33: 434-436.  Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, and Tillement JP (1983) The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.  Br. J. Clin. Pharmacol. 16: 245-252.  Raghuram TC and Krishnaswamy K (1982) Pharmacokinetics and plasma steady-state levels of doxycycline in undernutrition.  Br. J. Clin. Pharmacol. 14: 785-789.",
216,DP-b 99,222315-88-0,222315-88-0,N(c1c(OCCOc2c(N(CC(=O)O)CC(=O)OCCOCCCCCCCC)cccc2)cccc1)(CC(=O)O)CC(=O)OCCOCCCCCCCC,FTGBVHPWUIHWRH-UHFFFAOYSA-N,1.1,"Rosenberg G, Angel I, and Kozak A (2005) Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans.  Br. J. Clin. Pharmacol. 60: 7-16. ",
217,Drotaverine,14009-24-6,14009-24-6,O(c1c(OCC)cc2c(/C(=C/c3cc(OCC)c(OCC)cc3)/NCC2)c1)CC,OMFNSKIUKYOYRG-MOSHPQCFSA-N,1.9,"Bojali OO, Onyeji CO, Ogundani AO, Olugbade TA, and Ogunbona FA (1996) Pharmacokinetics and bioavailability of drotaverine in humans.  Eur. J. Drug Metab. Pharmacokinet. 21: 217-221.  Vargay Z, Deutsch T, Szatmari I, Szuts T, Varkonyi P, Kerpel-Fronius S, and Eckhardt S (1984) The fate of drtoaverine-acephyllinate in rat and man II.  Human pharmacokinetics of drotaverine-14C-acephyllinate.  Eur. J. Drug Metab. Pharmacokinet. 9: 17-29.",VDss calculated from C vs t data obtained by digitization of the data provided in the reference.
218,Edrophonium,312-48-1,312-48-1,c1(cccc(c1)O)[N+](CC)(C)C,VWLHWLSRQJQWRG-UHFFFAOYSA-O,1.1,"Morris RB, Cronnelly R, Miller RD, Stanski DR, and Fahey MR (1981) Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man.  Anesthesiol. 54: 399-402.",
219,Eletriptan,143322-58-1,143322-58-1,S(=O)(=O)(c1ccccc1)CCc1cc2c(c[nH]c2cc1)C[C@@H]1N(CCC1)C,PWVXXGRKLHYWKM-LJQANCHMSA-N,1.6,"Milton AK, Scott NR, Allen MJ, Abel S, Jenkins VC, James GC, Rance DJ, and Eve MD (2002) Pharmacokinetics, pharmacodynamics, and safety of the 5-HT1B/1D agonist eletriptan following intravenous and oral administration.  J. Clin. Pharmacol. 42: 528-539.  Relpax Product Label.",VDss was calculated from C vs t data obtained by digitization of the plot (0.102 mg/kg dose only) included in the reference.
220,Eltanolone,128-20-1,128-20-1,C1C[C@H](C[C@H]2CC[C@@H]3[C@@H]([C@@]12C)CC[C@]1([C@H]3CC[C@@H]1C(=O)C)C)O,AURFZBICLPNKBZ-YZRLXODZSA-N,2.0,"Dale O, Hynne H, Parivar K, Johansson E, and Widman M (1999) Pharmacokinetics of etanolone in male and female patients following intravenous bolus injection.  Acta Anaesthesiol. Scand.  43: 415-420.",
221,Enalaprilat,76420-72-9,76420-72-9,O=C(N1[C@@H](CCC1)C(=O)O)[C@@H](N[C@H](C(=O)O)CCc1ccccc1)C.O.O,MZYVOFLIPYDBGD-MLZQUWKJSA-N,0.38,"Hockings N, Ajayi AA, and Reid JL (1986) Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.  Br. J. Clin. Pharmacol. 21: 341-348.  Mujais  SK, Quintanilla A, Zahid M, Koch K, Shaw W, and Gibson T (1992) Renal handling of enalaprilat.    Am. J. Kidney Dis. 19: 121-125.",
222,Encainide,66778-36-7,66778-36-7,COc1ccc(cc1)C(=O)Nc1ccccc1CCC1CCCCN1C,PJWPNDMDCLXCOM-UHFFFAOYSA-N,2.2,"Wensing G, Monig H, Ohnhaus EE, and Hoensch HP (1991) Pharmacokinetics of encainide in patients with cirrhosis.  Cardiovasc. Drugs Ther. 5: 733-740.   C Funck-Brentano, J Turgeon, RL Woosley, and DM Roden (1989) Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics.  Influence of genetic polymorphism.    Journal of Pharmacology and Experimental Therapeutics  249:  134-42.  Jaillon P (1990) Pharmacokinetics and metabolism of encainide.  Cardiovasc. Drugs Ther.  4(Suppl 3): 561-565.","EM data only from Funck-Bretano, et al. and Wensing et al. reports."
223,Endralazine,39715-02-1,39715-02-1,O=C(N1Cc2c(n[nH]/c(=N\N)/c2)CC1)c1ccccc1,ALAXZYHFVBSJKZ-UHFFFAOYSA-N,2.2,"Reece PA, Cozamanis I, and Zacest R (1983) Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.  Eur. J. Clin. Pharmacol. 25: 553-556.",
224,Eniporide,176644-21-6,176644-21-6,NC(=NC(=O)c1cc(c(cc1C)n1cccc1)S(=O)(=O)C)N,UADMBZFZZOBWBB-UHFFFAOYSA-N,1.1,"Kovar A, Peters T, Beier N, and Derendorf H (2001) Pharmacokinetic/pharmacodynamic evaluation of the NHE inhibitor Eniporide.  J. Clin. Pharmacol. 41: 139-148.",
225,Enoxacin,74011-58-8,74011-58-8,CCn1cc(c(=O)c2c1cc(cc2)N1CCNCC1)C(=O)O,GHRVKTJOLCCNCJ-UHFFFAOYSA-N,2.0,"Nix DE, Lebsack ME, Chapelsky M, Sedman AJ, Busch J, and Norman A (1993)  Effect of oral antacids on disposition of intravenous enoxacin.    Antimic. Agents Chemother. 37: 775-777.   Wise R, Lister D, McNulty CAM, Griggs D, and Andrews JM (1986) The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.  Infection  14: S196-S202.  Bergogne-Berezin E (2002)  Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",
226,Enprofylline,41078-02-8,41078-02-8,O=c1[nH]c(=O)c2c(n1CCC)[nH]cn2,SIQPXVQCUCHWDI-UHFFFAOYSA-N,0.63,"Lunell E, Borga O, and Alarsson R (1984) Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.  Eur. J. Clin. Pharmacol. 26: 87-93.  Kraan J, Borgstrom L, Koeter GH, Laseur M, Jonkman JHG, and deNoord OE (1988) Creation of four consecutive intantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with expoonentially decreasing delivery rates. Eur. J. Clin. Pharmacol. 35: 657-661.  Borga O, Larsson R, and Lunell E (1986) Effects of probenecid on enprofylline kinetics in man.  Eur. J. Clin. Pharmacol. 30: 221-223.  Tegner K, Borga O, and Svensson I (1983) Protein binding of enprofylline.  Eur. J. Clin. Pharmacol. 25: 703-708.",
227,Entacapone,130929-57-6,130929-57-6,O=C(N(CC)CC)/C(=C/c1cc([N+](=O)[O-])c(O)c(O)c1)/C#N,JRURYQJSLYLRLN-BJMVGYQFSA-N,0.27,"Heikkinen H, Saraheimo M, Antila S, Ottoila P, and Pentikainen PJ (2001) Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique.   Eur. J. Clin. Pharmacol. 56: 821-826.   Najib J (2001)  Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease. Clin. Ther. 23: 802-832.",
228,Epirubicin,56420-45-2,56420-45-2,O([C@@H]1c2c(c(O)c3c(c2O)C(=O)c2c(C3=O)cccc2OC)C[C@](O)(C1)C(=O)CO)[C@@H]1O[C@H]([C@H](O)[C@@H](N)C1)C,AOJJSUZBOXZQNB-VTZDEGQISA-N,45,"Carmaggi CM, Comparsi R, Strocchi E, Testoni F, Angelli B, and Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics.  Canc. Chemother. Pharmacol. 21: 221-228.  Carmaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, anmd Pannuti F (1985) Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.  Drugs Exptl. Clin. Res. 11: 285-294.  Eksborg S, Ehrsson H, and Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin.  Canc. Chemother. Pharmacol. 10: 7-10.",
229,Epristeride,119169-78-7,119169-78-7,O=C(NC(C)(C)C)[C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4(C(=CC3)C=C(CC4)C(=O)O)C)CC2)CC1)C,VAPSMQAHNAZRKC-PQWRYPMOSA-N,0.54,"Benincosa LJ, Audet PR, Lundberg D, Zariffa N, and Jorkasky DK (1996) Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.  Biopharm, Drug Dispos. 17: 249-258.  Li JT, Zheng Z, and Jin J (2000) Pharmacokinetics of epristeride in healthy male volunteers.  Zhongguo Linchuang Yaolixue Zazhi 16: 424-428.",
230,Eprosartan,133040-01-4,133040-01-4,s1c(CC(=Cc2n(c(nc2)CCCC)Cc2ccc(cc2)C(=O)O)C(=O)O)ccc1,OROAFUQRIXKEMV-UHFFFAOYSA-N,0.17,"Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D (1998)  Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.  Biopharm. Drug Dispos. 19: 351-356.  Kovacs SJ, Tenero DM, Martin DE, Ilson BE, and Jorkasky DK (1999) Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.  Pharmacotherapy 19: 612-619. ",
231,Eptifibatide,188627-80-7,188627-80-7,C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CCCCNC(=N)N)C(=O)N)CCC2)Cc1c[nH]c2c1cccc2)CC(=O)O,CZKPOZZJODAYPZ-LROMGURASA-N,0.17,"Gretler D, Guerciolini R, and Williams PJ (2004) Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther. 26: 390-398.  Integrilin Product Label.",
232,Ergotamine,113-15-5,113-15-5,O1[C@]2(O)N(C(=O)[C@@]1(NC(=O)[C@@H]1C=C3[C@H](N(C1)C)Cc1c4c3cccc4[nH]c1)C)[C@H](C(=O)N1[C@H]2CCC1)Cc1ccccc1,XCGSFFUVFURLIX-VFGNJEKYSA-N,3.6,"Ibraheem JJ, Paalzow L, and Tfelt-Hansen P (1985) Linear pharmacokinetics of intravenous ergotamine tartrate.  Eur. J. Clin. Pharmacol. 29: 61-66.",VDss calculated from compartmental parameters provided in the reference.
233,Eritoran,185955-34-4,185955-34-4,[C@H]1([C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)NC(=O)CC(=O)CCCCCCCCCCC)OCCCCCCCCCC)O)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)OP(=O)(O)O)OCC[C@H](OC)CCCCCCC)NC(=O)CCCCCCCCC/C=C\CCCCCC,BPSMYQFMCXXNPC-MFCPCZTFSA-N,0.048,"Wong YN, Rossignol D, Rose JR, Kao R, Carter A, and Lynn M (2003) Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.  J. Clin. Pharmacol. 43: 735-742.  Rossignol DP, Wasan KM, Choo E Yau E, Wong N, Rose J, Moran J, and Lynn M (2003) Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.    Antimic. Agents Chemother. 48: 3233-3240.",Protein binding driven by lipoproteins--not reported directly
234,Ertapenem,153832-46-3,153832-46-3,N12C(=C([C@@H]([C@@H]2[C@H](C1=O)[C@H](O)C)C)S[C@H]1C[C@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C(=O)O,JUZNIMUFDBIJCM-IXADOMCXSA-N,0.12,"Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, and Rogers JD (2002) Pharmacokinetics of ertapenem in healthy young volunteers.  Antimic. Agents Chemother. 46: 3506-3511.",Protein binding non-linear over the concentration range studied in vivo; median value used.
235,Erythromycin,114-07-8,114-07-8,O([C@@H]1[C@@H]([C@@H]([C@@](C[C@H](C(=O)[C@@H]([C@@H]([C@@]([C@H](OC(=O)[C@@H]1C)CC)(C)O)O)C)C)(C)O)O[C@@H]1[C@H]([C@@H](C[C@@H](O1)C)N(C)C)O)C)[C@H]1C[C@]([C@H](O)[C@@H](O1)C)(OC)C,ULGZDMOVFRHVEP-UIGVSETDSA-N,0.95,Welling PG and Craig WA (1978) Pharmacokinetics of intravenous erythromycin.  J. Pharm. Sci. 67: 1057-1059.,Plasma concentrations determined using a bioassay.
236,Esmolol,81147-92-4,81147-92-4,O(c1ccc(cc1)CCC(=O)OC)CC(O)CNC(C)C,AQNDDEOPVVGCPG-UHFFFAOYSA-N,1.2,"Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, and Lai CM (1983) Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin. Pharmacol. Ther. 34: 427-434.  Okamura M, Kumagai M, Murasaki Y, Ohkura T, Miyamoto Y, Kawai Y, Tamura T, Takariki Y, and Tomisawa H (2001) Stereoselective pharmacokinetics of esmolol enantiomers.  Yakubutsu Dotai 16: 427-435.",
237,Estradiol,50-28-2,50-28-2,Oc1ccc2c(c1)CC[C@H]1[C@@H]2CC[C@]2(C)[C@H](O)CC[C@H]12,VOXZDWNPVJITMN-ILOCAZANSA-N,1.2,"Kuhnz W, Gansau C, and Mahler M (1993) Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17beta estradiol.  Arz. Forsch. 43: 966-973.  Bruning PF and Bonfrer JMG (1986) Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma.  Cancer Res. 46: 2606-2609.",
238,Estramustine phosphate,4891-15-0,4891-15-0,C1C[C@@H]([C@]2(CC[C@@H]3c4c(CC[C@H]3[C@H]12)cc(cc4)OC(=O)N(CCCl)CCCl)C)OP(=O)(O)O,ADFOJJHRTBFFOF-RBRWEJTLSA-N,0.12,"Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, and Hartley-Asp B (2002) Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.  J. Clin. Oncol.  20: 1115-1127.  Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, and Plym-Forshell G (1984) Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.  Eur. J. Clin. Pharmacol. 26: 113-119.","Compartmental model parameters from Gunnarsson, et al. were used in the calculation of VDss."
239,Ethacrynic Acid,58-54-8,58-54-8,Clc1c(C(=O)C(=C)CC)ccc(OCC(=O)O)c1Cl,AVOLMBLBETYQHX-UHFFFAOYSA-N,0.26,"Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, and O'Dwyer P (1994) Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.  J. Pharmacol. Exp. Ther. 270:  1186-1191.",
240,Ethambutol,74-55-5,74-55-5,OCC(NCCNC(CC)CO)CC,AEUTYOVWOVBAKS-UHFFFAOYSA-N,1.7,"Lee CS Brater DC, Gambertoglio JG, and Benet LZ (1980) Disposition kinetics of ethambutol in man.  J. Pharmacokinet. Biopharm. 8: 335-346.   Holdiness MR (1984) Clinical pharmacokinetics of the antituberculosis drugs.  Clin. Pharmacokinet. 9: 511-544.",
241,Ethinylestradiol,57-63-6,57-63-6,C[C@]12CCC3[C@@H](CCc4c3ccc(O)c4)C1CC[C@@]2(O)C#C,BFPYWIDHMRZLRN-RUDWHLCBSA-N,4.3,"Kuhnz W, Humpel M, Biere H, and Gross D (1996) Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women.  Eur. J. Clin. Pharmacol. 50: 231-235.  Kuhnz W, Pfeffer M, and Al-Yacoub G (1990) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.  J. Ster. Biochem.  35: 313-318.  Pacifici GM, Viani A, Rizzo G, and Carrai M (1989) Plasma protein binding of ethinylestradiol:  effect of disease and interaction with drugs.    Int. J. Clin. Pharmacol. Ther. Toxicol.  27: 362-365.",
242,Ethinylestradiol-17-Sulfate,75803-36-0,75803-36-0,S(=O)(=O)(O[C@@]1([C@@]2([C@H]([C@H]3[C@H](CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C)O,JHKCCDZKVDAGJH-SLHNCBLASA-N,0.61,"Goldzieber JW, Mileikowsky G, Newburger J, Dorantes A, and Stavchansky SA (1988) Human pharmacokinetics of ethinyl estradiol 3-sulfate and 17-sulfate.  Steroids 51: 63-79.",VDss calculated from reported micro-constants.
243,Ethinylestradiol-3-Sulfate,24560-70-1,24560-70-1,c1(c(cc2c(c1)CC[C@H]1[C@@H]3CC[C@H](O)[C@@]3(C)CC[C@H]21)C#C)OS(=O)(=O)O,FJSQDVSTMCDMAQ-SSGANFLRSA-N,2.3,"Goldzieber JW, Mileikowsky G, Newburger J, Dorantes A, and Stavchansky SA (1988) Human pharmacokinetics of ethinyl estradiol 3-sulfate and 17-sulfate.  Steroids 51: 63-79.  Reed MJ and Fotherby K (1980) Interaction of ethinyloestradiol sulphate with plasma proteins.  J. Steroid Biochem. 13: 495-497.",VDss calculated from reported micro-constants.
244,Etilefrine,709-55-7,709-55-7,OC(c1cc(O)ccc1)CNCC,SQVIAVUSQAWMKL-UHFFFAOYSA-N,2.1,"Hengstmann JH, Weyand U, and Dengler HJ (1975) The physiological disposition of etilefrine in man.  Eur. J. Clin. Pharmacol.  9: 179-187.",VDss calculated from reported micro-constants.
245,Etomidate,33125-97-2,33125-97-2,OC[C@@H](O)C=O,MNQZXJOMYWMBOU-VKHMYHEASA-N,2.7,"Van hamme MJ, Ghoneim MM, and Ambre JJ (1978) Pharmacokinetics of etomidate, a new intravenous anesthetic.  Anesthesiology 49: 274-277.   de Ruiter G, Popescu DT, deBoer AG, Smeekens JB, Breimer DD (1981) Pharmacokinetics of etomidate in surgical patients. Arch. Int. Pharmacodynam. Ther. 249: 180-188.  Meuldermans WEG and Heykants JJP (1976) The plasma protein binding and distribution of etomidate in dog, rat and human blood.  Arch. Int. Pharmacodynam. Ther. 221: 150-162.","Microconstant values from Van Hamme, et al., were used to estimate VDss.  Data were combined with deRuyter et al. "
246,Etoposide,33419-42-0,33419-42-0,C[C@H]1OC[C@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@@H]1c2cc3c(cc2[C@H]([C@@H]2[C@@H]1COC2=O)c1cc(c(c(c1)OC)O)OC)OCO3)O)O,VJJPUSNTGOMMGY-FDFYAPTKSA-N,0.18,"Pfluger KH, Schmidt L, Merkel M, Jungelas H, and Havemann K (1987) Drug monitoring of etoposide (VP16-213).  Canc. Chemother. Pharmacol. 20: 59-66.  Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, et al. (1995) Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.  J. Clin. Oncol. 13: 2835-2841.  Lee, KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.   Pharm. Res. 20: 1015-1021.",
247,Etoricoxib,202409-33-4,202409-33-4,S(=O)(=O)(NC(=O)CC)c1ccc(c2c(noc2C)c2ccccc2)cc1,TZRHLKRLEZJVIJ-UHFFFAOYSA-N,1.5,"Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, and Agrawal NGB (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.    Drug Metab. Dispos. 31: 224-232.  Agrawal NGB, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC,  Lasseter KC, Alam I, Petty KJ, and Gottesdiener KM (2003) Pharmacokinetics of etoricoxib in patients with hepatic impairment.  J. Clin. Pharmacol. 43: 1136-1148.",
248,Exatecan (acid),276680-63-8,276680-63-8,CC[C@@](O)(C(O)=O)C1=C(CO)C(=O)N2CC3=C4[C@@H](N)CCC5=C(C)C(F)=CC(N=C3C2=C1)=C45,,0.44,"Royce ME, Rowinsky EK, Hoff PM, Coyle J, DeJager R, Pazdur R, and Saltz LB (2004) A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patiets with metastatic adenocarcinoma of the colon or rectum.  Invest. New Drugs 22: 53-61.",PK data are for ring-opened acid form
249,Famotidine,76824-35-6,76824-35-6,S(CC/C(=N/S(=O)(=O)N)/N)Cc1nc(sc1)N=C(N)N,XUFQPHANEAPEMJ-UHFFFAOYSA-N,1.2,"Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, Antonello J, Vlasses P, Ryan JR, and Williams RL (1987) Single-dose pharmacokinetics and bioavailability of famotidine in man.  Results of multicenter collaborative studies.  Biopharm. Drug Dispos. 8: 549-560.",VDss calculated from C vs t data obtained by digitization of the plots provided in the reference.
250,Felodipine,72509-76-3,72509-76-3,C([2H])([2H])([2H])OC(=O)C1=C(NC(=C(C1c1c(Cl)c(Cl)ccc1)C(=O)OC([2H])([2H])[2H])C)C,VEACAIASCBTOFS-LIJFRPJRSA-N,4.4,"Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, and Ronn O (1985) Felodipine kinetics in healthy men.  Clin. Pharmacol. Ther. 38: 305-211.","VDss calculated from compartmental parameters provided in the reference by Edgar, et al., 1985."
251,Fenoterol,13392-18-2,13392-18-2,Oc1ccc(cc1)N(C(C)C)CC(c1cc(O)cc(c1)O)O,OJVMEPTWKHZYNS-UHFFFAOYSA-N,1.2,"Warnke K, Hildebrandt R, Gunther K, Langen U, and Gundert-Remy U (1992) The pharmacokinetics of the beta2-adrenoreceptor agonist fenoterol in healthy women.  Eur. J. Clin. Pharmacol.  43: 663-665.  Heel RC, Brigden RN, Speight TM, and Avery GS (1978) Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma.  Drugs 15: 3-32.","Study subjects all women, so a body weight of 55 kg was assumed."
252,Fenoximone,77671-31-9,77671-31-9,S(c1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1)C,ZJKNESGOIKRXQY-UHFFFAOYSA-N,1.8,"Alken RG, Belz GG, Haegele KD, Meinicke T, and Schechter PJ (1984) Kinetics of fenoximone, a new cardiotonic, in healthy subjects. Clin. Pharmacol. Ther. 36: 209-216.  Hook RH, Boxenbaum H, Thompson GA, and Okerholm RA (1988) Human serum and plasma protein binding of enoximone and its sulfoxide metabolite.  J. Pharm. Sci. 77: 1012-1017.  ",
253,Fenspiride,5053-06-5,5053-06-5,O1C2(CNC1=O)CCN(CC2)CCc1ccccc1,FVNFBBAOMBJTST-UHFFFAOYSA-N,3.0,"Montes B, Catalan M, Roces A, Jeanniot JP, and Honorato JM (1993) Single-dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial.  Eur. J. Clin. Pharmacol. 45: 169-172.  ",VDss calculated from C vs t data included in the reference.
254,Fentanyl,437-38-7,437-38-7,O=C(N(C1CCN(CC1)CCc1ccccc1)c1ccccc1)CC,PJMPHNIQZUBGLI-UHFFFAOYSA-N,0.89,"Fung DL and Eisele JH (1980) Fentanyl pharmacokinetics in awake volunteers.  J. Clin. Pharmacol.  20: 652-658.  Schleimer R, Benjamani E, Eisele J, and Henderson G (1977) Pharmacokinetics of fentanyl as determined by radioimmunoassay.  Clin. Pharmacol. Ther.  23: 188-194.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.    Arch. Int. Pharmacodyn. Ther. 257: 4-19.",
255,Finasteride,98319-26-7,98319-26-7,O=C(NC(C)(C)C)[C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4([C@H](NC(=O)C=C4)CC3)C)CC2)CC1)C,DBEPLOCGEIEOCV-WSBQPABSSA-N,1.1,"Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride.  Clin. Pharmacokinet. 30: 16-27.  Carlin JR, Hoglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, and Andersson KE (1992) Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans.  Drug Metab. Dispos. 20: 148-155",
256,Flavopiridol,146426-40-6,146426-40-6,Clc1c(c2oc3c([C@H]4[C@@H](O)CN(CC4)C)c(O)cc(O)c3c(=O)c2)cccc1,BIIVYFLTOXDAOV-PXAZEXFGSA-N,1.5,"Zhai S Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, and Figg WD (2003) Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.  Anti-Cancer Drugs. 14: 125-135.  Rudek MA, Bauer KS, Lush RM, Stinson SF,  Senderowicz AM, Headlee DJ, Arbuck SG,  Cox MC, Murgo AJ, Sausville EA, and Figg WD (2003) Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.  Ann. Pharmacother. 37: 1369-1374. ",
257,Flecainide,54143-55-4,54143-55-4,O=C(c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F)NCC1CCCCN1,DJBNUMBKLMJRSA-UHFFFAOYSA-N,6.1,"Wang T, Siddoway LA, Thompson KA, Conard GJ, Bergstrand RH, Kvam D, Roden DM, and Woosley RL (1988) The development and testing of intravenous dosing regimens: application to flecainide for teh suppression of ventricular arrhythmias.  Clin. Pharmacol. Ther. 43: 499-508.  Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, and DeSchepper PJ (1986) Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.  Br. J. Clin. Pharmacol. 22: 309-316.  Munafo A, Buchlin T, Tuto D, and Biollaz J (1992) The effect of low dose quinidine on the disposition of flecainide in healthy volunteers.  Eur. J. Clin. Pharmacol. 43: 441-443.  Johnston A, Muhiddin KA, and Hamer J (1982) Serum protein binding of flecainide.  Br. J. Clin. Pharmacol. 13: 606P.","VDss from the reference by Wang, et al, was calculated using the compartmental parameters reported in the reference."
258,Fleroxacin,79660-72-3,79660-72-3,Fc1c2n(cc(c(=O)c2cc(F)c1N1CCN(CC1)C)C(=O)O)CCF,XBJBPGROQZJDOJ-UHFFFAOYSA-N,1.6,"Weidekamm E, Portmann R, Suter K, Partos C, Dell D, and Lucker PW (1987) Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.  Antimic. Ag. Chemother. 31: 1909-1914.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",
259,Flucloxacillin,5250-39-5,5250-39-5,Clc1c(c2noc(c2C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)O)(C)C)C)c(F)ccc1,UIOFUWFRIANQPC-JKIFEVAISA-N,0.19,"Adam D, Koeppe P, and Heilmann (1983) Pharmacokinetics of amoxicillin and flucloxacillin following the simultaneous intravenous administration of 4 g and 1 g respectively.  Infection  11: 150-154.  Bergan T, Engeset A, Olszewski W, Oestby N, and Solberg R (1986) Extravascular penetration of highly protein-bound flucloxacillin.  Antimic. Agents Chemother. 30: 729-732.  Roder BL, Frimodt-Moller, Espersen F, and Rasumussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bacteriocidal titers in healthy subjects after oral administration.  Infection 23: 107-112.",
260,Fluconazole,86386-73-4,86386-73-4,Fc1ccc(c(c1)F)C(Cn1cncn1)(Cn1cncn1)O,RFHAOTPXVQNOHP-UHFFFAOYSA-N,0.75,"Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, and Gibson P (1988) Steady state parenteral kinetics of fluconazole in man.  Ann. N.Y. Acad. Sci. 544: 427-30.  Humphrey MJ, Jevons S, and Tarbit MH (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Animic. Agents Chemother. 28: 648-653.",
261,Flucytosine,2022-85-7,2022-85-7,O=c1nccc(NF)[nH]1,OFWYDAWNZVVNRO-UHFFFAOYSA-N,0.68,"Cutler RE, Blair AD, and Kelly MR (1978) Flucytosine kinetics in subjects with normal and impaired renal function.  Clin. Pharmacol. Ther. 24; 333-342.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",
262,Fludarabine,21679-14-1,21679-14-1,n1(cnc2c1nc(nc2N)F)[C@H]1C(C([C@H](O1)CO)O)O,HBUBKKRHXORPQB-VKJDSPIKSA-N,2.2,"Kuo GM, Boumpas DT, Illei GG, Yarboro C, Pucino F, and Burstein AH (2001) Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Pharmacother. 21: 528-533.  Knebel W, David JC, Sanders WD, Fessler B, Yarboro C, Pucino F, and Boumpas DT (1998) The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis.  Pharmacotherapy 18: 1124-1229.   Fludara Product Label","Data from Kuo, et al were digitized prior to calculation of VDss.  Micro rate constants from Knebel were used to calculated VDss."
263,Flumazenil,78755-81-4,78755-81-4,c1cc(cc2c1n1c(CN(C2=O)C)c(nc1)C(=O)OCC)F,OFBIFZUFASYYRE-UHFFFAOYSA-N,0.80,"Janssen U, Walker S, Maier K, von Gaisberg U, and Klotz U (1989) Flumazenil disposition and elimination in cirrhosis.  Clin. Pharmacol. Ther.  46: 317-323. Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, and Butterworth RF (1989) Pharmacokinetics of benzodiazepine antagonist RO 15-1788 in cirrhotic patients with moderate or severe liver dysfunction.  Hepatology  10: 969-972.  Klotz U, Ziegler G, and Reimann IW (1984)  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.  Eur. J. Clin. Pharmacol. 27: 115-117. ",
264,Flunitrazepam,1622-62-4,1622-62-4,Fc1c(C2=NCC(=O)N(c3c2cc([N+](=O)[O-])cc3)C)cccc1,PPTYJKAXVCCBDU-UHFFFAOYSA-N,1.9,"Kangas L, Kanto J, and Pakkanen A (1982) A pharmacokinetic and pharmacodynamic study of flunitrazepam.  Int. J. Clin. Pharmacol. Ther. Toxicol.  20: 585-588.  Lucek RW and Coutinho CB (!976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-619.",VDss calculated from C vs t data obtained by digitization of the plot included in the reference.
265,Fluorescein,2321-07-5,2321-07-5,Oc1ccc2c(c1)Oc1c(C32OC(=O)c2c3cccc2)ccc(c1)O,GNBHRKFJIUUOQI-UHFFFAOYSA-N,0.14,"Larsen M, Loft S, Hommel E, and Lund-Andersen H (1988) Fluorescein and fluorescein glucuronide in plasma after intravenous injection of fluorescein.  Acta Opthamol. 66: 427-432.  ",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
266,"Fluorouracil, 5-",51-21-8,51-21-8,Fc1c[nH]c(=O)[nH]c1=O,GHASVSINZRGABV-UHFFFAOYSA-N,0.23,"Port RE, Daniel B, Ding RW, and Herrmann R (1991) Relative importance of dose, body surface area, sex, and age for 5-flurouracil clearance.  Oncology 48: 277-281.  Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1987) Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.  Eur. J. Clin. Pharmacol. 32: 411-418.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180.",5-FU shows dose dependent kinetics; low dose data cited.
267,Flupirtine,56995-20-1,56995-20-1,Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1,JUUFBMODXQKSTD-UHFFFAOYSA-N,1.1,Hlavica VP and Niebch G (1985) Untersuchungen zur pharmakokinetik und biotransformation des analgetikums flupirtin beim menschen.  Arz. Forsch. 35: 67-74. ,VDss calculated from C vs t data obtained by digitization of the plots in the reference.
268,Fluticasone propionate,80474-14-2,80474-14-2,S(C(=O)[C@]1(OC(=O)CC)[C@@]2([C@H](C3[C@](F)([C@@H](O)C2)[C@@]2(C(=CC(=O)C=C2)[C@@H](F)C3)C)C[C@H]1C)C)CF,WMWTYOKRWGGJOA-ZHLGSTKJSA-N,3.6,"Brutsche MH, Brutsche IC, Munavvar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A., and Woodcock A (2000) Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.  Lancet  356: 556-561.  Mackie AE, Ventresca GP, Fuller RW, and Bye A (1996) Pharmacokinetics of intravenous fluticasone propionate in healthy subjects.  Br. J. Clin. Pharmacol. 41: 539-542.",
269,Fluvastatin,93957-54-1,93957-54-1,[Na+].Fc1ccc(c2c3c(n(c2C=CC(O)CC(O)CC(=O)[O-])C(C)C)cccc3)cc1,ZGGHKIMDNBDHJB-UHFFFAOYSA-M,0.42,"Tse F L; Jaffe J M; Troendle A  Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.    Journal of clinical pharmacology  (1992),  32(7),  630-8.  Tse FLS, Nickerson DF, and Yardley WS (1993) Binding of fluvastatin to blood cells and plasma proteins.  J. Pharm. Sci. 82: 942-947.",
270,Folinic acid,58-05-9,58-05-9,[Ca].[C@H](NC(=O)c1ccc(NCC2N(c3c(NC2)[nH]c(nc3=O)N)C=O)cc1)(CCC(=O)O)C(=O)O.O.O.O.O.O,DZNHRKNLTYYMQA-ZIGBGYJWSA-N,0.25,"Greiner PO, Zittoun J, Marquet J, and Cheron JM (1989) Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Br. J. Clin. Pharmacol. 28: 289-295.  Christophidis N, Louis WJ, Lucas I, Moon W, and Vajda FJ (1981) Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.  Cancer Chemother Pharmacol. 6: 59-64.  ",Data from (-) enantiomer used.
271,Foscarnet,4428-95-9,4428-95-9,P(=O)(O)(O)C(=O)O,ZJAOAACCNHFJAH-UHFFFAOYSA-N,0.50,"Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.    Clin. Pharmacol. Ther. 57: 403-412.  Sjovall J, Bergdahl S, Movin G, Ogenstad S, and Saarimaki M (1989) Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.  Antimic. Agents Chemother. 33: 1023-1031.",Long terminal phase t1/2 of 88 h reported in Sjovall with a 3-compartment model.
272,Fosfluconazole,194798-83-9,194798-83-9,CC(O)C1C2C(C)C(=C(N2C1=O)C(=O)O)SC1CNC(CNS(=O)(=O)N)C1,AVAACINZEOAHHE-UHFFFAOYSA-N,0.15,"Sobue S, Tan K,  Layton G, Leclerc V, and Weil A (2004) The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.  Br. J. Clin. Pharmacol. 57: 773-784.",
273,Fosfomycin,23155-02-4,23155-02-4,P(=O)(O)(O)[C@H]1O[C@H]1C,YMDXZJFXQJVXBF-STHAYSLISA-N,0.32,"Goto M, Sugiyama M, Nakajima S, and Yamashina H (1981) Fosfomycin kinetics after intravenous and oral administration to human volunteers.    Antimic. Agents Chemother. 20: 393-397.  Potel G, Meignier M, Baron D, Reynaud A, Touze MD, and Cortieu AL (1989) Pharmacokinetics of fosfomycin in normal and burn patients.  Effect of probenecid.  Drugs Exptl. Clin. Res. 15: 177-184.  Kestle DG and Kirby WMM (1970) Clinical pharmacology and in vitro activity of phosphonomycin.  Antimic. Agents Chemother. 332-337 (Chem Abstr. 75:62036).",
274,Fosinoprilat,95399-71-6,95399-71-6,P(=O)(O)(CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(=O)O)CCCCc1ccccc1,WOIWWYDXDVSWAZ-RTWAWAEBSA-N,0.13,"Kostis JB, Garland WT, Delaney C, Norton J, and Liao WC (1995) Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.  Clin. Pharmacol. Ther. 58: 660-665",
275,Fostriecin,87810-56-8,87810-56-8,P(=O)(O[C@@H]([C@](O)(/C=C/[C@H]1OC(=O)C=CC1)C)C[C@@H](O)/C=C\C=C/C=C/CO)(O)O,ZMQRJWIYMXZORG-GZIFKOAOSA-N,0.086,"de Jong RS, Mulder NH, Uges DRA, Sleijfer DT, Hoppener FJP, Groen HJM, Willemse PHB, van der Graaf WTA, and de Vries EGE (1999) Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.  Br. J. Cancer 79: 882-887.",
276,Frovatriptan,158747-02-5,158747-02-5,O=C(N)c1cc2c3CC(NC)CCc3[nH]c2cc1,XPSQPHWEGNHMSK-UHFFFAOYSA-N,3.6,"Buchan P, Keywood C, Wade A, and Ward C (2002) Clinical pharmacokinetics of frovatriptan.  Headache  42(Suppl 2): s54-s62.",
277,Furosemide,54-31-9,54-31-9,c1c(c(cc(c1Cl)S(=O)(=O)N)C(=O)O)NCc1ccco1,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,0.12,"Smith DE, Lin ET, and Benet LZ (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.  Drug Metab. Dispos. 8: 337-342.  Hammerlund MM, Paalzow LK, and Odlind B (1984) Pharmacokinetics of furosemide in man after intravenous and oral administration.  Application of moment analysis. Eur. J. Clin. Pharmacol. 26: 197-207",
278,Gabapentin,60142-96-3,60142-96-3,O=C(O)CC1(CCCCC1)CN,UGJMXCAKCUNAIE-UHFFFAOYSA-N,0.71,"Vollmer KO, Anhut H, Thomann P, Wagner F, and Jahnchen D (1989) Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin.  Adv. Epileptol. 17: 209-211.  Neurontin Product Label.",
279,Gadoversetamide,131069-91-5,131069-91-5,[Gd+3].O=C(NCCOC)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],HBEAOBRDTOXWRZ-UHFFFAOYSA-K,0.16,OptiMARK Product Label.,
280,Galanthamine,357-70-0,357-70-0,[C@H]1(C[C@@H]2Oc3c4[C@@]2(C=C1)CCN(Cc4ccc3OC)C)O,ASUTZQLVASHGKV-JDFRZJQESA-N,2.3,"Westra P, van Thiel MJS, Vermeer GA, Soeterbroek AM, Scaf AH, and Claessens HA (1986) Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients.  Br. J. Anaesth. 58: 1303-1307.  Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, and Kewitz H (1991) Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.  Clin. Pharmacol. Ther. 50: 420-428.  Zhao Q, Iyer GR, Verhaeghe T, and Truyen L (2002) Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J. Clin. Pharmacol. 42: 428-436",
281,Ganciclovir,82410-32-0,82410-32-0,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,IRSCQMHQWWYFCW-UHFFFAOYSA-N,1.0,"Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, and Smith RB (1995) Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus seropositive patients.  Clin. Ther.  17: 425-432.   Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.  Clin. Pharmacol. Ther. 57: 403-412.  Cytovene-IV Product Label",
282,Gatifloxacin,112811-59-3,112811-59-3,O=C(c1cn(C2CC2)c2c(cc(F)c(N3CC(C)NCC3)c2OC)c1=O)O,XUBOMFCQGDBHNK-UHFFFAOYSA-N,1.7,"Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, and Grasela DM (2000) A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.  Pharmacotherapy  20: 49S-58S.  Perry C, Balfour J, and Lamb H (1999) Gatifloxacin.  Drugs 58: 683-698.",
283,Gefitinib,184475-35-2,184475-35-2,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,XGALLCVXEZPNRQ-UHFFFAOYSA-N,23,"Swaisland, HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, and Duvauchelle T (2005) Single-dose clinical pharmacokinetics studies of gefitinib.  Clin. Pharmacokinet. 44: 1165-1177.  McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CMF, Clarkson-Jones JA, Herron W, and Swaisland HC (2004) Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.  Xenobiotica 34: 917-934",
284,Gemcitabine,95058-81-4,95058-81-4,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SDUQYLNIPVEERB-QPPQHZFASA-N,1.5,"Paitnik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, terada K, Gentner L, Rybak ME, Richards H, Zhang S, and Rowinsky EK (2003) A phase I pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.  Clin. Canc. Res. 9: 4761-4771.  Gemzar Product Label.",Parameters calculated from data obtained by digitization of the plot provided in the reference.
285,Genaconazole,120924-80-3,120924-80-3,S(=O)(=O)([C@@H]([C@](O)(Cn1ncnc1)c1c(F)cc(F)cc1)C)C,HFGZFHCWKKQGIS-NOZJJQNGSA-N,0.62,"Mojavrian P, Radwanski E, Affirme MB, Cayen MN, and Lin CC (1994) Pharmacokinetics of the triazole antifungal agent geneconazole in healthy men after oral and intravenous administration.  Antimic. Agents Chemother.  38: 2758-2762.",VDss calculated from digitized plots.
286,Gentamicin,1403-66-3,1403-66-3,C1[C@H](O[C@@H]([C@@H](C1)N)O[C@@H]1[C@H](C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@H]([C@](CO1)(O)C)NC)O)N)N)C(NC)C,CEAZRRDELHUEMR-URQXQFDESA-N,0.33,"Bertino JS, Booker LA, Franck P, and Rybicki B (1991) Gentamicin pharmacokinetics in patients with malignancies.  Antimic. Agents Chemother.  35: 1501-1503.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",
287,Gestodene,60282-87-3,60282-87-3,O[C@@]1([C@@]2([C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)C=C1)CC)C#C,SIGSPDASOTUPFS-XUDSTZEESA-N,0.46,"Tauber U, Tack JW, and Matthes H (1989) Single dose phakmacokinetics of gestodene in women after intravenous and oral administration.  Contraception 40: 461-476.    Kuhnz W, Pfeffer M,and Al-Yacoub G (1990) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.  J. Steroid Biochem. 35: 313-318.  Gui LQ and Humpel M (1990) Serum protein binding characteristics of cyproterene acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man.  J. Steroid Biochem. 35: 319-326.","VDss deteremined from Cvs t data obtained by digitization of plots in Tauber, 1989.  Protein binding very different in two reports: 0.006 in Kuhnz et al vs 0.04 in Gui and Humpel; value entered is the average."
288,Ginkgolide A,15291-75-5,15291-75-5,[C@]123C4(C5(C(O3)OC(=O)[C@@H]5O)[C@@H]([CH][C@H]4OC2=O)C(C)(C)C)[CH][C@H]2[C@@]1([C@H](C(=O)O2)C)O,HZVPKDKMOQFQOE-WUYQXGIUSA-N,0.62,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144.",
289,Ginkgolide B,15291-77-7,15291-77-7,O=C1O[C@@H]2[C@@]([C@@H]1C)(O)[C@]13C4([C@H]2O)C2(C(O1)OC(=O)[C@@H]2O)[C@H](C(C)(C)C)C[C@H]4OC3=O,SQOJOAFXDQDRGF-NWQIMBJLSA-N,0.91,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144.",
290,Glimepiride,93479-97-1,93479-97-1,S(=O)(=O)(c1ccc(cc1)CCNC(=O)N1CC(=C(C1=O)CC)C)NC(=O)N[C@H]1CC[C@@H](CC1)C,WIGIZIANZCJQQY-RUCARUNLSA-N,0.19,"Badian M, Korn A, Lehr KH, Malerczyk V, and Waldhaust W (1994) Absolute bioavailability of glimepiride (Amaryl) after oral administration.  Drug Metab. Drug Inter. 11: 331-339.  Amaryl Product Label.",Parameters calculated from C vs t data digitized from a plot provided in the reference.  Data reported in the table in the reference did not correspond to data obtained from the plot.
291,Glipizide,29094-61-9,29094-61-9,O=C(c1ncc(C)nc1)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,0.16,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1983) Pharmacokinetics and pharmacodynamics of glipizide in health volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 21: 98-107.  Fuccella LM, Tamassia V, and Valzelli G (1973) Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.  J. Clin. Pharmacol. New Drugs 13: 68-75.",
292,Glyburide,10238-21-8,10238-21-8,CC(c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)NC(=O)c1cc(ccc1OC)Cl,SAXQMDVJWUXSFZ-UHFFFAOYSA-N,0.080,"Jonsson A, Chan JCN, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JAJH, and Melander A (2000) Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes.    Eur. J. Clin. Pharmacol. 55: 721-727. Spraul M, Streeck A, Nieradzik M, and Berger M (1989) Uniform elimination pattern for glibenclamide in healthy caucasian males.  Arz. Forsch. 39: 1449-1450. George S, McBurney A, and Cole A (1990) Possible protein binding displacement interaction between glibenclamide and metolazone.  Eur. J. Clin. Pharmacol. 38: 93-95.",
293,Granisetron,109889-09-0,109889-09-0,c1(nn(C([2H])([2H])[2H])c2c1cccc2)C(=O)N[C@@H]1C[C@H]2N([C@@H](C1)CCC2)C,MFWNKCLOYSRHCJ-JQHPXDLNSA-N,3.7,"Allen A, Asgill CC, Pierce DM, Upward J, and Zussman BD (1994) Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects.  Eur. J. Clin. Pharmacol.  46: 159-162.  Kytril Product Label.","VDss calculated from CL and MRT provided in Allen, et al., 1994."
294,Guanfacine,29110-47-2,29110-47-2,Clc1c(c(Cl)ccc1)CC(=O)NC(=N)N,INJOMKTZOLKMBF-UHFFFAOYSA-N,5.6,"Carchman SH, Crowe JT, and Wright GJ (1987) The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers.  J. Clin. Pharmacol. 27: 762-767.",CL and VDss were calculated from C vs t data obtained by digitization of the plot provided in the reference.
295,Haloperidol,52-86-8,52-86-8,Clc1ccc(C2(O)CC[NH+](CC2)CCCC(=O)c2ccc(F)cc2)cc1,LNEPOXFFQSENCJ-UHFFFAOYSA-O,17,"Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, and Hollister LE (1983) Haloperidol kinetics after oral and intravenous administration.  Clin. Pharmacol. Ther. 33: 477-484.  Chang WH, Lam YWF, Jann MW, and Chen H (1992) Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.  Psychopharmacology 106: 517-522.  Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO, Lindberg A, and Lindstrom L (1987) Pharmacokinetics of haloperidol in psychotic patients.  Psychopharmacology 91: 410-414.  Forsman A and Ohman R (1977) Studies on serum protein binding of haloperidol.  Curr. Ther. Res. 21: 245-255.",
296,Hexobarbital,56-29-1,56-29-1,O=C1N(C(=O)NC(=O)C1(C1=CCCCC1)C)C,UYXAWHWODHRRMR-UHFFFAOYSA-N,1.1,"Breimer DD, Honhoff C, Zilly W, Richter E, and van Rossum JM (1975) Pharmacokinetics of hexabarbital in man after intravenous infusion.  J. Pharmacokinet. Biopharm. 3: 1-11.  Zilly W, Breimer DD, and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.  Eur. J. Clin. Pharmacol. 9: 219-227.  Zilly W, Breimer DD, and Richter E (1978) Hexobarbital disposition in compensated and decompensated cirrhosis of the liver.  Clin. Pharmacol. Ther. 23: 525-534.",
297,Hydralazine,86-54-4,86-54-4,Cl.n1ncc2c(c1NN)cccc2,ZUXNZUWOTSUBMN-UHFFFAOYSA-N,1.5,"Ludden TM, Shepherd AMM, McNay JL, and Lin MS (1983) Effect of intravenous dose on hydralazine kinetics after administration.  Clin. Pharmacol. Ther.  34: 148-152.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ","From Ludden, et al., used 1.02 umol/kg dose group.  Blood values corrected to plasma using B/P=1.68.  "
298,Hydrocortisone,50-23-7,50-23-7,[C@]12([C@@](C(=O)CO)(CC[C@H]1[C@H]1[C@@H]([C@@]3(C(=CC(=O)CC3)CC1)C)[C@H](C2)O)O)C,JYGXADMDTFJGBT-VWUMJDOOSA-N,0.38,"Derendorf H, Moellmann H, Barth J, Mollman C, Tunn S, and Krieg M (1991) Pharmacokinetics and oral bioavailability of hydrocortisone.    J. Clin. Pharmacol. 31: 473-476.   Toothaker RD and Welling PG (1982) Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression.  J. Pharmacokinet. Biopharm. 10: 147-156.  Mager DE and Jusko WJ (2002) Quantitative structure pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.  J. Pharm. Sci. 91: 2441-2451.",
299,Hydroflumethazide,135-09-1,135-09-1,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,DMDGGSIALPNSEE-UHFFFAOYSA-N,2.2,Broers O and Jacobsen S (1979) Distribution and elimination of hydroflumethiazide in man.  Eur. J. Clin. Pharmacol. 16: 125-131.,VDss calculated from reported micro constants.  CL calculated from Vdbeta and t1/2
300,Hydromorphone,466-99-9,466-99-9,O1C2C34C(C(N(CC3)C)Cc3c4c1c(O)cc3)CCC2=O,WVLOADHCBXTIJK-UHFFFAOYSA-N,4.3,Dilaudid-HP Product Label,
301,Hydroxychloroquine,118-42-3,118-42-3,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,700,"Tett SE, Cutler DJ, Day RO, and Brown KF (1988) A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br, J. Clin. Pharmacol. 26: 303-313.  Brocks DR, Skeith KJ, Johnston C, Emamibafrani J, Davis P, Russell AS, and Jamali F (1994) Hematologic disposition of hydroxychloroquine enantiomers. J. Clin. Pharmacol. 34: 1088-1097. ",
302,"Hydroxycotinine, 3'-",34834-67-8,34834-67-8,OC1C[C@H](N(C1=O)C)c1cccnc1,XOKCJXZZNAUIQN-IENPIDJESA-N,0.85,"Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
303,"Hydroxydihydroquinidine, 3(S)-",85405-59-0,85405-59-0,O[C@]1([C@@H]2C[C@@H](N(C1)CC2)[C@@H](O)c1c2c(ncc1)ccc(OC)c2)CC,QJYVSAYVZYKUJL-LGWHJFRWSA-N,6.8,"Jaillon P, Poirier JM, Lecocq B, Jarreau C, Pays M, Richard MO, and Cheymol G (1986) Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.  Eur. J. Drug Metab. Pharmacokinet. 11: 233-238.  Leroyer R, Varoquaux O, Guillebastres R, Jarreau C, Normand JP, Jaillon P, Advenier C, and Pays M (1986) Study on protein binding of 3-(R)- and 3-(S)-hydroxy derivatives of quinidine and dihydroquinidine.  Therapie 41: 159-162.",
304,"Hydroxyimipramine, 2-",303-70-8,303-70-8,Oc1cc2c(N(CCCN(C)C)c3c(CC2)cccc3)cc1,ROTCPJFWLNDKHU-UHFFFAOYSA-N,6.6,"Ciraulo DA, Barnhill JG, Jaffe JH, Ciraulo AM, and Tarmey MF (1990) Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls.  J. Studies Alcohol 51: 366-372.",VDss calclated from C vs t data obtained by digitization of the plot included in the reference.
305,"Hydroxystaurosporine, 7-",112953-11-4,112953-11-4,O1[C@@]2(n3c4c5n([C@@H]1C[C@@H](NC)[C@H]2OC)c1c(c5c2c(c4c4c3cccc4)[C@@H](O)NC2=O)cccc1)C,PBCZSGKMGDDXIJ-VDKBNTJGSA-N,0.15,"Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, and Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.  Canc. Res. 58: 3248-3253.  Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, and Donehower RC (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.  Clin. Canc. Res.  11: 664-671.",Used data from 95 mg/m2 group.
306,Hydroxyurea,127-07-1,127-07-1,C(=O)(N)[NH+][O-],ZWWFYVVYQIMLRX-UHFFFAOYSA-N,0.52,"Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.  Blood 91:1533-1541",
307,Hypericin,548-04-9,548-04-9,O=C1c2c3c4c5c6c(c3c(O)cc2O)c(O)cc(O)c6C(=O)c2c5c(c3c4c1c(O)cc3C)c(cc2O)C,BTXNYTINYBABQR-UHFFFAOYSA-N,0.25,"Kerb R, Brockmuller J, Staffeldt B, Ploch M, and Roots I (1996) Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin.  Antimic. Agents Chemother.  40: 2087-2093.",Data from two subjects with very high variability.
308,Ibandronic Acid (Ibandronate),114084-78-5,114084-78-5,C(C(P(=O)(O)O)(O)P(=O)(O)O)CN(C)CCCCC,MPBVHIBUJCELCL-UHFFFAOYSA-N,0.55,"Barrett J, Worth E, Bauss F, and Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update.  J. Clin. Pharmacol. 44: 951-965",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
309,Ibuprofen,15687-27-1,15687-27-1,[O-]C(=O)[C@@H](c1ccc(CC(C)C)cc1)C,HEFNNWSXXWATRW-SNVBAGLBSA-M,0.15,"Martin W, Koselowske G, Toberich H, Kerkmann T, Mangold B, and Augustin J (1990) Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man.  Biopharm. Drug Dispos. 11: 265-278.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",
310,Ibutilide,122647-31-8,122647-31-8,S(=O)(=O)(Nc1ccc(C(O)CCCN(CCCCCCC)CC)cc1)C.OC(=O)/C=C/C(=O)O,PAXBPNBQGZYWHP-WLHGVMLRSA-N,12,"Jungbluth GL, Della-Coletta ASA, and VanderLugt JT (1991) Evaluation of the pharmacokinetics and pharmacodynamics of ibutilide fumarate and its enantiomers in healthy male volunteers.  Pharm. Res. 8: S-249.  Howard PA (1999) Ibutilide: an antiarrythmic agent for the treatment of atrial fibrillation or flutter.  Ann Pharmacother. 33: 38-47.",
311,Idarubicin,58957-92-9,58957-92-9,O(C1CC(O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)C)C1OC(C(O)C(N)C1)C,XDXDZDZNSLXDNA-UHFFFAOYSA-N,38,"Robert J (1993) Clinical pharmacokinetics of idarubicin.  Clin. Pharmacokinet. 24: 275-288.  Kessel M, Gieseler F, and Woodcock BG (1999) Influence of serum protein on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells.  Eur. J. Clin. Pharmacol. 55: 369-373.",Compendium of intravenous data with median values.
312,Idazoxan,79944-58-4,79944-58-4,O1C(C2=NCCN2)COc2c1cccc2,HPMRFMKYPGXPEP-UHFFFAOYSA-N,3.3,"Muir NC, Lloyd-Jones JG, Nichols JD, and Clifford JM (1986) The pharmacokinetics after intravenous and oral administration in man of the alpha2-adrenoreceptor antagonist idazoxan (RX781094).  Eur. J. Clin. Pharmacol.  29: 743-745.",VDss calculated from digitized plots.
313,Ifetroban,143443-90-7,143443-90-7,C1C[C@H]2[C@H]([C@H]([C@@H]1O2)Cc1c(cccc1)CCC(=O)O)c1occ(n1)C(=O)NCCCCC,BBPRUNPUJIUXSE-DXKRWKNPSA-N,4.4,"Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, and Barbhaiya RH (2000) Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.  Drug Metab. Dispos. 28: 973-980.",
314,Ifosfamide,3778-73-2,3778-73-2,ClCCN1P(=O)(OCCC1)NCCCl,HOMGKSMUEGBAAB-UHFFFAOYSA-N,0.62,"Corlett SA, Parker D, and Chrystyn H (1995) Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.  Br. J. Clin. Pharmacol. 39: 452-455.  ",
315,Iloprost,78919-13-8,78919-13-8,O[C@H]1[C@@H]([C@@H]2[C@H](C1)C/C(=C\CCCC(=O)O)/C2)/C=C/[C@@H](O)C(CC#CC)C,HIFJCPQKFCZDDL-ACWOEMLNSA-N,0.37,Krause W and Krais T (1986) Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloproset in man.  Eur. J. Clin. Pharmacol. 30: 61-68.  Hildebrand M (1997) Pharmacokinetics and tolerablity of oral iloprost in thromboangitis obliterans patients.  Eur. J. Clin. Pharmacol. 53: 51-56.  Ventavis Product Label.,VDss calculated from digitized plots.  VDss and CL data are the average of the two reports; t1/2 data are only from Hildebrandt. 
316,Imatinib,152459-95-5,152459-95-5,C[C@H](NCc1ccccc1)c1ccccc1,ZYZHMSJNPCYUTB-ZDUSSCGKSA-N,3.9,"Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Sieberling M, Pokorny R, Capdeville R, and Lloyd P (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.  J. Clin. Pharmacol. 44: 158-162. Gleevec Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
317,Imipenem,64221-86-9,64221-86-9,S(C1=C(N2[C@@H]([C@H](C2=O)[C@H](O)C)C1)C(=O)O)CCNC=N,ZSKVGTPCRGIANV-ZXFLCMHBSA-N,0.24,Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy 39(Suppl. 3): 227-235.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.,VDss calculated from C vs t data provided in the reference.
318,Imipramine,50-49-7,50-49-7,CN(CCCN1c2ccccc2CCc2c1cccc2)C,BCGWQEUPMDMJNV-UHFFFAOYSA-N,12,Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.  Clin. Pharmacol. Ther.  43: 400-406.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.   Danon A and Chen Z (1979) Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia.  Clin. Pharmacol. Ther. 25: 316-321.,VDss was calculatd using C vs t data obtained from plots provided in the reference.
319,Imipramine N-oxide,6829-98-7,6829-98-7,[O-][N+]1(CCCN(C)C)c2c(CCc3c1cccc3)cccc2,CADMPLPEJHVVFU-UHFFFAOYSA-N,1.9,Nagy A and Hansen T (1978) The kinetics of imipramine N-oxide in man.  Acta Pharmacol. Toxicol. 42: 58-67.,VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.
320,Indinavir,150378-17-9,150378-17-9,c1ccncc1CN1CCN([C@@H](C1)C(=O)NC(C)(C)C)C[C@H](C[C@H](C(=O)N[C@H]1c2c(cccc2)C[C@H]1O)Cc1ccccc1)O,CBVCZFGXHXORBI-PXQQMZJSSA-N,0.82,"Yeh KC, Stone JA, Carides AD, Rolan P, Woolf E, and Ju WD (1999) Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.  J. Pharm. Sci. 88: 568-573.  Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, and Back DJ (2002) The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.  Br. J. Clin. Pharmacol. 54: 262-268.",VDss and t1/2 were calculated from data obtained by digitization of C vs t plots (group C) provided in the report.
321,Indocyanine Green,3599-32-4,3599-32-4,[Na]OS(=O)(=O)CCCCN1c2c3ccccc3ccc2C(C)(C)/C/1=C/C=C\C=C\C=C/C1=[N+](CCCCS(=O)(=O)[O-])c2c3ccccc3ccc2C1(C)C,BOOGXKILWMKFIU-UHFFFAOYSA-M,0.035,"Vanakoski J, Idanpaan-Heikkila JJ, and Seppala T (1996) Exposure to high environmental temperature in the sauna does not change plasma indocyanine green (ICG) clearance in healthy subjects.  Pharmacol. Toxicol. 78: 94-98.   IC-Green Product Label.",
322,Indomethacin,53-86-1,53-86-1,Clc1ccc(C(=O)n2c3c(c(c2C)CC(=O)[O-])cc(OC)cc3)cc1,CGIGDMFJXJATDK-UHFFFAOYSA-M,0.096,"Yeh KC, Berger ET, Breault GO, and Lei BE (1982) Effect of sustained release on the pharmacokinetic profile of indomethacin in man.  Biopharm. Drug Dispos. 3: 219-230.  Indocin Product Label.",CL and half-life were calculated from C vs t data included in the reference.  VDss was calculated using micro rate constants provided.
323,Indoramin,26844-12-2,26844-12-2,O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1,JXZZEXZZKAWDSP-UHFFFAOYSA-N,4.9,"Norbury HM, Franklin RA, Marrott PK, and Warrington SJ (1983) Pharmacokinetics of intravenous indoramin in middle aged male and female volunteers.  Eur. J. Clin. Pharmacol.  25: 243-246.",Cited fu value at lowest concentration which was relevant to the plasma concentrations.  VDss calclated from digitized plot.
324,Intoplicine,125974-72-3,125974-72-3,Oc1cc2c(c3c4c([nH]c3cc2)c(cnc4NCCCN(C)C)C)cc1,QROONAIPJKQFMC-UHFFFAOYSA-N,11,"Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, and Catimel G (1996) Phase I and pharmacology study of  intoplicine  (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer  patients.  Anti-Cancer Drugs 7: 166-174",
325,Iohexol,66108-95-0,66108-95-0,Ic1c(c(I)c(c(I)c1C(=O)NCC(O)CO)C(=O)NCC(O)CO)C(=O)NCC(O)CO,BAFFCVCLJHSNGO-UHFFFAOYSA-N,0.16,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
326,Iopamidol,60166-93-0,60166-93-0,CC(O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,XQZXYNRDCRIARQ-UHFFFAOYSA-N,0.28,"McKinstry DN, Rommel AJ, and Sugerman AA (1984) Pharmacokinetics, metabolism, and excretion of iopamidol in healthy subjects.  Invest. Radiol. 19: s171-s174.",
327,Iopromide,73334-07-3,73334-07-3,Ic1c(c(I)c(c(I)c1NC(=O)COC)C(=O)NCC(O)CO)C(=O)N,LRDUZSWGOGRJCK-UHFFFAOYSA-N,0.22,"Krause W, Schuhmann-Giampieri G, Staks T, and Kaufmann J (1994) Dose proportionality of iopromide pharmacokinetics and tolerability after IV injection in healthy volunteers.  Eur. J. Clin. Pharmacol.  46: 339-343.  Ultravist Product Label",
328,Iothalamic acid (Iothalamate),2276-90-6,2276-90-6,Ic1c(c(I)c(NC(=O)C)c(I)c1C(=O)O)C(=O)NC,UXIGWFXRQKWHHA-UHFFFAOYSA-N,0.17,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.  Bollerup AC, Hesse B, and Steiness E (1975) Renal handling of iodamide and diatrizoate.  Evidence of active tubular secretion of iodamide.  Eur. J. Clin. Pharmacol. 9: 63-67.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
329,Irbesartan,138402-11-6,138402-11-6,O=C1N(Cc2ccc(c3ccccc3c3nnn[nH]3)cc2)C(=NC21CCCC2)CCCC,YOSHYTLCDANDAN-UHFFFAOYSA-N,0.94,"Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH (1998) Oral bioavailabiity and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.  J. Clin. Pharmacol. 38: 702-707.  Avalide Product Label.",
330,Irinotecan,97682-44-5,97682-44-5,CCC1(O)C(=O)OCc2c1cc1c3nc4ccc(cc4c(c3Cn1c2=O)CC)OC(=O)N1CCC(CC1)N1C([2H])([2H])C([2H])([2H])C(C(C1([2H])[2H])([2H])[2H])([2H])[2H],UWKQSNNFCGGAFS-KPVZPXKXSA-N,3.5,"Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, and Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.  Clin. Pharmacol. Ther. 72: 265-275.  Camptosar Product Label.","No t1/2 reported from Xie, et al."
331,Irofulven,158440-71-2,158440-71-2,O[C@@]1(C2(C(=C3C(=CC(=C3CO)C)C1=O)C)CC2)C,NICJCIQSJJKZAH-AWEZNQCLSA-N,3.1,"Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, and Lokiec F (2006) Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.  Drug Met. Disp. 34: 1918-1926.",
332,Isepamicin,58152-03-7,58152-03-7,CNC1C(O)C(OC2C(O)C(O)C(N)CC2NC(=O)C(O)CN)OCC1(C)OC1OC(CN)C(O)C(O)C1O,WVUXLNQATJQHLA-UHFFFAOYSA-N,0.32,"Nomeir AA, Radwanski E, Cutler D, Affrime M, Christopher D, Korduba C, Batra V, Lin C, and Cayen MN (1997) Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers.  J. Clin. Pharmacol. 37: 1021-1030.  Tod M, Padoin C, and Petitjean O (2000)  Clinical pharmacokinetics and pharmacodynamics of isepamicin.  Clin. Pharmacokinet. 38: 205-223.  ",
333,Isoniazide,54-85-3,54-85-3,N(N)OC(=O)c1ccncc1,LRNFBKZFFSMJIA-UHFFFAOYSA-N,0.82,"Advenier C, St.Aubin A, Gobert C, Houin G, Albengres E, and Tillement JP (1980) Pharmacokinetics of isoniazid in the elderly.  Br. J. Clin. Pharmacol. 10: 167-169.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.","VDss calculated from reported micro rate constants.  CL and t1/2 are for fast acetylators.  CL and t1/2 for slow acetylatore were 3.7 mL/min/kg and 3.1h, respectively."
334,Isoproterenol,7683-59-2,7683-59-2,Cl.Oc1c(O)ccc(c1)C(O)CNC(C)C,IROWCYIEJAOFOW-UHFFFAOYSA-N,1.5,"Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, and Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.  Clin. Pharmacol. Ther. 58: 221-227.  Sager G, Bratlid H, and Little C (1987) Binding of catecholamines to alpha-1 acid glycoprotein, albumin and lipoproteins in human serum.  Biochem. Pharmacol. 36:  3607-3612.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
335,Isosorbide Dinitrate,87-33-2,87-33-2,O=[N+]([O-])O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1,MOYKHGMNXAOIAT-JGWLITMVSA-N,1.9,"Platzer R, Reutemann G, and Galeazzi RL (1982) Pharmacokinetics of intravenous isosorbide dinitrate.  J. Pharmacokinet. Biopharm. 10: 575-586.  Santoni Y, Iliadis A, Cano JP, Luccioni R, and Frances Y (1986) Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.  J. Pharmacokinet. Biopharm. 14: 1-17.  Straehl P and Galeazzi RL (1985) Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin Pharmacol Ther. 38:140-149",
336,Isosorbide-2-Mononitrate,16106-20-0,16106-20-0,[C@H]12[C@H]([C@H](CO1)O[N+](=O)[O-])OC[C@H]2O,YWXYYJSYQOXTPL-VANKVMQKSA-N,0.86,"Straehl P, Galeazzi RL, and Soliva M (1984) Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.  Clin. Pharmacol. Ther.  36: 485-491.",
337,Isosorbide-5-Mononitrate,16051-77-7,16051-77-7,O1[C@H]2[C@H](OC[C@@H]2O)[C@H](O[N+](=O)[O-])C1,YWXYYJSYQOXTPL-SLPGGIOYSA-N,0.70,"Major RM, Taylor T, Chasseaud LF, Darragh A, and Lambe RF (1984) Isosorbide 5-mononitrate kinetics.  Clin. Pharmacol. Ther. 35: 653-659.  Straehl P, Galeazzi RL, and Soliva M (1984) Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.  Clin. Pharmacol. Ther.  36: 485-491.",
338,Isoxicam,34552-84-6,34552-84-6,S1(=O)(=O)N(/C(=C(/O)\Nc2noc(c2)C)/C(=O)c2c1cccc2)C,LXLDMERTXJKSMN-WYMLVPIESA-N,0.19,"Kolle EU and Vollmer KO (1986) Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.  Br. J. Clin. Pharmacol. 22(Suppl 2): 135S-141S.  Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, and Tillement JP (1997) Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.  Pharm. Res. 14: 650-656.",VDss calculated from C vs t data obtained by digitization of plots in the reference.
339,Isradipine,75695-93-1,75695-93-1,o1nc2c(C3C(=C(NC(=C3C(=O)OC)C)C)C(=O)OC(C)C)cccc2n1,HMJIYCCIJYRONP-UHFFFAOYSA-N,1.5,"Christensen HR, Antonsen K, Simonsen K, Lindekar A, Bonde J, Angelo HR, and Kampmann JP (2000) Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?  Pharmacol. Toxicol. 86: 178-182.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.
340,Itraconazole,84625-61-6,84625-61-6,Clc1c([C@]2(O[C@@H](CO2)COc2ccc(N3CCN(CC3)c3ccc(n4c(=O)n(nc4)C(CC)C)cc3)cc2)Cn2ncnc2)ccc(Cl)c1,VHVPQPYKVGDNFY-AVQIMAJZSA-N,7.4,"Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, and Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview.  Mycoses  32(Suppl 1): 67-87.  ",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.
341,IVL745,229627-58-1,229627-58-1,COC1=CC=C(CN(CCC(O)=O)C(=O)CNC(=O)CC2=CC(OC)=C(NC(=O)NC3=C(C)C=CC=C3)C=C2)C=C1OC,WZFRNNCNGXELDE-UHFFFAOYSA-N,0.25,"Rohatagi S, Shah B, Zhang J, Zeng Z, Kirkesseli S, and Jensen BK (2004) Estimating mass balance for inhaled drugs in humans: An example with a VLA-4 antagonist, IVL745.  J. Clin. Pharmacol. 44: 348-358.",
342,Ixabepilone,219989-84-1,219989-84-1,s1cc(nc1C)/C=C(/[C@H]1NC(=O)C[C@H](O)C(C(=O)[C@@H]([C@@H](O)[C@@H](CCC[C@]2(O[C@H]2C1)C)C)C)(C)C)\C,FABUFPQFXZVHFB-PVYNADRNSA-N,11,"Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, and Fojo T (2003)  Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on daily schedule for five days.  J. Clin. Oncol. 21: 1866-1873.",
343,Kanamycin,59-01-8,59-01-8,O([C@@H]1[C@@H](O)[C@H](OC2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CN)[C@@H](N)C[C@H]1N)[C@H]1O[C@@H]([C@@H](O)[C@H](N)[C@H]1O)CO,SBUJHOSQTJFQJX-MMBTZOPTSA-N,0.26,"Kirby WMW, Clarke JT, Libke RD, and Regamey C (1976) Clinical pharmacology of amikacin and kanamycin.  J. Infect. Dis. 134: S312-S315.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.    Clarke JT, Libke RD, Regamey C, and Kirby WMM (1974) Comparative pharmacokinetics of amikacin and kanamycin.  Clin. Pharmacol. Ther. 15: 610-616.","VDss, CL not reported in Clarke paper but could be digitized."
344,Ketamine,6740-88-1,6740-88-1,Clc1c([C@@]2([NH2+]C)CCCCC2=O)cccc1,YQEZLKZALYSWHR-ZDUSSCGKSA-O,2.9,"Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, and Brune K (1993) Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method.  Br. J. Anaesth. 70: 666-671.  Pedraz JL, Lanao JM, Calvo MB, Muriel C, Hernandez-Arbeiza J, and Dominguez-Gil A (1987) Pharmacokinetic and clinical evaluation of ketamine administered by i.v. and epidural routes.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 77-80.  Clements JA and Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man.  Br. J. Anaesth. 53: 27-30.  Dayton PG, Stiller RL, Cook DR, and Perel JM (1983) The binding of ketamine to plasma proteins:  emphasis on human plasma.  Eur. J. Clin. Pharmacol. 24: 825-831.  Hijazi Y and Boulieu R (2002) Protein binding of ketamine and its active metabolites in human serum.  Eur. J. Clin. Pharmacol. 58: 37-40.",Racemate; data were combined.
345,Ketanserin,74050-98-9,74050-98-9,O=c1n(CCN2CCC(C(=O)c3ccc(F)cc3)CC2)c(=O)c2c([nH]1)cccc2,FPCCSQOGAWCVBH-UHFFFAOYSA-N,3.9,"Heykants J, Van Peer A, Woestenborghs R, Gould S, and Mills J (1986) Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 31: 343-350.  Persson B, Pettersson A, and Hedner T (1987) Pharmacokinetics of ketanserin in patients wuith essential hypertension.  Eur. J. Clin. Pharmacol. 32: 259-265.  Trenk D, Mosler A, Kirch W, Meinertz T, and Jahnchen E (1983) Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.  J. Cardiovasc. Pharmacol. 5: 1034-1039.  Barendregt JN, Van Peer A, Van Der Hoeven JG, Van Oene JC, and Tjandra YI (1990) Ketanserin pharmacokinetics in patients with renal failure. Br. J. Clin. Pharmacol. 29: 715-723.  Reimann IW, Okonkwo PO, and Klotz U (1983) Pharmacokinetics of ketanserin in man. Eur. J. Clin. Pharmacol. 25: 73-76.  ",
346,Ketobemidone,469-79-4,469-79-4,O=C(C1(c2cc(O)ccc2)CCN(CC1)C)CC,ALFGKMXHOUSVAD-UHFFFAOYSA-N,0.48,"Bondesson U, Arner S, Anderson P, Boreus LO, and Hartvig P (1980) Clinical pharmacokinetics and oral bioavailability of ketobemidone.  Eur. J. Clin. Pharmacol.  17: 45-50.",Calculated from reported rate micro-constants.
347,Ketoprofen,22071-15-4,22071-15-4,OC(=O)C(c1cccc(c1)C(=O)c1ccccc1)C,DKYWVDODHFEZIM-UHFFFAOYSA-N,0.13,"Debruyne D, de Ligny BH, Ryckelynck JP, Albessard F, and Moulin M (1987) Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion.  Clin. Pharmacokinet. 12: 214-221.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",
348,Ketorolac,74103-06-3,74103-06-3,c1(C(=O)c2n3c(C(C(=O)O)CC3)cc2)c(c(c(c(c1[2H])[2H])[2H])[2H])[2H],OZWKMVRBQXNZKK-RALIUCGRSA-N,0.11,"Jung D, Mroszczak E, and Bynum L (1988) Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 35: 423-425.  Reed MD, Myers CM, and Blumer JL (2001) Influence of midazolam on the protein binding of ketorolac.  Curr. Ther. Res.  62: 558-565.  Mroszczak EJ, Lee FM, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, and Cho DK (1987) Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans.  Drug Metab. Dispos. 15: 618-626",
349,KRN-5500,151276-95-8,151276-95-8,O1[C@H]([C@H](NC(=O)CNC(=O)/C=C/C=C/CCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1Nc1ncnc2nc[nH]c12)[C@@H](O)CO,LQIPDFIUPOYMPR-BKYURJJWSA-N,0.17,"Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, and Clark JW (2003) Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.  Clin. Canc. Res. 9: 5178-5186.",
350,KW-2170,207862-44-0,207862-44-0,Cl.Cl.O=c1c2c3n(nc(c3ccc2NCCCN)CNCCO)c2c1c(O)ccc2O,VPJUIFWAPQSXSP-UHFFFAOYSA-N,12,"Saeki T, Eguchi K, Takashima S, Sugiura T, Hida T, Horikoshi N, Aiba K, Kuwabara T, and Ogawa M (2004) Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors.  Cancer Chemother. Pharmacol.  54: 459-468.",
351,Labetalol,36894-69-6,36894-69-6,OC(CNC(CCc1ccccc1)C)c1cc(c(O)cc1)C(=O)N,SGUAFYQXFOLMHL-UHFFFAOYSA-N,4.8,"Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol. 43: 563-570.  Martin LE, Hopkins R, and Bland R (1976) Metabolism of labetalol by animals and man.  Br. J. Clin. Pharmacol. (Supp): 695-710",
352,Lamifiban,144412-49-7,144412-49-7,O(C1CCN(CC1)C(=O)[C@@H](NC(=O)c1ccc(cc1)C(=N)N)Cc1ccc(O)cc1)CC(=O)O,FPKOGTAFKSLZLD-FQEVSTJZSA-N,0.29,"Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, and Chou RC (1996) Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggergeation inhibitor.  J. Pharm. Pharmacol.  48: 573-577.",
353,Lamivudine,134678-17-4,134678-17-4,Nc1ccn(c(=O)n1)[C@@H]1CS[C@@H](O1)CO,JTEGQNOMFQHVDC-NKWVEPMBSA-N,1.3,"Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, and Hussey EK (1995) Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35: 1174-1180.  Takubo T, Hirayama S, Moriya T, Minamide Y, Kato T, Nakamura R, and Kinami J (1997) Studies on the metabolic fate of lamivudine (II): tissue distribution, transfer into fetus and milk, plasma protein binding and distribution to erythrocytes of lamivudine in rats.  Yakubutsu Dotai 12: 92-101.",
354,Lansoprazole,103577-45-3,103577-45-3,S(=O)(c1nc2c([nH]1)cccc2)Cc1nccc(OCC(F)(F)F)c1C,MJIHNNLFOKEZEW-UHFFFAOYSA-N,0.28,"Gerloff J, Mignot A, Barth H, and Heintze K (1996) Pharmacokinetics and absolute bioavailability of lansoprazole.  Eur. J. Clin. Pharmacol. 50: 293-297.  Freston JW, Pilmer BL, Chiu YL, Wang Q, Stolle JC, Griffin JS, and Lee CQ (2004) Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.  Alimentary Pharmacol. Ther. 19: 1111-1122.  Karol MD, Machinist JM, and Cavanaugh JM (1995) Pharmacokinetics of lansoprazole in hemodialysis patients.  J. Clin. Pharmacol.  35: 815-820.",
355,Letrozole,112809-51-5,112809-51-5,c1cc(ccc1C#N)C(c2ccc(cc2)C#N)n3cncn3,HPJKCIUCZWXJDR-UHFFFAOYSA-N,1.9,"Sioufi A, Gauducheau N, Pineau V, Marfil F, Jaouen A, Cardot JM, Godbillon J, Czendlik C, Howald H, Pfister C, and Vreeland F (1997) Absolute bioavailability of letrozole in healthy postmenopausal women.  Biopharm Drug Dispos. 18: 779-89.   Colussi DM, Parisot CY, and Lefevre GY (1998) Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor.  J. Clin. Pharmacol. 38: 727",
356,Leuprolide,53714-56-0,53714-56-0,C(=O)([C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c2c([nH]c1)cccc2)NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1nc[nH]c1)CO)Cc1ccc(cc1)O)CC(C)C)CC(C)C)CCCNC(=N)N)N1[C@@H](CCC1)C(=O)NCC,GFIJNRVAKGFPGQ-LIJARHBVSA-N,0.38,"Sennello LT, Finley RA, Chu SY, Jagst C, Max D, Rollins DE, and Tolman KGJ (1986) Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.  Pharm. Sci. 75: 158-160.  Eligard Product Label",
357,Levodopa,59-92-7,59-92-7,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,WTDRDQBEARUVNC-LURJTMIESA-N,1.7,"Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, and George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.  Br. J. Clin. Pharmacol. 28: 61-69.  Rizzo V, Memmi M, Moratti R, Melzi d'Eril G, and Perucca E (1996) Concentrations of L-dopa in plasma and plasma ultrafiltrates.  J. Pharm. Biomed. Anal. 14: 1043-1046",
358,Levofloxacin,100986-85-4,100986-85-4,Fc1c(N2CCN(CC2)C)c2OC[C@@H](n3c2c(c(=O)c(c3)C(=O)O)c1)C,GSDSWSVVBLHKDQ-JTQLQIEISA-N,1.2,"Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, and Pea F (2003) Pharmacokinetic aspects of levofloxacin 500mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.  J. Antimic. Chemother. 51: 101-106.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 41: 741-750.",
359,Levomepromazine,60-99-1,60-99-1,S1c2c(N(CC(CN(C)C)C)c3c1cccc3)ccc(OC)c2,JOZGNVRNTPTRTB-UHFFFAOYSA-N,12,"Bagli M, Hoflich G, Rao, ML, Langer M, Baumann P, Kolbinger M, Barlage U, Kasper S, and Moller HJ (1995) Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.  Int. J. Clin. Pharmacol. Ther. 33: 646-652.",
360,Levonorgestrel,797-63-7,797-63-7,[C@]12(C([C@H]3C([C@@H]4C(=CC(=O)CC4)CC3)CC1)CC[C@@]2(C#C)O)CC,WWYNJERNGUHSAO-GTVOAPJKSA-N,1.5,"Stead RJ, Grimmer SFM, Rogers SM, Back DJ, Orme MLE, Hodson ME, and Batten JC (1987) Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.  Thorax 42: 59-64.  Aviane Product Label.",
361,Levosimendan,141505-33-1,141505-33-1,O=C1NN=C(c2ccc(NN=C(C#N)C#N)cc2)[C@@H](C1)C,WHXMKTBCFHIYNQ-SECBINFHSA-N,0.24,"Sundberg S, Antila S, Scheinin H, Hayha M, Virtanen M, and Lehtonen L (1998) Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.  Int. J. Clin. Pharmacol. Ther. 36: 629-635.  Lilleberg J, Antila S, Karlsson M, Mieminen MS, and Pentkainen PJ (1994) Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.  Clin. Pharmacol. Ther. 56: 554-563.  Wikberg T, Korkolainen T, and Karlsson M (1996) Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatigraphy.  Chirality 8: 511-517.",
362,Lidocaine,137-58-6,137-58-6,O=C(Nc1c(cccc1C)C)CN(CC)CC,NNJVILVZKWQKPM-UHFFFAOYSA-N,1.8,"Bauer LA, Brown T, Gilbaldi M, Hudson L, Nelson S, Raisys V, and Shea JP (1982) Influence of long-term infusions on lidocaine kinetics.  Clin. Pharmacol. Ther. 31: 433-437.  Bennett PN, Aarons LJ, Bending MR, Steiner JA, and Rowland M (1982) Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependecy studies in man.  J. Pharmacokinet. Biopharm. 10: 265-281.  Grossman SH, Davis D, Kitchell BB, Shand DG, and Routledge PA (1982) Diazepam and lidocaine plasma protein binding in renal disease.  Clin. Pharmacol. Ther. 31: 350-357.  Barry M, Keeling PW, Weir D, and Feely J (1990) Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine.  Clin. Pharmacol. Ther.  47: 366-370.",
363,Lincomycin,154-21-2,154-21-2,[C@H]1([C@H](NC(=O)C2C[C@H](CN2C)CCC)[C@@H](C)O)O[C@@H]([C@@H]([C@H]([C@H]1O)O)O)SC,OJMMVQQUTAEWLP-ISVUEQNNSA-N,1.0,Gwilt PR and Smith RB (1986) Protein binding and pharmacokinetics of incomycin following intravenous administration of high doses.  J. Clin. Pharmacol.  26: 87-90.,Averaged values over three doses.  Saturable protein binding reported.
364,Linezolid,165800-03-3,165800-03-3,Fc1c(N2CCOCC2)ccc(N2C(=O)O[C@H](C2)CNC(=O)C)c1,TYZROVQLWOKYKF-ZDUSSCGKSA-N,0.58,"Stalker DJ, Jungbluth GL, Hopkins NK, and Batts DH (2003) Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.  J. Antimic. Chemother. 51: 1239-1246.  Zyvox Product Label.",
365,Lisinopril,76547-98-3,76547-98-3,O=C(N1[C@@H](CCC1)C(=O)O)[C@@H](N[C@H](C(=O)O)CCc1ccccc1)CCCCN,RLAWWYSOJDYHDC-BZSNNMDCSA-N,0.89,"Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, and Junggren IL (1989) Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers.  Biopharm. Drug Dispos. 10: 397-409.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482. ",VDss calculated using C vs t data obtained by digitization of the plots provided in the reference.  Dose levels averaged.
366,Lithium Carbonate,554-13-2,554-13-2,OC(=O)[O-].[Li+],HQRPHMAXFVUBJX-UHFFFAOYSA-M,0.62,"Waring WS, Webb DJ, Maxwell SR (2002) Lithium carbonate as a potential pharmacological vehicle: intravenous kinetics
of single-dose administration in healthy subjects.  Eur. J. Clin. Pharmacol. 58: 431-434.",
367,Lorazepam,846-49-1,846-49-1,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2N=C1O,DIWRORZWFLOCLC-UHFFFAOYSA-N,1.3,"Wermeling DPH, Miller JL, Archer SM, Manaligod JM, and Rudy AC (2001) Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J. Clin. Pharmacol. 41: 1225-1231.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson, GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.  ",
368,Lorcainide,59729-31-6,59729-31-6,Clc1ccc(N(C2CCN(CC2)C(C)C)C(=O)Cc2ccccc2)cc1,XHOJAWVAWFHGHL-UHFFFAOYSA-N,6.6,"Klotz U, Mueller-Seydlitz P, and Heimburg P (1979) Disposition and antiarrythmic effect of lorcainide.  Int. J. Clin. Pharmacol. Biopharm. 17: 152-158.  Klotz U, Mueller-Seydlitz P, and Heimburg P (1978) Pharmacokinetics of lorcainide in man:  a new antiarrhythmic agent.  Clin. Pharmacokinet. 3: 407-418.",
369,Lormetazepam,848-75-9,848-75-9,Clc1c(C2=NC(O)C(=O)N(c3c2cc(Cl)cc3)C)cccc1,FJIKWRGCXUCUIG-UHFFFAOYSA-N,1.6,"Humpel M, Illi V, Milius W, Wendt H, and Kurowski M (1979) The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 4: 237-243.",Pharmacokinetic parameters were calculated from C vs t obtained by digitization of the plot included in the reference.
370,Losartan,114798-26-4,114798-26-4,Clc1nc(n(c1CO)Cc1ccc(c2c(c3nnn[nH]3)cccc2)cc1)CCCC,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,0.37,"Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 58: 641-649.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",
371,Lovastatin (acid),75225-51-3,75225-51-3,[Na+].O([C@@H]1[C@@H]2[C@H]([C@H](C=CC2=C[C@@H](C1)C)C)CC[C@@H](O)C[C@@H](O)CC(=O)[O-])C(=O)[C@H](CC)C,LXZBFUBRYYVRQJ-AXHZAXLDSA-M,0.87,"Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S (1989) The physiological disposition of lovastatin.  Drug Metab Dispos. 17: 166-173.",Pharmacokinetic paramaters were calculated using C vs t data obtained by digitization of the plot provided in the reference.
372,Loxiglumide,107097-80-3,107097-80-3,Clc1cc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)ccc1Cl,QNQZBKQEIFTHFZ-UHFFFAOYSA-N,0.24,"Setnikar I, Chiste R, Makovec F, Rovati LC, and Warrington SJ (1988) Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.  Arz. Forsch. 38: 716-720.",VDss was calculated from rate micro-contants provided in the reference.
373,Maprotiline,10262-69-8,10262-69-8,CNCCCC12CCC(c3c1cccc3)c1c2cccc1,QSLMDECMDJKHMQ-UHFFFAOYSA-N,45,"Maguire KP, Norman TR, Burrows GD, and Scoggins BA (1980) An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.  Eur. J. Clin. Pharmacol.18: 249-254.  Lynn K, Braithwaite R, Dawling S, and Rosser R (1981) Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis.  Eur. J. Clin. Pharmacol. 19: 73-77.","VDss calculated from reported compartmental paramaters included in the reference by Maguire, et al."
374,Maxipost,187523-35-9,187523-35-9,Clc1cc([C@@]2(F)c3c(NC2=O)cc(cc3)C(F)(F)F)c(OC)cc1,ULYONBAOIMCNEH-HNNXBMFYSA-N,10,"Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans.  Drug Metab. Dispos. 33: 83-93.  Krishna R, Yao M, Kaczor D, Vachharajani N, and Srinivas NR. (2001) In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum.  Biopharm. Drug Dispos. 22: 41-44.",
375,Mebendazole,31431-39-7,31431-39-7,O=C(c1cc2nc([nH]c2cc1)NC(=O)OC)c1ccccc1,OPXLLQIJSORQAM-UHFFFAOYSA-N,1.2,"Dawson M, Braithwaite PA, Roberts MS, Watson TR (1985) The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.  Br. J. Clin. Pharmacol. 19: 79-86.",
376,Medroxalol,56290-94-9,56290-94-9,O1c2c(OC1)ccc(c2)CCC(NCC(O)c1cc(c(O)cc1)C(=O)N)C,MPQWSYJGFLADEW-UHFFFAOYSA-N,7.9,"Haegele KD, Jaillion P, Cheymol G, Alken RG, Schechter PJ, and Koch-Weser J (1983) Kinetics of medroxalol, a beta and alpha-adrenoceptor antagonist.  Clin. Pharmacol. Ther.34: 785-791.  Keeley FJ, Weiner DL, and Okerholm RA (1983) Bioavailability of medroxalol in man.  Biopharm. Drug Dispos.  4: 305-309.",Calculations were done using data from digitization of the C vs t plot in the reported reference by Keeley et al. and from C vs t data listed in Haegele et al..
377,Melagatran,159776-70-2,159776-70-2,O=C(N1[C@@H](CC1)C(=O)NCc1ccc(cc1)C(=N)N)[C@H](NCC(=O)O)C1CCCCC1,DKWNMCUOEDMMIN-PKOBYXMFSA-N,0.23,"Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.  Drug Metab. Dispos. 31: 294-305.",
378,Meloxicam,71125-38-7,71125-38-7,Cc1cnc(s1)NC(=O)C1=C(c2ccccc2S(=O)(=O)N1)O,INYLJXGSWGWXFU-UHFFFAOYSA-N,0.15,"Narjes H, Turck D, Busch U, Heinzel G, and Nehmiz G (1996) Pharmacokinetics and tolerability of meloxicam after i.m. administration.  Br. J. Clin. Pharmacol. 41: 135-139.  Busch U, Heinzel G, and Narjes H (1995) The effect of cholestyramine on the pharmaciokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.  Eur. J. Clin. Pharmacol. 48: 269-272.   Turck D, Busch U, Heinzel G, and Narjes H (1997) Clinical pharmacokinetics of meloxicam.  Arz. Forsch. 47: 253-258. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, and Kummer M (1995) Meloxicam. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab. Dispos. 23: 1206-1213.  Tuerck D, Schwarz A, Hoeffler D, Narjes HH, Nehmiz G, and Heinzel G (1996) Pharmacokinetics of meloxicam in patients with end-stage renal failure on hemodialysis. A comparison with healthy volunteers.  Eur. J. Clin. Pharmacol.  51: 309-313.",
379,Melperone,3575-80-2,3575-80-2,Fc1ccc(C(=O)CCCN2CCC(CC2)C)cc1,DKMFBWQBDIGMHM-UHFFFAOYSA-N,14,"Borgstrom L, Larsson H, and Molander L (1982) Pharmacokinetics of parenteral and oral melperone in man.  Eur. J. Clin. Pharmacol.  23: 173-176.",Data from 20 mg dose.  All pharmacokinetic parameters calculated from digitized C vs t plot in the reported reference.
380,Melphalan,148-82-3,148-82-3,N(CCCl)(CCCl)C.C(=O)([C@H](Cc1ccccc1)N)O,FLTVLZYQDKQTKG-QRPNPIFTSA-N,0.48,"Woodhouse KW, Hamilton P, Lennard A, and Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dosing regimen.  Eur. J. Clin. Pharmacol. 24: 283-285.  Hersh MR, Ludden TM, Kuhn JG, and Knight WA (1983) Pharmacokinetics of high dose melphalan.  Invest. New Drugs. 1: 331-334.  Gera S, Musch E, Osterheld HKO, and Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.  Canc. Chemother. Pharmacol. 23: 76-80.  Grieg NH, Sweeney DJ, and Rapoport SI (1987) Melphalan concentration dependent protein binding in healthy humans and rats.  Eur. J. Clin. Pharmacol. 32: 179-185.",
381,MEN-10755,169317-77-5,169317-77-5,Cl.O([C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)CO)[C@@H]1O[C@H]([C@@H](O[C@@H]2O[C@H]([C@@H](O)[C@@H](N)C2)C)[C@@H](O)C1)C,BSRQHWFOFMAZRL-BODGVHBXSA-N,2.4,"Bos AME, deVries EGE, Dombernovsky P, Aamdal S, Uges DRA, Schrijvers D, Wanders J, Roelvink MWJ, Hanauske AR, Bortini S, Capriati A, Crea AEG, and Vermorken JB (2001) Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase 1 studies in adults with advanced solid tumors.  Canc. Chemother. Pharmacol. 48: 361-369.",
382,Meperidine,57-42-1,57-42-1,O(C(=O)C1(c2ccccc2)CCN(CC1)C)CC,XADCESSVHJOZHK-UHFFFAOYSA-N,2.3,"Chan K, Tse J, Jennings F, and Orme ML (1987) Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction.  J. Clin. Pharmacol. 27: 516-22.  Verbeek RK, Cardinal JA, and Wallace SM (1984) Effect of age and sex on the plasma binding of acidic and basic drugs.  Eur. J. Clin. Pharmacol. 27: 91-97.",VDss calculated from C vs t data provided in the reference.
383,Mepivacaine,96-88-8,96-88-8,CN1CCCCC1C(=O)Nc1c(C)cccc1C,INWLQCZOYSRPNW-UHFFFAOYSA-N,0.95,"Burm AGL, Cohen IMC, van Kleef JW, Vletter AA, Olieman W, and Groen K (1997) Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers.  Anesth. Analg. 84: 85-89.  Allgayer H, Zahringer J, Bach P, and Bircher J (1984) Lack of effect of haemodialysis on mebendazole kinetics: studies in a patient with echinococcosis and renal failure.  Eur. J. Clin. Pharmacol. 27: 243-245.",Average of two enantiomers.
384,Meprobamate,57-53-4,57-53-4,O(CC(COC(=O)N)(CCC)C)C(=O)N,NPPQSCRMBWNHMW-UHFFFAOYSA-N,0.70,"Held H and Oldershausen HF (1969) Zur pharmakokinetik von meprobamat bei chronischen hepatopathien und arzneimittelsucht. Klin. Wschr. 47: 78-80.  Douglas JF, Bradshaw WH, Ludwig BJ, and Powers D (1964) Interaction of plasma protein with related 1,3-propanediol dicarbamates.  Biochem. Pharmacol. 13: 537-539.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
385,Meptazinol,54340-58-8,54340-58-8,CN1CC(c2cc(O)ccc2)(CC)CCCC1,JLICHNCFTLFZJN-UHFFFAOYSA-N,3.3,"Norbury HM, Franklin RA, and Graham DF (1983) Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers.  Eur. J. Clin. Pharmacol. 25: 77-80.  Gepts E, Sonck WA, Camu F, and Vercruysse A (1987) Pharmacokinetics of intravenously administered meptazinol during general anesthesia in man.  Eur. J. Anaesth. 4: 35-43.  Franklin RA (1988) The clinical pharmacokinetics and metabolism of the analgesic meptazinol.  Xenobiotica 18: 105-112.","VDss was calculated from C vs t data provided in the reference by Norbury, et al."
386,"Mercaptopurine, 6-",50-44-2,50-44-2,S=C1NCN=C2N=CN=C12,CUZDKDJIGVUXCI-UHFFFAOYSA-N,1.0,"Coffey JJ, White CA, Lesk AB, Rogers WI, and Seppick AA (1972) Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine *NSC 755) in cancer patients.  Cancer Res. 32: 1283-1289.  Esposito M, Rosso R, and Santi L (1974)  Plasma protein binding of antineoplastic drugs in rats and humans.    IRCS Library Compendium  2: 1180.",Pharmacokinetic parameters were calculated using the mean C vs t values from three study subjects receiving intravenous 500 mg/m2. 
387,Meropenem,96036-03-2,96036-03-2,S(C1=C(N2[C@@H]([C@H](C2=O)[C@H](O)C)[C@H]1C)C(=O)O)[C@H]1C[C@H](NC1)C(=O)N(C)C,DMJNNHOOLUXYBV-PQTSNVLCSA-N,0.30,"Burman LA, Nilsson-Ehle I, Hutchinson M, Haworth SJ, and Norrby SR (1991) Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.  J. Antimic. Chemother. 27: 219-224.  Leroy A, Fillastre JP, Etienne I, Borsa-Lebas F, and Humbert G (1992) Pharmacokinetics of meropenem in subjects with renal insufficiency.  Eur. J. Clin. Pharmacol. 42: 535-538.  Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, and Humbert G (1992) Pharmacokinetics of meropenem (ICI 194660) and its metabolite (ICI 213689) in healthy subjects and in patients with renal impairment.  Antimic. Agents Chemother. 36: 2794-2798.  Sumita Y, Nouda H, Tada E, Kohzuki T, Kato M, Okuda T, and Fukasawa M (1992) Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals.  Chemotherapy 40(Suppl. 1): 123-131.",
388,Metformin,657-24-9,657-24-9,N(C(=N)NC(=N)N)(C)C,XZWYZXLIPXDOLR-UHFFFAOYSA-N,0.64,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man.  Eur. J. Clin. Pharmacol. 16: 195-202.",VDss calculated from reported rate micro-constants.
389,Methadone,76-99-3,76-99-3,C(c1ccccc1)(c1ccccc1)(C(=O)CC)CC(N(C([2H])([2H])[2H])C)C,USSIQXCVUWKGNF-HPRDVNIFSA-N,4.4,"Nilsson MI, Gronbladh L, Widerlov E, and Anggard E (1983) Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.  Eur. J. Clin. Pharmacol. 25: 497-501.  Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, and Sjoegren P (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients.  Ther. Drug Monit. 18: 221-227.  Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.  Clin. Pharmacokinet. 1: 219-230. ",
390,Methamphetamine,537-46-2,537-46-2,N([C@H](Cc1ccccc1)C)C,MYWUZJCMWCOHBA-VIFPVBQESA-N,4.3,"Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, and Jones RT (2003) The bioavailability of intranasal and smoked methamphetamine.  Clin. Pharmacol. Ther. 74: 475-486.  Cook CE, Jeffcoat AR, Hill JM, Pugh DE,  Patetta PK, Sadler BM, White WR, and Perez-Reyes M (1993) Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.  Drug Metab. Dispos. 21: 717-723.  Mendelson J, Jones RT, Upton R, and Jacob P (1995) Methamphetamine and ethanol interactions in humans.  Clin. Pharmacol. Ther. 57: 559-568.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",Values for individual stereoisomers were averaged.
391,Methicillin,61-32-5,61-32-5,S1[C@H]2N([C@H](C1(C)C)C(=O)O)C(=O)[C@H]2NC(=O)c1c(OC)cccc1OC,RJQXTJLFIWVMTO-TYNCELHUSA-N,0.32,"Yaffe SJ, Gerbacht LM, Mosovich LL, Mattar ME, Danish M, and Jusko WJ (1977) Pharmacokinetics of methicillin in patients with cystic fibrosis.  J. Infect. Dis. 135: 828-831.  Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Ag. Chemother. 42-48.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.  Baur G, Kurz H, Trunk H (1977) Alteration of  protein binding during storage of human plasma preparations.  Anaesthesist 26: 148-150.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  "
392,Methimazole,60-56-0,60-56-0,Cn1cc[nH]c1=S,PMRYVIKBURPHAH-UHFFFAOYSA-N,0.86,Hengstmann JH and Hohn H (1985) Pharmacokinetics of methimazole in humans.  Klin. Wochenschr. 63: 1212-1217.,
393,Methohexital,151-83-7,151-83-7,O=C1N(C(=O)NC(=O)C1(C(C#CCC)C)CC=C)C,NZXKDOXHBHYTKP-UHFFFAOYSA-N,1.1,"Breimer DD (1976) Pharmacokinetics of methohexitone following intravenous infusion in humans.  Br. J. Anaesth. 48: 643-649.  Brand L, Mark LC, Snell MM, Vrindten P, and Dayton PG (1963) Physiologic disposition of methohexital in man.  Anesthesiol. 24: 331-335.",
394,Methotrexate,59-05-2,59-05-2,c1(nc(nc2c1nc(cn2)CN(C)c1ccc(cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)N,FBOZXECLQNJBKD-ZDUSSCGKSA-N,0.43,"Bore P, Bruno R, Lena N, Favre R, and Cano JP (1987) Methotrexate and 7-hydroxymethotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate.  Eur. J. Canc. Clin. Oncol. 23: 1385-1390.  Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, and Furst DE (1989) Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.  J. Pharm. Sci. 78: 165-171.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180.",
395,Methyldopa,555-30-6,555-30-6,OC(=O)[C@](Cc1ccc(c(c1)O)O)(N)C,CJCSPKMFHVPWAR-JTQLQIEISA-N,0.69,"Skerjanec A, Campbell NRC, Robertson S, and Tam YK (1995) Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects.  J. Clin. Pharmacol. 35: 275-280.  Stenbaek O, Myhre E, Rugstag HE, Arnold E, and Hansen T (1977) Pharmacokinetics of methyldopa in healthy man.  Eur. J. Clin. Pharmacol. 12: 117-123.  Myhre E, Rugstad HE, and Hansen T (1982) Clinical pharmacokinetics of methyldopa.  Clin. Pharmacokinet. 7: 221-233.",
396,Methylnaltrexone,73232-52-7,73232-52-7,[Br-].O1[C@@H]2[C@@]34[C@](O)([C@H]([N+](CC4)(CC4CC4)C)Cc4c3c1c(O)cc4)CCC2=O,IFGIYSGOEZJNBE-KNLJMPJLSA-N,2.6,"Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, Israel RJ, and Moss J (2005) Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.  J. Clin. Pharmacol.  45: 538-546.",
397,"Methylnortestosterone, 7α-, 19-",3764-87-2,3764-87-2,OC1C2(C(C3C(CC2)C2C(=CC(=O)CC2)C[C@H]3C)CC1)C,YSGQGNQWBLYHPE-BRIGUCEYSA-N,0.80,"Kumar N, Suvisaari J, Tsong YY, Aguillaume C, Bardin CW, Lahteenmaki P, and Sundaram K (1997) Pharmacokinetics of 7a-methyl-19-nortestosterone in men and cynomolgus monkeys.  J. Androl. 18: 352-358.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
398,Methylphenidate,113-45-1,113-45-1,O(C(=O)C(C1NCCCC1)c1ccccc1)C,DUGOZIWVEXMGBE-UHFFFAOYSA-N,2.2,"Srinivas NR, Hubbard JW, Korchinski ED, and Midha KK (1993) Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.  Pharm. Res. 10: 14-21.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",Data for individual stereoisomers were averaged.
399,Methylprednisolone,83-43-2,83-43-2,O[C@]1([C@@]2([C@H]([C@H]3[C@@H]([C@@]4(C(=CC(=O)C=C4)[C@H](C3)C)C)[C@@H](O)C2)CC1)C)C(=O)CO,VHRSUDSXCMQTMA-PJHHCJLFSA-N,1.2,"Booker BM, Magee MH, Blum RA, Lates CD, and Jusko WJ (2002)  Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers.  Clin. Pharmacol. Ther. 72: 370-382.",
400,"Methylthiomethylpaclitaxel, 7-",160237-25-2,160237-25-2,S(CO[C@@H]1[C@@]2([C@@H]([C@@]3(OC(=O)C)[C@H](OC3)C1)[C@H](OC(=O)c1ccccc1)[C@@]1(O)C(C(=C([C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C1)C)[C@@H](OC(=O)C)C2=O)(C)C)C)C,UBJAHGAUPNGZFF-XOVTVWCYSA-N,11,"Sun W, Stevenson JP, Gallagher ML, Vaughn D, Hahn SM, Haller DG, Cohen M, Kopit J, Gallant G, and O'Dwyer PJ (2003) Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.  Clin. Canc. Res. 9: 5221-5227.",
401,Metoclopramide,364-62-5,364-62-5,O=C(NCCN(CC)CC)c1cc(Cl)c(N)cc1OC,TTWJBBZEZQICBI-UHFFFAOYSA-N,3.2,"Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, and Taburet AM (1991) Pharmacokinetics of metoclopramide in patients with liver cirrhosis.  Br. J. Clin. Pharmacol. 31: 185-187.  Webb D, Buss DC, Fifield R, Bateman DN, and Routledge PA  The plasma protein binding of metoclopramide in health and renal disease. Br. J. Clin. Pharmacol. 21: 334-336.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
402,Metocurine,5152-30-7,5152-30-7,O=C(Nc1ccc(c2ccccc2)cc1)CC(=O)C,RFNJJAXRANPLRG-UHFFFAOYSA-N,0.40,"Brotherton WP and Matteo RS (1981) Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure.  Anesthesiology 55: 273-276.  Avram MJ, Shanks CA, Henthorn TK, Ronai AK, Kinzer J, and Wilkinson CJ (1987) Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass.  Clin. Pharmacl. Ther. 42: 576-581.",VDss calculated from micro rate constants provided in the reference.
403,Metolazone,17560-51-9,17560-51-9,c1c(c(cc2c1NC(N(C2=O)c1c(cccc1)C)C)S(=O)(=O)N)Cl,AQCHWTWZEMGIFD-UHFFFAOYSA-N,1.6,"Tilstone WJ, Dargie H, Dargie EN, Morgan HC, and Kennedy AC (1974) Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure.  Clin. Pharmacol. Ther. 16: 322-329.","C vs t data was for total radioactivity, justified in the reference that radioactivity in plasma was due to just unchanged drug."
404,Metoprolol,51384-51-1,51384-51-1,CC(C)NCC(COc1ccc(cc1)CCOC)O,IUBSYMUCCVWXPE-UHFFFAOYSA-N,3.1,"Jordo L, Attman PO, Aurell M, Johansson L, Johnsson G, and Regardh CG (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.  Clin. Pharmacokinet. 5: 169-180.  Schaaf LJ, Campbell SC, Mayersohn MB, Vagedes T, and Perrier DG (1987) Influence of smoking and gender on the disposition kinetics of metoprolol.  Eur. J. Clin. Pharmacol. 33: 355-361.  Richard J, Cardot JM, and Godbillon J (1994) Inter-and intra-subject variability of metoprolol kinetics after intravenous administration.  Eur. J. Drug metab. Pharmacokinet. 19: 157-162.  Johnsson G and Regardh CG (1976) Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.  Clin. Pharmacokinet. 1: 233-263.",VDss calculated using micro rate constants reported in the reference by Richard et al.  
405,Metrizoate,1949-45-7,1949-45-7,O=C1CC2C(CCCC2)CC1,LGVJRKCQQHOWAU-UHFFFAOYSA-N,0.17,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
406,Metronidazole,443-48-1,443-48-1,Cc1ncc(n1C(C)O)[N+](=O)[O-],VUANVTIMGVANQP-UHFFFAOYSA-N,0.40,"Sanvordekar DR, Chien YW, Lin TK, Lambert HJ (1975) Binding of metronidaole and its derivatives to plasma proteins: an assessment of drug binding phenomenon.  J. Pharm Sci. 64: 1797-1803.   Bergan T and Thorsteinsson SB (1986) Pharmacokinetics of metronidazole and its metabolites in reduced renal function.  Chemotherapy 32: 305-318.",Plasma concentraions determined using a bioassay.
407,Mexiletine,31828-71-4,31828-71-4,O(c1c(cccc1C)C)CC(N)C,VLPIATFUUWWMKC-UHFFFAOYSA-N,5.9,"Pentikainen PJ, Hietakorpi S, Halinen MO, and Lampinen LM (1986) Cirrhosis of the liver markedly impairs the elimination of mexiletine.  Eur. J. Clin. Pharmacol. 30: 83-88.  McErlane KM, Igwemezie L., Kerr CR (1987) Stereoselective serum protein binding of mexiletine enantiomers in man.  Res. Comm. Chem. Path. Pharmacol. 56: 141-144.",Average of two enantiomers.
408,Mezlocillin,51481-65-3,51481-65-3,N12[C@@H]([C@@H](C1=O)NC(=O)[C@@H](NC(=O)N1C(=O)N(S(=O)(=O)C)CC1)c1ccccc1)SC([C@H]2C(=O)O[Na])(C)C,GTGQRSIMEUWHPA-BEDQTAKTSA-M,0.09,"Modr Z, Dvoracek K, Janku I, and Krebs V (1982) Beitrag zur pharmakokinetik und dosierung von mezlocillin bei intravenoser infusion. Infection 10(Supp 3): s190-s195.   Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated using micro rate constants reported in the reference.  
409,Mibefradil,116644-53-2,116644-53-2,Fc1cc2c([C@@H]([C@](OC(=O)COC)(CC2)CCN(CCCc2nc3c([nH]2)cccc3)C)C(C)C)cc1,HBNPJJILLOYFJU-VMPREFPWSA-N,3.1,"Welker HA (1998) Single- and multiple-dse mibefradil pharmacokinetics in normal and hypertensive subjects.  J. Pharm. Pharmacol. 50: 983-987.  Welker HA, Wiltshire H, and Bullingham R (1998) Clinical pharmacokinetics of mibefradil. Clin. Pharmacokinet. 35: 405-423.",
410,Micafungin,235114-32-6,235114-32-6,S(=O)(=O)(Oc1cc([C@H](O)[C@@H](O)[C@@H]2NC(=O)[C@H]3N(C[C@H](O)C3)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c3ccc(cc3)c3noc(c3)c3ccc(OCCCCC)cc3)C[C@@H](O)[C@@H](O)NC(=O)[C@H]3N(C[C@@H]([C@@H]3O)C)C(=O)[C@@H](NC2=O)[C@H](O)CC(=O)N)[C@@H](O)C)ccc1O)O,PIEUQSKUWLMALL-NFGJWQNFSA-N,0.21,"Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, and Bekersky I (2005) Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.  J. Clin. Pharmacol. 45: 1018-1024.  Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, and Bekersky I (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol.  45: 1145-1152.",
411,Midazolam,59467-70-8,59467-70-8,C(=C\C(=O)O)\C(=O)O.c12c(C(=NCc3n1c(nc3)C)c1c(c(c(c(c1[2H])[2H])[2H])[2H])F)cc(cc2)Cl,XYGVIBXOJOOCFR-BRZXBJTJSA-N,1.1,"Heizmann P, Eckert M, and Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam in man.  Br. J. Clin. Pharmacol. 16: 43s-49s.  Pentikainen PJ, Valisalmi L, Himberg JJ, and Crevoisier C (1989) Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.  J. Clin. Pharmacol. 29: 272-277.  ",
412,Miglitol,72432-03-2,72432-03-2,[C@@H]1(C(N(CC(C1O)O)CCO)CO)O,IBAQFPQHRJAVAV-DJAIAVIWSA-N,0.28,"Ahr AH, Boberg M, Brendel E, Krouse HP, and Steinke W (1997) Pharmacokinetics of miglitol.  Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.  Arz. Forsch. 47: 734-745.",Pharmacokinetic parameters were calculated from plasma total radioactivity measurements after administration of radiolabelled miglitol.  Analysis of samples showed that miglitol parent drug was the only drug-related entity.
413,Milrinone,78415-72-2,78415-72-2,O=C(C(=O)c1ccc(C(C)(C)C)cc1)OCC,VQDPLASXAHWKJX-UHFFFAOYSA-N,0.25,"Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C, and Edelson J (1984) Oral and intravenous pharmacokinetics of milrinone in human volunteers.  J. Pharm. Sci. 73: 1438-1441.  Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, and Greenslade D (1995) Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.  J. Pharm. Pharmacol. 47: 651-655.",
414,Minocycline,10118-90-8,10118-90-8,O[C@@]12[C@@H](C[C@H]3C(=C(O)c4c(C3)c(N(C)C)ccc4O)C1=O)[C@H](N(C)C)C(=O)/C(=C(\O)/N)/C2=O,CUJCFMVUUMIFDR-XVLNIUNCSA-N,1.6,"Simon VC, Malerczyk V, Preuss I, Schmidt K, and Grahman H (1976) In vitro aktivitat und pharmakokinetik von minocyclin.  Arz. Forsch. 26: 556-560.","Calculated from C vs t data given in Table 4 for the 200 mg dose in Simon, et al."
415,Mirtazapine,85650-52-8,85650-52-8,c1ccc2c([nH+]1)N1[C@@H](C[NH+](CC1)C)c1c(C2)cccc1,RONZAEMNMFQXRA-INIZCTEOSA-P,4.2,"Voortman G and Paanakker JE (1995) Bioavailability of mirtazepine from Remeron tablets after single and multiple oral dosing.  Human Psychopharmacol. 10: s83-s96.  Timmer CJ, Sitsen JM, and Delbressine LP (2000) Clinical pharmacokinetics of mirtazapine.  Clin. Pharmacokinet. 38: 461-74.",
416,Mitoxantrone,65271-80-9,65271-80-9,O=C1c2c(C(=O)c3c1c(O)ccc3O)c(NCCNCCO)ccc2NCCNCCO,KKZJGLLVHKMTCM-UHFFFAOYSA-N,12,"Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, and Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high dose chemotherapeutic regimen for refractory lymphomas.  Canc. Res. 53: 4850-4854.  Scott LJ and Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis.  CNS Drugs 18: 379-396.",
417,Mivacurium (cis/cis),106791-40-6,106791-40-6,O(CCC[N+]1([C@@H](c2c(CC1)cc(OC)c(OC)c2)Cc1cc(OC)c(OC)c(OC)c1)C)C(=O)CCC=CCCC(=O)OCCC[N+]1([C@@H](c2c(CC1)cc(OC)c(OC)c2)Cc1cc(OC)c(OC)c(OC)c1)C,ILVYCEVXHALBSC-XBCOOEMPSA-N,0.27,"Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM (1994) Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth.  73: 613-618.  Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",
418,Moclobemide,71320-77-9,71320-77-9,C(=O)(c1ccc(cc1)Cl)NCCN1CCOCC1,YHXISWVBGDMDLQ-UHFFFAOYSA-N,1.1,"Schoerlin MP, Mayersohn M, Korn A, and Eggers H (1987) Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.  Clin. Pharmacl. Ther. 42: 395-404.  Raaflaub J, Haefelfinger P, and Trautman KH (1984) Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.  Arz. Forsch. 34: 80-82.  Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, and Pfefen JP (1991) Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.  Clin. Pharmacol. Ther. 49: 32-38.  Schoerlin MP, Horber FF, Frey FJ, and Mayersohn M (1990) Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.  J. Clin. Pharmacol. 30: 272-284.  Schoerlin MP and Guentert TW (1989) Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human.  Psychiatrische Praxis  16(Suppl 1): 11-17.",
419,Montelukast,158966-92-8,158966-92-8,C1CCCC[N+]1(C1CC2C3CCC4CC(OC(=O)C)C(N5CCCCC5)CC4(C)C3CCC2(C)C1OC(=O)C)C.[Br-],VEPSYABRBFXYIB-UHFFFAOYSA-M,0.15,"Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, and Cheng H (1997) Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.  Biopharm. Drug Dispos. 18: 769-777.  Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, and Somers G (1996) Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.  Pharm. Res. 13: 445-448.",
420,Morphine,57-27-2,57-27-2,O1[C@@H]2[C@@]34[C@H]([C@H](N(CC4)C)Cc4c3c1c(O)cc4)C=C[C@@H]2O,BQJCRHHNABKAKU-KBQPJGBKSA-N,2.3,"Owen JA, Sitar DS, Berger L, Briwnell L, Duke PC, and Mitenko PA (1983) Age related morphine kinetics.  Clin. Pharmacil. Ther. 34: 364-368.  Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.  Clin. Pharmacokinet. 1: 219-230.  Lotsch J, Weiss M, Kobal G, and Geisslinger G (1998) Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.  Clin. Pharmacol. Ther. 63: 629-639.  Aitkenhead AR, Vater M, Achola K, Cooper MS, and Smith G (1984) Pharmacokinetics of single-dse I.V. morphine in normal volunteers and patients with end-stage renal disease.  Br. J. Anaesth. 56: 813-819.",
421,Morphine-6-Glucuronide,20290-10-2,20290-10-2,[C@H]12C=C[C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(=O)O)[C@H]3Oc4c5c(C[C@H]1N(C)CC[C@@]235)ccc4O,GNJCUHZOSOYIEC-VJXYMCLOSA-N,0.12,"Lotsch J, Weiss M, Kobal G, and Geisslinger G (1998) Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.  Clin. Pharmacol. Ther. 63: 629-639.",
422,Moxalactam,64952-97-2,64952-97-2,CO[C@@]1(NC(=O)[C@H](C(=O)O)c2ccc(O)cc2)C(=O)N2C(=C(CSc3nnnn3C)CO[C@H]12)C(=O)O,JWCSIUVGFCSJCK-LIUKBUMOSA-N,0.17,"Wise R, Baker S, and Livingston R (1980) Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.  Antimic. Ag. Chemother. 18: 369-371.  Standiford HC, Drusano GL, Bustamante CI, Rivera G, Forrest A, Tatem B, Leslie J, and Moody M (1986) Imipenem coadministered with cilastatin compared with moxalactam:  integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.  Antimic. Agents Chemother. 29: 412-417.",
423,Moxifloxacin,151096-09-2,151096-09-2,O=C(c1cn(C2CC2)c2c(cc(F)c(N3C[C@H]4[C@@H](C3)NCCC4)c2OC)c1=O)O,FABPRXSRWADJSP-MEDUHNTESA-N,1.4,Avelox IV Product Label,VDss calculated using C vs t data obtained by digitization of the plot provided in the label.
424,Moxonidine,75438-57-2,75438-57-2,Clc1nc(nc(OC)c1NC1=NCCN1)C,WPNJAUFVNXKLIM-UHFFFAOYSA-N,1.8,"Theodor R, Weimann HJ, Weber W, and Michaelis K (1991) Absolute bioavailability of moxonidine.  Eur. J. Drug Met. and Pharmacokin. 16: 153-159.  Schaefer HG, Toublanc N, and Weimann HJ (1998) The pharmacokinetics of moxonidine.  Rev. Contemp. Pharmacother.  9: 481-490.",
425,Nadolol,42200-33-9,42200-33-9,OC1C(O)Cc2c(C1)c(OCC(O)CNC(C)(C)C)ccc2,VWPOSFSPZNDTMJ-UHFFFAOYSA-N,1.9,"Morrison RA, Singhvi SM, Creasey WA, and Willard DA (1988) Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.  Eur. J. Clin. Pharmacol. 33: 625-628.  Patel L, Johnston A, and Turner P (1984) Nadolol binding to human serum proteins.  J. Pharm. Pharmacol. 36: 414-415.",
426,Nafcillin,147-52-4,147-52-4,S1[C@H]2N(C(C1(C)C)C(=O)[O-])C(=O)[C@H]2C(=O)Nc1c2c(ccc1OCC)cccc2.[Na+],OYVVEFUBKFQRSG-BBKAHLRJSA-M,0.22,"Waller ES, Sharanevych MA, and Yakatan GJ (1982) The effect of probenecid on nafcillin disposition.  J. Clin. Pharmacol.  22: 482-489.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated using micro rate constants reported in the reference.  Note: Plasma concentrations determined by bioassay; assumes no active metabolites.
427,Nalbuphine,20594-83-6,20594-83-6,O1C2[C@]34[C@](O)([C@H](N(CC3)CC3CCC3)Cc3c4c1c(O)cc3)CC[C@@H]2O,NETZHAKZCGBWSS-XDWDPSITSA-N,4.6,"Aitkenhead AR, Lin ES, and Achola KJ (1988) The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.  Br. J. Clin. Pharmacol. 25: 264-268.   Jaillion P, Gardin ME, Lecocq B, Richard MO, Meignan S, Blondel Y, Grippat JC, Bergnieres J, and Vergnoux O (1989) Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.  Clin. Pharmacol. Ther. 46: 226-233",
428,Nalmefene,55096-26-9,55096-26-9,[CH]12(O)CCC(=C)[C@@H]3Oc4c(O)ccc5c4[C@]13CCN(CC1CC1)[C@H]2C5,NWROHNKZXCUKBE-RFFXKOPCSA-N,8.2,"Frye RF, Matzke GR, Jallad NS, Wilhelm JA, Bikhazi GB (1996) The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.  Br. J. Clin. Pharmacol. 42: 301-306.  Dixon R, Ghowes J, Gentile J, Hsu HB, Hsaio J, Garg D, Weidler D, Meyer M, and Tuttle R (1986) Nalmefene: inravenous safety and kinetics of a new opioid antagonist.  Clin. Pharmacol. Ther. 39: 49-53.  Frye RF, Matzke GR, Schade R, Dixon R, and Rabinovitz M (1997) Effects of liver disease on the disposition of the opioid antagonist nalmefene.  Clin. Pharmacol. Ther. 61: 15-23.  Matzke GR, Frye RF, Alexander ACM, Reynolds R, Dixon R, Johnston J, and Rault RM (1996) The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.  J. Clin. Pharmacol. 36: 144-151. ",
429,Naloxone,465-65-6,465-65-6,C=CCN1CC[C@@]23c4c5c(O)ccc4C[C@@H]1[C@]2(O)CCC(=O)[C@@H]3O5,UZHSEJADLWPNLE-GRGSLBFTSA-N,1.7,"Ngai SH, Berkowitz BA, Yang JC, Hempstead J, and Spector S (1976) Pharmacokinetics of naloxone in rats and man: basis for its potency and short duration of action.  Anesthesiology 44: 398-401.  Asali LA and Brown KF (1984) Naloxone protein binding in adult and fetal plasma. Eur. J. Clin. Pharmacol. 27: 459-463.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
430,Naltrexone,16590-41-3,16590-41-3,O1[C@@H]2[C@@]34[C@](O)([C@H](N(CC4)CC4CC4)Cc4c3c1c(O)cc4)CCC2=O,DQCKKXVULJGBQN-XFWGSAIBSA-N,7.6,"Wall ME, Brine DR, and Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration.  Drug Metab. Dispos.  9: 369-375.  Ludden TM, Malspeis L, Baggot JD, Sokoloski TD, Frank SG, and Reuning RH (1976) Tritiated naltrexone binding in plasma from several species and tissue distribution in mice.  J. Pharm. Sci. 65: 712-716",Calculated from C vs t data provided in the report.
431,Napsagatran,154397-77-0,154397-77-0,S(=O)(=O)(N[C@H](C(=O)N(C1CC1)CC(=O)O)CC(=O)NCC1CCCN(C1)C(=N)N)c1cc2c(cc1)cccc2,BYDKEYCXCIVOOV-UGNFMNBCSA-N,0.36,Hauptmann J. (2002) Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs A review of small-molecule thrombin inhibitors.  Eur J Clin Pharmacol  57: 751-758. ,
432,Naratriptan,121679-13-8,121679-13-8,CNS(=O)(=O)CCc1ccc2c(c1)cc[nH]2,PPXMUBLAPJLGNE-UHFFFAOYSA-N,2.4,Amerge Product Label.,
433,Nateglinide,105816-04-4,105816-04-4,c1ccc(cc1)CC(NC(=O)[C@@H]1CCC(CC1)C(C)C)C(=O)O,OELFLUMRDSZNSF-YAUDXCEOSA-N,0.15,"Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, Mcleod JF, and Mangold JB (2001) Pharmacokinetics and metabolism of nateglinide in humans.  Drug Metab. Dispos. 29: 415-421.  Choudhury S, Hirschberg Y, Filipek R, Lasseter K, and McLeod JF (2000) Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.  J. Clin. Pharmacol. 40: 634-640.",
434,Nebivolol,118457-14-0,118457-14-0,c12c(cc(cc1)F)CC[C@H](O2)[C@@H](CNC[C@H]([C@H]1CCc2c(O1)ccc(c2)F)O)O,KOHIRBRYDXPAMZ-YHBROIRLSA-N,11,"Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol. 43: 563-570.",
435,Nefazodone,83366-66-9,83366-66-9,Clc1cc(N2CCN(CCCn3nc(n(c3=O)CCOc3ccccc3)CC)CC2)ccc1,VRBKIVRKKCLPHA-UHFFFAOYSA-N,0.51,"Barbhaiya RH, Dandekar KA, and Greene DS (1996) Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.  Drug Metab. Dispos. 24:  91-5.  PPB data from http://www.drugs.com/ppa/nefazodone_hydrochloride.html",
436,Nefopam,13669-70-0,13669-70-0,CN1CCOC(c2c(C1)cccc2)c1ccccc1,RGPDEAGGEXEMMM-UHFFFAOYSA-N,5.6,"Chawla J, Le Guern ME, Alquier C, Kalhorn TF, and Levy RH (2005)  Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.  Ther. Drug Monit. 25: 203-210.  ",VDss calculated from digitized C vs t data for (+) enantiomer.
437,Nelarabine,121032-29-9,121032-29-9,n1cn(c2nc(nc(c12)OC)N)[C@H]1C(O)C(O)[C@H](O1)CO,IXOXBSCIXZEQEQ-DGPXGRDGSA-N,4.9,Arranon Product Label.,
438,Neostigmine,59-99-4,59-99-4,c1(cc(ccc1)[N+](C)(C)C)OC(=O)N(C)C,ALWKGYPQUAPLQC-UHFFFAOYSA-N,0.74,"Morris RB, Cronnelly R, Miller RD, Stanski DR, and Fahey MR (1981) Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man.  Anesthesiol. 54: 399-402.",
439,Netilmicin,56391-56-1,56391-56-1,O([C@@H]1[C@@H](O)[C@H](O[C@H]2OC(=CC[C@H]2N)CN)[C@@H](N)C[C@H]1NCC)[C@H]1OC[C@](O)([C@H](NC)[C@H]1O)C,CIDUJQMULVCIBT-MQDUPKMGSA-N,0.073,"Welling PG, Baumueller A, Lau CC, and Madsen PO  (1977) Netilmicin Pharmacokinetics After Single Intravenous Doses to Elderly Male Patients.  Antimic. Agents Chemother. 12: 328-334.  Contrepois A, Brion N, Garaud JJ, Faurisson F, Delatour F, Levy JC, Deybach JC, and Carbon C (1985) Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans.  Antimic. Agents Chemother. 27: 520-524.",Used data from group 1 (mean age 54 yr) and analyzed C vs t data provided in the reference by Welling et al.
440,Nevirapine,129618-40-2,129618-40-2,Cc1ccnc2c1N=C(c1cccnc1N2C1CC1)N,PMFNBEGRVUUDKX-UHFFFAOYSA-N,1.3,"Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, and  Robinson P (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.  Biopharm. Drug Dispos. 20: 285-291.  Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R,  Reynolds HE, Garazzino S, Sinicco A,  Khoo SH, Back DJ, and Di Perri G (2004) The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests.  AIDS Res. Human Retroviruses  20: 716-722.",
441,Nicardipine,55985-32-5,55985-32-5,Cl.O(C(=O)C1=C(NC(=C(C1c1cc([N+](=O)[O-])ccc1)C(=O)OC)C)C)CCN(Cc1ccccc1)C,AIKVCUNQWYTVTO-UHFFFAOYSA-N,1.0,"Guerret M, Cheymol G, Hubert M, Julien-Larose C, and Lavene D (1989) Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.  Eur. J.Clin. Pharmacol. 37: 381-385.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",
442,Nicotine,54-11-5,54-11-5,N1([C@H](c2cnccc2)CCC1)C,SNICXCGAKADSCV-JTQLQIEISA-N,2.6,"Benowitz NL, Jacob P, Jones RT, and Rosenberg J (1982) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.  J. Pharmacol. Exp. Ther. 221: 368-372. ",
443,Nifedipine,21829-25-4,21829-25-4,Cc1cccc(c1[N+](=O)[O-])C1C(=C(N(C(=C1C(=O)OC)C)C)C)C(=O)OC,FVZVWQIZIMBLIE-UHFFFAOYSA-N,0.79,"Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, and George CF (1995) Factors affecting the absolute bioavailability of nifedipine.  Br. J. Clin. Pharmacol. 40: 51-58.  Robertson DRC, Waller DG, Renwick AG, and George CF (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.  Br. J. Clin. Pharmacol. 25: 297-305.  Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P, and Breimer DD (1986) Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin. Pharmacol. Ther. 40: 21-28.  Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, and Breimer DD (1984) Nifedipine: kinetics and dynamics in healthy subjects.  Clin. Pharmacol. Ther. 35: 742-749.    Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  ",
444,Nimodipine,66085-59-4,66085-59-4,N1C(=C(C(C(=C1C)C(=O)OC(CC(C)OC)C)c1cccc(c1)[N+](=O)[O-])C(=O)O)C,TXFXHUMTAPZAMP-UHFFFAOYSA-N,1.1,"Muck W, Breuel HP, and Kuhlmann J (1996) The influence of age on the pharmacokinetics of nimodipine.  Int. J. Clin. Pharmacol. Ther. 34: 293-298.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.    Hynymen M, Siltanen T, Sahlman A, Pohjasvaara T, Muck W, and Kaste M (1995) Continuous infusion of nimodipine during coronary artery surgery: hemodynamics and pharmacokinetic study.  Br. J. Anaesth.  74: 526-533.",
445,Nisoldipine,63675-72-9,63675-72-9,O(C(=O)C1=C(NC(=C(C1c1cc([N+](=O)[O-])ccc1)C(=O)OC)C)C)CC(C)C,MRSJBSHLMOBYSH-UHFFFAOYSA-N,5.5,"van Harten J, van Brummelen P, Lodewijks MTM, Danhof M, Breimer DD (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.  Clin. Pharmacol. Ther. 43: 332-341.  van Harten J, van Brummelen P, Wilson JHP, Lodewijks MTM, and Breimer DD (1988) Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 387-394.  ",
446,Nitrazepam,146-22-5,146-22-5,Clc1cc2C(=NC(C(C)C)C(=O)Nc2cc1)c1ccccc1,GIUZMTLJQCHDOJ-UHFFFAOYSA-N,1.7,"Jochemsen R, VanBeusekom BR, Spoelstra P, Janssens AR, and Breimer DD (1983) Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.  Br. J. Clin. Pharmacol. 15: 295-302.  Jochemsen R, Hogendoorn JJH, Dingemanse J, Hermans J, Boeijinga JK, and Breimer DD (1982) Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.  J. Pharmacokinet. Biopharm. 10: 231-245.",VDss calculated using C vs t data obtained by digitization of the plot provided in the references.
447,Nitrendipine,39562-70-4,39562-70-4,C1(=C(C(C(=C(N1CC)C)C(=O)[O-])c1c(c(ccc1)[N+](=O)[O-])C)C(=O)[O-])C,MQESJBJIGCTSLG-UHFFFAOYSA-L,6.1,"Mikus G, Fischer C, Heuer B, Langen C, and Eichelbaum M (1987) Application of stable isotope methodology to study the pharmacokinetics, bioavailability, and metabolism of nitrendipine after i.v. and p.o. administration.  Br. J. Clin. Pharmacol. 24: 561-569.  Soons PA, DeBoer AG, Van Brummelen P, and Breimer DD (1989) Oral absorption ptrofile of nitrendipine in healthy subjects: a kinetic and dynamic study.  Br. J. Clin. Pharmacol. 27: 179-189.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  ",
448,Nitrofurantoin,67-20-9,67-20-9,o1c(/C=N\N2CC(=O)NC2=O)ccc1[N+](=O)[O-],NXFQHRVNIOXGAQ-OQFOIZHKSA-N,0.57,"Hoener BA and Patterson SE (1981) Nitrofurantoin disposition.  Clin. Pharmacol. Ther. 29: 808-816.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.  Mannisto PT and Lamminsivu U (1982) Nitrofurantoin is highly bound to plasma protein. J. Antimic. Chemother. 9: 327-328.",
449,Nizatidine,76963-41-2,76963-41-2,C(=C\[N+](=O)[O-])(/N(C)CCSCc1nc(sc1)CN(C)C)\N,NRFDOJHZMQJSKN-IZZDOVSWSA-N,1.0,"Aronoff GR, Bergstrom RF, Bopp RJ, Sloan RS, and Callaghan JT, (1988) Nizatidine disposition in subjects with normal and imparired renal function.  Clin. Pharmacol. Ther. 43: 688-695.  Knadler MP, Bergestrom RF, Callaghan JT, and Rubin A (1986) Nizatidine, an H2-blocker.  Its metabolism and disposition in man.  Drug Metab. Dispos. 14: 175-82",VDss calculated using C vs t data obtained by digitization of the plot provided in the reference.
450,NK 611,105760-98-3,105760-98-3,Cl.O(C1C2C(C(c3c1cc1OCOc1c3)c1cc(OC)c(O)c(OC)c1)C(=O)OC2)C1OC2C(OC(OC2)C)C(O)C1N(C)C,PYLTTZZOZBYUEI-UHFFFAOYSA-N,0.30,"Mross K, Huettmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, and Hossfeld DK (1996) Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611: A study by the AIO groups PHASE-I and APOH. Cancer Chemother. Pharmacol. 38: 217-224. Rassmann I., Thodtmann R, Mross M, Huttmann A, Berdel WE, Manegold C, Fiebig HH, Kaeser-Frohlich A, Burk K, and Hanauske AR (1999) Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion.  Invest. New Drugs 16: 319-324.",
451,Nomifensine,24526-64-5,24526-64-5,CN1CC(c2ccccc2)c2c(C1)c(N)ccc2,XXPANQJNYNUNES-UHFFFAOYSA-N,6.0,"Lindberg RLP, Syvalahti EKG, and Pihlajamaki KK (1986) Disposition of nomifensine after acute and prolonged dosing.  Clin. Pharmacol. Ther. 39: 384-388.  Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species.  Arz. Forsch. 28: 58-64",VDss calculated from data obtained by digitization of a plot in the reference. 
452,Nortilidine,38677-94-0,38677-94-0,[C@@]1([C@@H](NC)C=CCC1)(C(=O)OCC)c1ccccc1,PDJZPNKVLDWEKI-GOEBONIOSA-N,2.5,"Hajda JP, Jahnchen E, Oie S, and Trenk D (2002) Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine.  J. Clin. Pharmacol. 42: 1257-1261.",VDss calculated from data obtained by digitization of a plot in the reference. 
453,Nortriptyline,72-69-5,72-69-5,N(CC/C=C\1/c2c(CCc3c1cccc3)cccc2)C,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,22,"Overo KF, Gram LF, and Hansen V (1977) Interaction of perphenazine with the kinetics of nortriptyline.  Acta Pharmacol. Toxicol. 40: 97-105.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.","VDss values were calculated for three of the subjects in the paper by Overo, et al, by digitizing the C vs t plots presented in the reference, and analyzing the resulting C vs t data."
454,Ofloxacin,82419-36-1,82419-36-1,Fc1c(N2CCN(CC2)C)c2OCC(n3c2c(c(=O)c(c3)C(=O)O)c1)C,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,1.6,"Gascon AR, Campo, E, Hernandez RM, Calvo B, Errasti J, and Pedraz JL (1998) Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.  Clin. Drug Invest. 15: 491-496.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",
455,Olcegepant,204697-65-4,204697-65-4,N1(CCC(CC1)N1C(=O)Nc2c(C1)cccc2)C(=O)N[C@@H](C(=O)NCCCCC(C(=O)N1CCN(CC1)c1ccncc1)N)Cc1cc(c(c(c1)Br)O)Br,ATGNXDDNAVZYOK-NFCCVXSLSA-N,0.31,"Iovino M, Feifel U, Yong CL, Wolters JM, and Wallenstein G (2004) Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers.    Cephalalgia 24: 645-56.",
456,Olsalazine,15722-48-2,15722-48-2,Oc1c(cc(N/N=C/2\C=C(C(=O)C=C2)C(=O)O)cc1)C(=O)O,ULGVHUUBIHTFAM-PXNMLYILSA-N,0.070,Ryde EM and Ahnfelt NO (1988) The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.  Eur. J. Clin. Pharmacol. 34: 481-488.,
457,Omeprazole,73590-58-6,73590-58-6,O=S(c1nc2cc(OC)ccc2[nH]1)Cc1ncc(C)c(OC)c1C,SUBDBMMJDZJVOS-UHFFFAOYSA-N,0.24,"Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, and Skanberg I (1990) The pharmacokinetics of omeprazole in humans-a study of single intravenous and oral doses.  Ther. Drug Monit. 12: 163-172.  Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, and Skanberg I (1985) Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.  Scand. J Gastroent.108(Suppl): 79-94.",CL and t1/2 values were reported as medians.
458,Ondansetron,99614-02-5,99614-02-5,O=C1c2c(n(c3c2cccc3)C)CCC1Cn1c(ncc1)C,FELGMEQIXOGIFQ-UHFFFAOYSA-N,1.8,"Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, and Powell JR (1992) Age and gender effects on ondansetron pharmacokinetics:  evaluation of healthy aged volunteers.  Clin. Pharmacol. Ther. 51: 51-55..  Zofran Product Label.",
459,Oseltamivir acid,187227-45-8,187227-45-8,CCC(OC1C=C(CC(C1NC(=O)C([2H])([2H])[2H])N)C(=O)O)CC,NENPYTRHICXVCS-HPRDVNIFSA-N,0.37,"He G, Massarella J, and Ward P (1999) Clinical pharmacokinetics of the progrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37: 471-484.",
460,Oxacillin,66-79-5,66-79-5,S1[C@H]2N([C@H](C1(C)C)C(=O)[O-])C(=O)C2NC(=O)c1c(noc1C)c1ccccc1.[Na+],VDUVBBMAXXHEQP-XUHZAHOXSA-M,0.19,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 42-48.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  "
461,Oxazepam,604-75-1,604-75-1,Clc1cc2C(=N[C@H](O)C(=O)Nc2cc1)c1ccccc1,ADIMAYPTOBDMTL-OAHLLOKOSA-N,0.59,"Sonne J, Loft S, Dossing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, and Andreasen PB (1988) Bioavailability and pharmacokinetics of oxazepam.  Eur. J. Clin. Pharmacol. 35: 385-389.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12: 612-619.  Desmond PV, Roberts RK,, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.",
462,Oxiracetam,62613-82-5,62613-82-5,O=C1N(CC(O)C1)CC(=O)N,IHLAQQPQKRMGSS-UHFFFAOYSA-N,0.55,"Perucca E, Albrici A, Gatti G, Spalluto R, Visconti M, and Crema A (1984) Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet.  3: 267-274.",
463,Oxybutynin,5633-20-5,5633-20-5,OC(c1ccccc1)(C1CCCCC1)C(=O)OCC#CCN(CC)CC,XIQVNETUBQGFHX-UHFFFAOYSA-N,0.85,"Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, and Herchuelz A (1988) The pharmacokinetics of oxybutynin in man.  Eur. J. Clin. Pharmacol. 35: 515-520.  Mizushima H, Takanaka K, Abe K, Fukazawa I, and Ishizuka H (2007) Stereoselective pharmacokinetics of oxynutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica 37: 59-73.",Parameters calculated from C vs t data obtained by digitization of the plot provided in the reference.  Used data from 1 mg dose.
464,Oxycodone,76-42-6,76-42-6,O1C2C34C(O)(C(N(CC3)C)Cc3c4c1c(OC)cc3)CCC2=O,BRUQQQPBMZOVGD-UHFFFAOYSA-N,2.5,"Leow KP, Smith MT, Watt JA, Williams BE, and Cramond T (1992) Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration.  Ther. Drug Monit. 14: 479-484.  Leow KP, Wright AWE, Cramond T, and Smith MT (1993) Determination of the serum protein binding of oxycodone and morphine using ultrafiltration.  Ther. Drug Monit. 15: 440-447. ",
465,Oxytetracycline,79-57-2,79-57-2,c1cc2c(C(=O)C3=C([C@@]4(CC(=C([C@H]([C@@H]4C(C3[C@@]2(O)C)O)N(C)C)O)C(=O)N)O)O)c(c1)O,MIPLPHCHOSAKNB-DTNUDMNXSA-N,1.7,"Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest.  38  1950-1963.",calculated from digitized plots 
466,Paclitaxel,33069-62-4,33069-62-4,O([C@]12[C@@H]3[C@](C(=O)[C@H](OC(=O)C)C4=C([C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)c5ccccc5)c5ccccc5)C[C@@](O)([C@H]3OC(=O)c3ccccc3)C4(C)C)C)([C@@H](O)C[C@H]1OC2)C)C(=O)C,RCINICONZNJXQF-MZXODVADSA-N,3.0,Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel.  Clin. Pharmacokinet. 27: 256-269.,"Averaged values listed in Table 1 of Sonnichsen and Relling.  For t1/2 values, used longest value reported in each reference."
467,Palonosetron,135729-61-2,135729-61-2,O=C1N(C2C3CCN(C2)CC3)CC2c3c1cccc3CCC2,CPZBLNMUGSZIPR-UHFFFAOYSA-N,6.3,"Stoltz R, Cyong JC, Shah A, and Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.  J. Clin. Pharmacol. 44: 520-531.   Siddiqui M, Asif A, and Scott LJ.(2004) Palonosetron.    Drugs 64: 1125-1132.",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.
468,Pamidronic acid (Pamidronate),40391-99-9,40391-99-9,P(=O)(O)(O)C(O)(P(=O)(O)O)CCN,WRUUGTRCQOWXEG-UHFFFAOYSA-N,1.8,"Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, and Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.  J. Clin. Pharmacol. 37: 285-290. ",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
469,Pancuronium,15500-66-0,15500-66-0,[C@@]12([C@H]([C@H]3[C@@H]([C@]4(C[C@H]([N+]5(C)CCCCC5)[C@H](C[C@@H]4CC3)OC(=O)C)C)CC2)C[C@@H](C1OC(=O)C)[N+]1(C)CCCCC1)C.[Br-].[Br-],NPIJXCQZLFKBMV-JNGDLLDGSA-L,0.20,"Caldwell JE, Castagnoli KP, Canfell PC, Fahey MR, Lynam DP, Fisher DM, and Miller RD (1988) Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.  Br. J. Anaesth. 61:  693-697.  Wood M, Stone WJ, and Wood AJJ (1983)  Plasma binding of pancuronium:  effects of age, sex, and disease.  Anesth. Analg.  62: 29-32",
470,Panipenem,87726-17-8,87726-17-8,S(C1=C(N2[C@@H]([C@H](C2=O)[C@H](O)C)C1)C(=O)O)[C@@H]1CN(CC1)C(=N)C,TYMABNNERDVXID-DLYFRVTGSA-N,0.19,Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy 39(Suppl. 3)4: 227-235.,VDss calculated from C vs t data provided in the reference.
471,Pantoprazole,102625-70-7,102625-70-7,O([C@H]1[C@H](N(C)C)[C@@H](O)[C@@H](O[C@@H]1C)O[C@@H]1[C@@H](OC)[C@H](OC(=O)C)CC(=O)O[C@@H](C/C=C/C=C/[C@H](O)[C@@H](C[C@@H]1CC=O)C)C)[C@@H]1O[C@H]([C@H](OC(=O)CC(C)C)[C@](O)(C1)C)C,XJSFLOJWULLJQS-NGVXBBESSA-N,0.17,"Pue MA, Laroche J, Meineke I, and deMey C (1993) Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.  Eur. J. Clin. Pharmacol. 44: 575-578.  Huber R; Hartmann M; Bliesath H; Luhmann R; Steinijans V W; Zech K  Pharmacokinetics of pantoprazole in man.    International journal of clinical pharmacology and therapeutics  (1996),  34(1 Suppl),  S7-16",
472,Papaverine,58-74-2,58-74-2,c12c(nccc2cc(c(c1)OC)OC)Cc1cc(c(cc1)OC)OC.C(=O)(C(c1ccccc1)c1ccccc1)O,QUNHZCAFGGHYEX-UHFFFAOYSA-N,1.0,"Garrett ER, Roseboom H, Green JR, and Schuermann W (1978) Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms.  Int. J. Clin. Pharmacol. Biopharm.  16: 193-208.  Berg G, Jonsson KA, Hammar M, and Norlander B (1988) Variable bioavailability of papaverine.  Pharmacol. Toxicol. 62: 308-310.","Parameters calculated from C vs t data obtained by digitization of the plots reported in Garrett, et al and averaged for two dose levels.  VDss was obtained by digitization of the plot in Berg, et al..  All data were averaged together weighted for the number of subjects in each study."
473,Paricalcitol,131918-61-1,131918-61-1,OC([C@H](C=C[C@H]([C@@H]1[C@@]2([C@@H](CC1)C(=C/C=C/1\C[C@@H](O)C[C@H](O)C1)CCC2)C)C)C)(C)C,BPKAHTKRCLCHEA-FOPGHSPUSA-N,0.41,"Carr RA, Andre AK, Chen P, Grabowski BA, Chang MS, Locke CS, Williams LA, and Chojkier M (2006) The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (ZemplarR).  Nephron  103: c100-c105.",Free fraction calculated by comparing free and total AUC values reported in the reference.
474,Paroxetine,61869-08-7,61869-08-7,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,AHOUBRCZNHFOSL-YOEHRIQHSA-N,18,"Lund J, Thayssen P, Mengel H, Pedersen OI, Kristensen CB, and Gram LF (1982) Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man.  Acta Pharmacol. Toxicol. 51: 351-357.  Paxil Product Label.",VDss was calculated from micro rate constants reported in the reference.
475,Pefloxacin,70458-92-3,70458-92-3,Fc1c(N2CCN(CC2)C)cc2n(cc(c(=O)c2c1)C(=O)O)CC,FHFYDNQZQSQIAI-UHFFFAOYSA-N,1.5,"Frydman AM, Le Roux Y, Lefebvre MA, Djebbar F, Fourtillan JB, and Gaillot J (1986) Pharmacokinetics of perfloxacin after repeated intravenous and oral administration (400mg bid) in young healthy volunteers.  J. Antimic. Chemother.  17(Suppl B): 65-79.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet.41: 741-750.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
476,Penciclovir,39809-25-1,39809-25-1,O=c1nc([nH]c2n(cnc12)CCC(CO)CO)N,JNTOCHDNEULJHD-UHFFFAOYSA-N,1.1,"Fowles SF, Pierce DM, Prince WT, and Staniforth D (1992) The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.  Eur. J. Clin. Pharmacol. 43: 513-516.  Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, and Ramji JV (1994) Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects.  Xenobiotica 24: 357-368.",Parameters calculated from digitized plots and averaged over all dose levels.
477,Penicillin G,61-33-6,61-33-6,N12[C@H](SC([C@@H]1C(=O)O)(C)C)C(C2=O)NC(=O)Cc1ccccc1,JGSARLDLIJGVTE-VBVNFKHJSA-N,0.24,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 42-48.  Malerczyk VV, Ruegenberg W, Seiler KU, and Simon C (1979) Untersuchungen zur konkurrenz verscheidener antibiotika um ihre bindungsstellen an serumeiweissen. Arzneim. Forsch. 29: 169-171.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  "
478,Pentamidine,100-33-4,100-33-4,O(c1ccc(cc1)C(=N)N)CCCCCOc1ccc(cc1)C(=N)N,XDRYMKDFEDOLFX-UHFFFAOYSA-N,53,"Conte JE, Duncan S, McKenna E, and Zurlinden E (1999) Effect of gender and race on the pharmacokinetics of pentamidine in HIV-infected patients.  Clin, Drug Invest. 17: 293-299. ",
479,Pentazocine,359-83-1,359-83-1,CCCCCC1=NC=CC=CC=C1,GOVKUODTXBRZDJ-RUAHWYGVSA-N,3.4,"Ritschel WA, Bykadi G, Hoffmann KA, Norman EJ, Lucker PJ, and Rindt W (1982) Disposition and clinical side effectsof pentazocine when administered day and night.  Arz. Forsch. 32: 64-68.  Ritschel WA, Hoffmann KA, Willig JL, Frederick KA, and Wetzelberger N (1986) The effect of age on the pharmacokinetics of pentazocine.  Meth. Find. Expt. Clin. Pharmacol. 8: 497-503.  Ehrnebo M, Agurell S, Boreus LO, Gordon E, and Lonroth U (1974) Pentazocine binding to blood cells and plasma proteins.  Clin. Pharmacol. Ther. 16: 424-429.",
480,Pentobarbital,76-74-4,76-74-4,O=C1NC(=NC(=O)C1(C(CCC)C)CC)[O-],WEXRUCMBJFQVBZ-UHFFFAOYSA-M,0.91,"Ehrenbo M (1974) Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration.  J. Pharm. Sci. 63: 1114-1118.  Bayliff CD, Schwartz ML, and Hardy BG (1985) Pharmacokinetics of high-dose pentobarbital in severe head trauma.    Clin. Pharmacol. Ther. 38: 457-461.  Ehrnebo M and Odar-Cederlof I (1975) Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.  Eur. J. Clin. Pharmacol. 8: 445-453.",VDss calculated using micro rate constants reported in the reference by Ehrenbo.
481,Pentoxifylline,6493-05-6,6493-05-6,CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,1.8,"Beermann B, Ings R, Mansby J, Chamberlain J, and McDonald A (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects.  Clin. Pharmacol. Ther. 37: 25-28.  Rames A, Poirier JM, LeCoz F, Midavaine M, Lecocq B, Grange JD, Poupon R, Cheymol G, and Jaillon P (1990) Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.  Clin. Pharmacol. Ther. 47: 354-359.",Calculated VDss from C vs t data obtained by digitization of plots included in the references. 
482,Perindoprilat,95153-31-4,95153-31-4,O=C(N1[C@@H]2[C@H](C[C@H]1C(=O)O)CCCC2)[C@@H](N[C@@H](CCC)C(=O)O)C,ODAIHABQVKJNIY-PEDHHIEDSA-N,0.76,"Devissaguet JP, Ammoury N, Devissaguet M, and Perret L (1990) Pharmacokinetics of perindopril and its metabolites in healthy volunteers.  Fundam. Clin. Pharmacol. 4: 175-189.  Parker E, Aarons L, Rowland M, and Resplandy G (2005) The pharmacokinetics of perindoprilat in normal volunteers and patients: Influence of age and disease state.  Eur. J. Pharm. Sci. 26: 104-113.",VDss calculated from data obtained by digitization of a plot in the reference. 
483,Perphenazine,58-39-9,58-39-9,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2,RGCVKNLCSQQDEP-UHFFFAOYSA-N,18,"Eggert Hansen C, Rosted CT, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen NE, Naestoft J, and Hvidberg  (1976) Clinical pharmacokinetics studies of perphenazine.  Br. J. Clin. Pharmacol. 3: 915-923.  Verbeek RK, Cardinal JA, Hill AG, and Midha KK (1983) Binding of phenothiazine neuroleptics to plasma proteins.  Biochem. Pharmacol. 32: 2565-2570.",VDss was determined from C vs t data obtained by digitization of the plots presented in the reference.
484,Phenacetin,62-44-2,62-44-2,CCOC1(CC=C(N)C=C1)C(=O)C,WQGDZJHNTFMMAG-UHFFFAOYSA-N,1.4,"Raaflaub J and Dubach UC (1975) On the pharmacokinetics of phenacetin in man.  Eur. J. Clin. Pharmacol.  8: 261-265.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss data calculated from C vs t data reported in the paper.  Values are for whole blood.
485,Phencyclidine,77-10-1,77-10-1,N1(C2(c3ccccc3)CCCCC2)CCCCC1,JTJMJGYZQZDUJJ-UHFFFAOYSA-N,6.9,"Cook CE, Brine DR, Jeffcoat AR, Hill JM, Wall ME, Perez-Reyes M, and Di Guiseppi SR (1982) Phencyclidine disposition after intravenous and oral doses. Clin. Pharmacol. Ther. 31: 625-634.",VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.
486,Phenethicillin,147-55-7,147-55-7,OC1CC2C(C1(C)O)(C)CCC1C2CCC2C1(C)Cc1c(C2O)[nH]nc1,BRYNGAICAJXOCY-UHFFFAOYSA-N,0.30,"Overbosch D, Mattie H, and van Furth R (1985) Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.  Br. J. Clin. Pharmacol.  19: 657-668.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated from reported rate micro-constants
487,Phenobarbital,50-06-6,50-06-6,O=C1NC(=O)NC(=O)C1(c1ccccc1)CC,DDBREPKUVSBGFI-UHFFFAOYSA-N,0.54,"Wilensky AJ, Friel PN, Levy RH, Confort CP, and Kaluzny SP (1982) Kinetics of phenobarbital in normal subjects an epileptic patients.  Eur. J. Clin. Pharmacol. 23: 87-92.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",
488,Phenoxymethylpenicillin,87-08-1,87-08-1,S1[C@H]2N([C@H](C1(C)C)C(=O)O)C(=O)[C@H]2NC(=O)COc1ccccc1,BPLBGHOLXOTWMN-MBNYWOFBSA-N,0.41,"Overbosch D, Mattie H, and van Furth R (1985) Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.  Br. J. Clin. Pharmacol.  19: 657-668.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated from reported rate micro-constants
489,Pimobendan,74150-27-9,74150-27-9,COc1ccc(cc1)c1nc2c([nH]1)C=CC(C2)C1=C(C)C=NC(=O)C1,KLURSSJEJXFGDM-UHFFFAOYSA-N,2.0,"Chu KM, Shieh SM, and Hu OYP (1995) Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.  Eur. J. Clin. Pharmacol. 47: 537-542. ",Data from enantiomers averaged.
490,Pindolol,13523-86-9,13523-86-9,O(c1c2c([nH]cc2)ccc1)CC(O)CNC(C)C,JZQKKSLKJUAGIC-UHFFFAOYSA-N,1.2,"Lavene D, Weiss YA, Safar ME, Loria Y, Agorus H, Georges D, and Milliez PL (1977) Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.  J. Clin. Pharmacol. 17: 501-508.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists. Br. J. Clin. pharmacol. 11: 119P-120P. ",VDss calcualted from reported micro rate constants.
491,Piperacillin,61477-96-1,61477-96-1,C12N(C(C(=O)O)C(S1)(C)C)C(=O)[C@H]2NC(=O)[C@@H](c1ccccc1)NC(=O)N1C(=O)C(=O)N(CC)CC1,IVBHGBMCVLDMKU-FXTZWWGYSA-N,0.27,"De Schepper PJ, Tjandramaga TB, Mullie A, Verbesselt R, van Hecken A, Verberckmoes R, and Verbist L (1982) Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.  J. Antimic. Chemother. 9(Suppl B) 49-57. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, and Verbist L (1978) Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.  Antimic. Ag. Chemother. 14: 829-837.   Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",
492,Pipercuronium,68399-58-6,68399-58-6,[Br-].[Br-].O([C@@H]1[C@@]2(C(C3C([C@@]4(C(CC3)C[C@H](OC(=O)C)[C@@H](N3CC[N+](CC3)(C)C)C4)C)CC2)C[C@@H]1N1CC[N+](CC1)(C)C)C)C(=O)C,TXWBOBJCRVVBJF-XRMDBSGISA-L,0.35,"D'Honneur G, Khalil M, Dominique C, Haberer JP, Kleef UW, and Duvaldestin P (1993) Pharmacokinetics and pharmacodynamics of pipercuronium in patients with cirrhosis.  Anesth. Analg. 77: 1203-1206.  Szeleczky G, Ronai-Lukacs S, and Vereczkey L (1984) Protein-binding of pipecuronium bromide (Arduan) in human plasma.  Stud. Org. Chem.  18: 251-254.",
493,Piretanide,55837-27-9,55837-27-9,OC(=O)c1cc(N2CCCC2)c(c(c1)S(=O)(=O)N)Oc1ccccc1,UJEWTUDSLQGTOA-UHFFFAOYSA-N,0.17,"Trenk D, Wagner F, Jaehnchen E, Spahn H, and Mutschler E (1987) Pharmacokinetics and bioavailability of piretanide in healthy volunteers following intramuscular administration. Arz.Forsch. 37: 1382-1385.  Elliott HL, Ansari AF, Campbell BC, and Lawrence JR (1982) Protein binding of piretanide in normal and uremic serum.  Eur. J. Clin. Pharmacol. 21: 311-313. ",
494,Piritramide,302-41-0,302-41-0,O=C(N)C1(N2CCCCC2)CCN(CC1)CCC(c1ccccc1)(c1ccccc1)C#N,IHEHEFLXQFOQJO-UHFFFAOYSA-N,4.7,"Keitzmann D, Briede I, Bouillon T, Gundert-Remy U, and Kettler D (1996) Pharmacokinetics of piritramide after and intravenous bolus in surgical patients.  Acta Anaesthesiol. Scand.  40: 898-903.",
495,Pirmenol,68252-19-7,68252-19-7,OC(CCCN1C(CCCC1C)C)(c1ccccc1)c1ncccc1,APUDBKTWDCXQJA-UHFFFAOYSA-N,1.4,"Hammill SC, Shand DG, Routledge PA. Hindman MC, Baker JT, and Pritchett ELC (1982) Pirmenol, a new antiarrhythmic agent:  initial study of efficacy, safety and pharmacokinetics.  Circulation 65: 369-375,  ",VDss calculated from reported rate microcnstants.
496,PNU-145156E,154788-16-6,154788-16-6,S(=O)(=O)([O-])c1c2c(cc(S(=O)(=O)[O-])c1)ccc(NC(=O)c1n(cc(NC(=O)c3n(cc(NC(=O)Nc4cc(n(c4)C)C(=O)Nc4cc(n(c4)C)C(=O)Nc4cc5c(cc(S(=O)(=O)[O-])cc5S(=O)(=O)[O-])cc4)c3)C)c1)C)c2.[Na+].[Na+].[Na+].[Na+],XUWLTCQVQARIFB-UHFFFAOYSA-J,0.27,"Groen HJM, deVries EGE, Wynendaele W, van der Graaf WTA, Fokkema W, Lechuga MJ, Poggesi T, Dirix LY, and van Oosterom AT (2001) PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.  Clin. Canc. Res.  7: 3928-3933.",VDss calculated from digitized plot of 200 mg/m2 dose.
497,Pravastatin (acid),81093-37-0,81093-37-0,C1[C@@H](C=C2C=C[C@H](C)[C@@H]([C@H]2[C@H]1OC(=O)[C@@H](C)CC)CC[C@@H](O)C[C@H](CC(=O)O)O)O,TUZYXOIXSAXUGO-PZAWKZKUSA-N,0.46,"Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Dispositon of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.  Br. J. Clin. Pharmacol. 29: 239-243.  Quion JA and Jones PH (1994) Clinical pharmacokinetics of pravastatin.  Clin. Pharmacokinet. 27: 94-103.",
498,Prazosin,19216-56-9,19216-56-9,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1,IENZQIKPVFGBNW-UHFFFAOYSA-N,0.73,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  Vanholder R, Van Landschoot N, De Smet R, Schoots A, and Ringoir S (1988) Drug protein binding in chronic renal failure: evaluation of nine drugs.  Kidney Int. 33: 996-1004.",
499,Prednisolone,50-24-8,50-24-8,C1=CC(=O)C=C2CC[C@H]3[C@H]4[C@](C[C@@H]([C@@H]3[C@@]12C)O)([C@](CC4)(C(=O)CO)O)C,OIGNJSKKLXVSLS-VWUMJDOOSA-N,0.86,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14.",Note: prednisolone demonstrates complex dose-dependent PK (Frey BM and Fey FJ (1990) Clinical pharmacokinetics of prednisone and prednisolone.  Clin. Pharmacokinet. 19: 126-146.
500,Prednisone,53-03-2,53-03-2,C1=C[C@]2(C(=CC1=O)CC[C@@H]1[C@H]2C(=O)C[C@]2([C@H]1CC[C@]2(C(=O)CO)O)C)C,XOFYZVNMUHMLCC-PBGGHTPGSA-N,0.57,"Georgitis JW, Flesher KA, and Szefler SJ (1982) Bioavailability assessment of a liquid prednisone preparation.  J. Allerg. Clin. Immunol. 70: 243-247.  Ferry JJ and Wagner JG (1987) The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednsolone in rabbit and human plasma.  Biopharm. Drug Dispos. 8: 261-272.",Calculated parameters from C vs t data provided in the reference.
501,Prilocaine,721-50-6,721-50-6,Cl.O=C(Nc1c(cccc1)C)C(NCCC)C,BJPJNTKRKALCPP-UHFFFAOYSA-N,3.7,"van der Meer AD, Blum AGL, Stienstra R, van Kleef JW, Vletter AA, and Olieman W (1999) Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity.  Aneasthesiol. 90: 988-992.",Data for individual stereoisomers were averaged.
502,Primaquine,90-34-6,90-34-6,COc1cc(NC(C)CCCN)c2ncccc2c1.CC(N)CCCNc1c2ncccc2cc(OC)c1,WKTUAGXXTZZGQA-UHFFFAOYSA-N,4.0,"Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme MLE, and Breckenrodge AM (1985) Pharmacokinetics of primaquine in man.  I.  Studies of the absolute bioavailability and effects of dose size.  Br. J. Clin. Pharmacol.  19: 745-750.",VDss calculated from digitized C vs t plot.
503,Probenecid,57-66-9,57-66-9,c1(ccc(cc1)C(=O)[O-])S(=O)(=O)N(CCC)CCC,DBABZHXKTCFAPX-UHFFFAOYSA-M,0.13,"Kartzinel R, Ebert MH, and Chase TN (1976) Intravenous probenecid loading.  Effect on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.  Neurology 26: 992-996.  Emanuelsson BM, Beermann B, and Paalzow LK (1987) Non-linear elimination and protein binding of probenecid.  Eur. J. Clin. Pharmacol. 32: 395-401.",Parameters were determined using C vs t data obtained by digitization of the plot provided in the reference.  Protein binding is saturable; the value at half maximum is reported.
504,Procainamide,51-06-9,51-06-9,O=C(NCCN(CC)CC)c1ccc(N)cc1,REQCZEXYDRLIBE-UHFFFAOYSA-N,2.2,"Christoff PB, Conti DR, Naylor C, and Jusko WJ (1983) Procainamide disposition in obesity.  Drug Intell. Clin. Pharm. 17: 516-522.  Reidenberg MM, Drayer DE, Levy M, and Warner H (1975) Polymorphic acetylation of procainamide in man.  Clin. Pharmacol. Ther. 17: 722-730",
505,Prochlorperazine,58-38-8,58-38-8,Clc1cc2N(c3c(Sc2cc1)cccc3)CCCN1CCN(CC1)C,WIKYUJGCLQQFNW-UHFFFAOYSA-N,22,Taylor WB and Bateman DN (1987) Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.  Br. J. Clin. Pharmacol. 23: 137-142. ,VDss was determined using C vs t data obtained by digitization of the plot provided in the reference.
506,Procyclidine,77-37-2,77-37-2,O(C(=O)NC1C2CC(C1)CC2)CC,BEEMRXRYLIWEJL-UHFFFAOYSA-N,0.74,"Whiteman PD, Fowle ASE, Hamilton MJ, Peck AW, Bye A, dean K, and Webster A (1985) Pharmacokinetics and pharmacodynamics of procyclidine in man.  Eur. J. Clin. Pharmacol. 28: 73-78.",VDss calculated from digitized C vs t plot.
507,Promazine,58-40-2,58-40-2,S1c2c(N(c3c1cccc3)CCCN(C)C)cccc2,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,8.1,"Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Hu OYP and Curry SH (1989) Stability, human blood distribution and rat tissue localization of promazine and desmonomethylpromazine.  Biopharm. Drug Dispos. 10: 537-548.",
508,Promethazine,60-87-7,60-87-7,S1c2c(N(c3c1cccc3)CC(N(C)C)C)cccc2,PWWVAXIEGOYWEE-UHFFFAOYSA-N,14,"Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Quinn J and Calvert R (1976) The disposition of promethazine in man.  J. Pharm. Pharmacol. 28(Suppl.)  59P.  Hu OYP and Curry SH (1989) Stability, human blood distribution and rat tissue localization of promazine and desmonomethylpromazine.  Biopharm. Drug Dispos. 10: 537-548.  Taylor G, Houston JB, Shaffer J, and Mawer G (1983) Pharmacokinetics of promethazine and its sulfoxide metabolite after intravenous and oral administration to man.  Br. J. Clin. Pharmacol. 15: 287-293.",
509,Propafenone,54063-53-5,54063-53-5,O(c1c(C(=O)CCc2ccccc2)cccc1)CC(O)CNCCC,JWHAUXFOSRPERK-UHFFFAOYSA-N,2.2,"Arboix M, Puigdemont A, Moya A, and Cinca J (1985) Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia.  Meth. Find. Exptl. Clin. Pharmacol. 7: 436-438.  Hollmann M, Brode E, Hotz D, Kaumeier S, and Kerhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man.  Arzn. Forsch. 33: 763-770.  Chan GLY, Axelson JE, Price JDE, McErlane KM, and Kerr CR (1989) In vitro protein binding of propafenone in normal and uremic human sera.  Eur. J. Clin. Pharmacol. 36: 495-499.  Tonn GR, Kerr CR, and Axelson JE (1992) In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins, and to red blood cells. J. Pharm. Sci. 81: 1098-1103.","VDss calculated from analysis of the C vs t data provided in the reference by Arboix, et al and Hollmann et al.."
510,Propofol,2078-54-8,2078-54-8,CC(C)c1cccc(c1C(C)C)O,ZEFOXNBIQIPHOP-UHFFFAOYSA-N,4.7,"Ibrahim A, Park S, Feldman J, Karim A, and Kharasch ED (2002) Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.  Anesthesiology 96: 88-95.  Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, and Farinotti R (1988) Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 69: 887-891.  Shafer A, Doze VA, Shafer SL, and White PF (1988) Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia.  Anesthesiology 69: 348-356.  Costela JL, Jimenez R, Calvo R, Suarez E, and Carlos R (1996) Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis.  Acta Anaesth. Scand. 40: 741-745.",
511,Propoxyphene,469-62-5,469-62-5,c1ccc(cc1)C(Cc1ccccc1)(C(CN(C)C)C)OC(=O)CC,XLMALTXPSGQGBX-UHFFFAOYSA-N,12,"Gram LF, Schmidt K, Christensen FN, and Schou J (1984) D-Propoxyphene kinetics in man: significance of a deep third compartment.  Eur. J. Clin. Pharmacol. 26: 749-752.  Giacomini KM, Gibson TP, and Levy G (1978) Plasma protein binding of d-propoxyphene in normal subjects and anephric patients.  J. Clin. Pharmacol. 18: 106-109.",VDss calculated from exponential three-compartment coefficients reported in the reference.
512,Propranolol,525-66-6,525-66-6,O(CC(O)CNC(C)C)c1c2c(ccc1)cccc2,AQHHHDLHHXJYJD-UHFFFAOYSA-N,3.1,"Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.  Br. J. Clin. Pharmacol. 11: 119P-120P.  Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers.  Br. J. Clin. Pharmacol. 43: 563-570. ",
513,Propylthiouracil,51-52-5,51-52-5,c1(cc(=O)[nH]c(=S)[nH]1)CC([2H])([2H])C([2H])([2H])[2H],KNAHARQHSZJURB-ZBJDZAJPSA-N,0.34,"Kampmann J and Skovsted L (1974) Pharmacokinetics of propylthiouracil.  Acta Pharmacol. Toxicol. 35: 361-369.   Giles HG, Roberts EA, Orrego H, and Sellers EM (1981) Disposition of intravenous propylthiouracil. J. Clin. Pharmacol. 21: 466-471.",VDss calculated from reported rate microconstants.
514,Pseudohypericin,55954-61-5,55954-61-5,O=C1c2c3c4c5c6c(c7c4c1c(O)cc7O)c(O)cc(O)c6C(=O)c1c5c(c3c(cc2O)CO)c(cc1O)C,YXBUQQDFTYOHQI-UHFFFAOYSA-N,0.56,"Kerb R, Brockmuller J, Staffeldt B, Ploch M, and Roots I (1996) Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin.  Antimic. Agents Chemother.  40: 2087-2093.",
515,Pyridostigmine,155-97-5,155-97-5,C(=O)(Oc1c[n+](ccc1)C)N(C)C,RVOLLAQWKVFTGE-UHFFFAOYSA-N,1.1,"Aquilonius SM, Eckernaes SA, Hartvig P, Lindstroem B, and Osterman PO (1980) Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur. J. Clin. Pharmacol. 18: 423-428.  Kornfeld P, Samuels AJ, Wolf RL, and Osserman KE (1970) Metabolism of pyridostigmine-14C in myasthenia gravis.  Evidence for multiple metabolites.  Neurology 20: 634-641.",VDss calculated from C vs t data obtained by digitization of plots in the reference.
516,Pyrimethamine,58-14-0,58-14-0,c1(nc(nc(c1c1ccc(cc1)Cl)CC)N)N,WKSAUQYGYAYLPV-UHFFFAOYSA-N,0.43,"Almond DS, Szwandt ISF, Edwards G, Lee MG, and Winstanley PA (2000) Disposition of intravenous pyrimethamine in healthy volunteers.  Antimic. Ag. Chemother.  44: 1691-1693.  Cavallito JC, Nichol CA, Brenckman WD, Deangelis RL, Stickney DR, Simmons WS, and Sigel CW (1978) Lipid-soluble inhibitors of dihydrofolate reductase.  I.  Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.  Drug Metab. Dispos. 6: 329-337.  Rudy AC and Poynor WJ (1990) Binding of pyrimethamine to human plasma proteins and erythrocytes.  Pharm. Res. 7: 1055-1060.",Note: Incorrect calculations in the original paper.
517,Quercetin,117-39-5,117-39-5,o1c2c(c(=O)c(O)c1c1cc(O)c(O)cc1)c(O)cc(O)c2,REFJWTPEDVJJIY-UHFFFAOYSA-N,0.12,"Ferry DR, Smith A, Malkhandi J, Fyfe DW,DeTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 2: 659-668.  Boulton DW, Walle UK, and Walle T (1998) Extensive binding of the bioflavonoid quercetin to human plasma proteins. J. Pharm. Pharmacol. 50: 243-249.  ",
518,Quinacrine,83-89-6,83-89-6,c1(ccc2c(c1)c(c1c(n2)cc(cc1)Cl)N[C@H](C)CCCN(CC)CC)OC,GPKJTRJOBQGKQK-MRXNPFEDSA-N,45,"Shannon JA, Earle DP, Brodie BB, Taggart JV, and Berliner RW (1944) The pharmacological basis for the rational use of atabrine in the treatment of malaria.  J. Pharmacol. Exp. Ther. 81: 307-330.",Pharmacokinetic parameters were calculated from C vs t provided in the reference. 
519,Quinaprilat,82768-85-2,82768-85-2,O=C(N1[C@@H](Cc2c(C1)cccc2)C(=O)O)[C@@H](N[C@H](C(=O)O)CCc1ccccc1)C,FLSLEGPOVLMJMN-YSSFQJQWSA-N,0.13,"Breslin E, Posvar E, Neub M, Trenk D, and Jahnchen E (1996) A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.  J. Clin. Pharmacol. 36: 414-421.  Accuretic Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
520,Quinidine,56-54-2,56-54-2,O[C@H]([C@@H]1[NH+]2C[C@@H]([C@@H](C1)CC2)C=C)c1c2c(ncc1)ccc(OC)c2,LOUPRKONTZGTKE-SMHQJORMSA-O,2.9,"Ueda CT, Williamson BJ, and Dzindzio BS (1976) Disposition kinetics of dihydroquinidine following quinidine administration.  Res. Comm. Chem. Path. Pharmacol. 14: 215-225.  Fremstad D, Nilson OG, Stirsein L, Amlie J, and Jacobson S (1979) Pharmacokinetics of quinidine related to protein binding in man.  Eur. J. Clin. Pharmacol. 15: 187-192.  Woo E and Greenblatt DJ (1979) Pharmacokinetic and clinical implications of quinidine protein binding.  J. Pharm. Sci. 68: 465-469.",
521,Quinine,130-95-0,130-95-0,c1cc(cc2c1nccc2[C@H]([C@@H]1C[C@@H]2[C@H](CN1CC2)C=C)O)OC,LOUPRKONTZGTKE-WZBLMQSHSA-N,1.8,"White NJ, Clinical pharmacokinetics of antimaliria drugs.  Clin. Pharmacokinet.  10: 187-215.  White NJ, Chanthavanich P, Krishna S, Bunch C, and Silamut K (1983) Quinine disposition kinetics.  Br. J. Clin. Pharmacol.  16: 399-403.",VDss calculated from reported rat micro-constants.
522,Quinupristin,120138-50-3,120138-50-3,S([C@H]1C2CCN(C1)CC2)C[C@@H]1CN2[C@@H](CC1=O)C(=O)N[C@@H](c1ccccc1)C(=O)O[C@@H]([C@H](NC(=O)c1ncccc1O)C(=O)N[C@@H](C(=O)N1[C@@H](CCC1)C(=O)N([C@H](C2=O)Cc1ccc(N(C)C)cc1)C)CC)C,WTHRRGMBUAHGNI-LCYNINFDSA-N,0.67,"Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, and Montay G (2001) Multiple-dose pharmacokinetics and safety of two regimens of quinupristine/dalfopristin (Synercid) in healthy volunteers.  J. Clin. Pharmacol. 41: 404-414.  Bergeron M and Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.  J. Antimic. Chemother. 39(Supp. A): 129-138.  Bearden DT (2004) Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin. Pharmacokinet. 43: 239-252.",
523,Rabeprazole,117976-89-3,117976-89-3,S(=O)(c1nc2c([nH]1)cccc2)Cc1nccc(OCCCOC)c1C,YREYEVIYCVEVJK-UHFFFAOYSA-N,0.22,"Setoyama T, Laurent A, Humphries T, and Hasegawa J (2005) Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.  Int. J. Clin. Pharmacol. Ther. 43:  37-42.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
524,Ranitidine,66357-35-5,66357-35-5,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,VMXUWOKSQNHOCA-UHFFFAOYSA-N,1.2,"Chau NP, Zech PY, Pozet N, and Hadj-Aissa A (1982) Ranitidine kinetics in normal subjects.  Clin. Pharmacol. Ther. 31: 770-774.  Van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, and De Schepper PJ (1982) Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.  Br. J. Clin. Pharmacol. 14: 195-200.  Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, and Schentag JJ (1984) Ranitidine disposition and systemic availability in hepatic cirrhosis.  Clin. Pharmacol. Ther. 35: 487-494.",VDss calculated from micro rate constants reported in the reference.
525,R-Apomorphine,58-00-4,58-00-4,[C@H]12[N@@H+](CCc3c1c(c1c(C2)ccc(c1O)O)ccc3)C,VMWNQDUVQKEIOC-CYBMUJFWSA-O,1.6,"Van Der Geest R, Van Laar T, Kruger PP, Gubbens-Stibbe JM, Bodde HE, Roos RAC, and Danhof M (1998) Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.  Clin. Neuropharmacol.  21: 159-168.  Smith RV, Velagapudi RB, McLean AM, and Wilcox RE (1985) Interactions of apomorphine with serum and tissue proteins.  J. Med. Chem. 28:  613-620.",
526,Reboxetine,71620-89-8,71620-89-8,[C@H]1(OCCNC1)[C@@H](c1ccccc1)Oc1c(OCC)cccc1.[C@@H]1(OCCNC1)[C@H](c1ccccc1)Oc1c(OCC)cccc1.CS(=O)(=O)O.CS(=O)(=O)O,OEQQXKDUXVTKMH-BGLVZNNJSA-N,0.65,"Fleishaker JC, Mucci M, Pellizzoni C, and Poggesi I (1999) Absolute bioavailability of reboxetine enantiomers and effect of gender of pharmacokinetics.  Biopharm. Drug Dispos.  20: 53-57.  Hendershot PE, Fleishaker JC, Lin KM, Nuccio ID, and Poland RE (2001) Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents.  Psychopharmacology 155: 148-53.",Administered as a racemate; averaged data for the two enantiomers.
527,Recainam,74738-24-2,74738-24-2,O=C(NCCCNC(C)C)Nc1c(cccc1C)C,WHJSFPCTWYLZRC-UHFFFAOYSA-N,1.4,"Anderson JL, Reddy P, Myerburg RJ, Waxman HL, and deVane PJ (1993) Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.  Am. J. Cardiol. 71: 686-694.  Scatina JA, Kimmel HB, Weinstein V, Troy SM, Sisenwine SF, and Cayen MN (1990) Species differences in the pharmacokinetics of recainam, a new antiarrythmic drug.  Biopharm. Drug Dispos. 11: 445-461.",
528,Remifentanil,132875-61-7,132875-61-7,O(C(=O)C1(N(c2ccccc2)C(=O)CC)CCN(CC1)CCC(=O)OC)C,ZTVQQQVZCWLTDF-UHFFFAOYSA-N,0.40,"Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stanski DR, and Shafer SL (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.  Anesthesiology  79: 881-892.  Ultiva Product Label.",Terminal half-life was calculated from a population pharmacokinetic analysis in which clearance and volume of distribution were identical to parameters determined from a standard pharmacokinetic study.
529,Remoxipride,80125-14-0,80125-14-0,Brc1c(OC)c(c(OC)cc1)C(=O)NC[C@H]1N(CCC1)CC,GUJRSXAPGDDABA-NSHDSACASA-N,0.65,"Widman M, Nilsson LB, Bryske B, and Lundstroem J (1993) Disposition of remoxipride in different species: species differences in metabolism.  Arz. Forsch. 43: 287-297.  von Bahr C, Movin G, Yisak WA, Jostell KG, and Widman M (199) Clinical pharmacokinetics of remoxipride.  Acta Psych Scand. 358(Suppl) 41-44.",Note probable typo in the article by von Bahr et al stating that CL is 119 liter/min--interpreted as 119 mL/min
530,Repaglinide,135062-02-1,135062-02-1,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,OIOAIKUIIYGBIO-JESVACHVSA-N,0.35,"Hatorp V, Oliver S, and Su CAPF (1998) Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.  Int. J. Clin. Pharmacol. Ther.  36: 636-641.  Plum A, Muller LK, and Jansen JA (2000) The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.  Meth. Find. Exp. Clin. Pharmacol. 22: 139-143.",
531,Repinotan,144980-29-0,144980-29-0,S1(=O)(=O)N(CCCCNC[C@@H]2Oc3c(CC2)cccc3)C(=O)c2c1cccc2,YGYBFMRFXNDIPO-QGZVFWFLSA-N,0.21,"Heining R,  Sundaresan P, Shah A and Boettcher M (2005) Effect of Gender and Age on the Pharmacokinetics of Repinotan.  Clin. Drug. Invest. 25: 125-134.  ",
532,Ribavirin,36791-04-5,36791-04-5,O1[C@@H]([C@@H](O)C(O)[C@@H]1n1nc(nc1)C(=O)N)CO,IWUCXVSUMQZMFG-UKAPAXSZSA-N,14,"Paroni R, DelPuppo M, Borghi C, Sirtoni CR, and Galli Kienle M (1989) Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 27: 302-307.  Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, and McNamara P (1999) Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.  Antimic. Agents Chemother. 43: 2451-2456.  Morse GD, Shelton MJ, and O'Donnell AM (1993) Comparative pharmacokinetics of antiviral nucleoside analogues.  Clin. Pharmacokinet. 24: 101-123.",
533,Ribostamycin,25546-65-0,25546-65-0,[C@@H]1(O[C@H]([C@@H]([C@@H]1O)O)O[C@H]1[C@@H]([C@H](C[C@H](C1O)N)N)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CN)O)O)N)CO,NSKGQURZWSPSBC-SSXIAAKRSA-N,0.25,"Yamasaku F, Suzuki Y, and Umemura K (1980) Pharmacokinetics of ribostamycin in healthy volunteers and patients with impaired renal function.  Jap. J. Antibiot. 33: 1318-1331.",VDss calculated from micro rate constants reported in the reference.
534,Rifabutin,72559-06-9,72559-06-9,C12(CCN(CC1)CC(C)C)N=C1c3c4C(=O)C(=C1N2)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/O[C@]1(Oc(c(c4O)C)c3C1=O)C)OC)C)OC(=O)C)C)O)C)O)C)/C,ATEBXHFBFRCZMA-FRIMEUIBSA-N,9.3,"Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, and Blaschke TF (1989) Pharmacokinetics of rifabutin.  Antimic. Agents Chemoter. 33: 1237-1241.",
535,Rifampin,13292-46-1,13292-46-1,O1c2c3c4c(c(O)c2C)c(O)c(NC(=O)/C(=C\C=C\[C@@H]([C@H](O)[C@H]([C@@H](O)[C@H]([C@H](OC(=O)C)[C@@H]([C@@H](OC)/C=C/O[C@@]1(C3=O)C)C)C)C)C)/C)cc4O,HJYYPODYNSCCOU-ODRIEIDWSA-N,0.97,"Houin G, Beucler A, Richelet S, Brioude R, Lafaix C, and Tillement JP (1983) Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculosis patients after different rates of infusion.  Ther. Drug Monit. 5: 67-72.","One compartment model described, so VD was assumed as VDss."
536,Risedronic acid (Risedronate),105462-24-6,105462-24-6,c1ccncc1CC(P(=O)(O)O)(O)P(=O)(O)O,IIDJRNMFWXDHID-UHFFFAOYSA-N,6.3,"Mitchell DY, Barr WH, Eusebio RA, Stevens KAP, Duke FP, Russell DA, Nesbitt JD, Powell JH, and Thompson GA (2001) Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.  Pharm. Res. 18: 166-170.  Actonel Product Label.",
537,Risperidone,106266-06-2,106266-06-2,O=C1CC(=O)CCN1,RDNZDMDLRIQQAX-UHFFFAOYSA-N,1.1,"Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, and Jonkman JHG (1993)  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.  Clin. Pharmacol. Ther.  54: 257-268.  Mannens G, Meuldermans W, Snoeck E, and Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood.    Psychopharmacology 114: 566-572.",CYP2D6 EM data only.
538,Ritodrine,26652-09-5,26652-09-5,O[C@H](c1ccc(O)cc1)[C@@H](NCCc1ccc(O)cc1)C,IOVGROKTTNBUGK-SJCJKPOMSA-N,4.4,"Caritis SN, Venkataramanan R, Darby MJ, Chiao JP, and Krew M (1990) Pharmacokinetics of ritodrine administered intravenously: recommendations for changes in the current regimen.  Am. J. Obstet. Gynecol. 162: 429-437.  Gross AS and Brown KF (1985) Plasma protein binding of ritodrine at parturition and in nonpregnant women.  Eur. J. Clin. Pharmacol. 28: 479-481.",Data from pregnant women.
539,Rivastigmine,123441-03-2,123441-03-2,O(c1cc([C@@H](N(C)C)C)ccc1)C(=O)N(CC)C,XSVMFMHYUFZWBK-NSHDSACASA-N,1.3,"Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.  Clin. Ther. 20: 634-647. Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, and Cutler NR (2002) Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.  Clin. Pharmacokinet.  41: 225-234.","VDss calculated from data digitized from Hossain, et al.,"
540,Rizatriptan,144034-80-0,144034-80-0,[nH]1cc(c2cc(ccc12)Cn1ncnc1)CCN(C)C.C(Cc1c[nH]c2c1cc(cc2)Cn1ncnc1)N(C)C,OXJXVJRWEXFGNG-UHFFFAOYSA-N,1.9,"Vyas KP, Halpin RA, Geer LA, Ellis JD, Liu L, Cheng H, Chavez-Eng C, Matuszewski BK, Varga SL, Guiblin AR, and Rogers JD (2000) Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.  Drug Metab. Dispos. 28: 89-95.  Lee Y, Conroy JA, Stepanavage ME, Mendel CM, Somers G, McLoughlin DA, Olah TV, De Smet M, Keymeulen B, and Rogers JD (1999) Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.  Br. J. Clin. Pharmacol.  47: 373-378.  Lee Y, Ermlich SJ, Sterrett AT, Goldberg MR, Blum RA, Brucker MJ, McLoughlin DA, Olah TV, Zhao J, and Rogers JD (1998) Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females.  Biopharm Drug Dispos. 19: 577-581.  Cheng H, Polvino WJ, Sciberras D, Yogendran L, Cerchio KA, Christie K, Olah TV, McLaughlin D, James I, and Rogers JD (1996) Pharmacokinetics and food interaction of MK-462 in healthy males.  Biopharm. Drug Dispos. 17: 17-24.  Hargreaves RJ, Longmore J, Beer M, Shepheard S, Cumberbatch M, Williamson D, Stanton J, Razzaque Z, Sohal B, Street L, Seabrook G, and Hill R (2000) The pharmacology and mechanisms of action of rizatriptan.  Monogr. Clin. Neurosci. 17: 141-161.",
541,Rocuronium,143558-00-3,143558-00-3,[C@H]1([C@H](C[C@H]2[C@](C1)([C@@H]1[C@@H](CC2)[C@H]2[C@](CC1)([C@H]([C@H](C2)[N+]1(CCCC1)CC=C)OC(=O)C)C)C)O)N1CCOCC1,YXRDKMPIGHSVRX-OOJCLDBCSA-N,0.21,"Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, and Fitzpatrick KT (1993) Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaethesia in patients with and without renal failure.  Br. J. Anaesth. 71: 222-226.  Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",
542,Rolitetracycline,751-97-3,751-97-3,O[C@@]12[C@@H](CC3[C@](O)(c4c(C(=C3C1=O)O)c(O)ccc4)C)[C@H](N(C)C)C(=O)/C(=C(/O)\NCN1CCCC1)/C2=O,YHDPWEWZPGTMMU-DLPVWNROSA-N,0.54,Dimmling T and Vanderbeke O (1975) Pharmakokinetik oral und intravenos verabreichbarer tetracyclinpraparate.  Med. Klin. 70: 279-285.  Rinati MV and Fleischmann L (1973) Legame con sieroproteine di alcune tetracicline e loro derivati idrosolubili. Cl. Terap. 71: 57-61.,Calculations made from reported C vs t data.  Plasma concentrations were determined using bioassay.
543,Romidepsin,128517-07-7,128517-07-7,C/C=C/1\C(=O)N[C@H](C(=O)O[C@H]2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C\2)C(=O)N1)C(C)C)C(C)C,OHRURASPPZQGQM-UBQUJCNUSA-N,1.2,"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, and Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clin. Cancer Res. 8: 718-728. ",
544,Ropivacaine,84057-95-4,84057-95-4,Oc1cc(O)c2c(c1)OC(C(C2c1c(O)cc(c2c1OC(C(C2)OC(=O)c1cc(O)c(c(c1)O)O)c1ccc(c(c1)O)O)O)OC(=O)c1cc(O)c(c(c1)O)O)c1ccc(c(c1)O)O,KTLUHRSHFRODPS-UHFFFAOYSA-N,0.75,"Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, and Widman M (1996) Metabolism and excretion of ropivacaine in humans.  Drug Metab. Dispos. 24: 962-968.  Jokinen MJ, Olkkola KT, Ahonen J, and Neuvonen PJ (2003) Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.  Eur. J. Clin. Pharmacol. 58: 653-657.  Jokinen MJ, Olkkola KT, Ahonen J, and Neuvonen PJ (2001) Effect of rifampin and tobacco smoling on the pharmacokinetics of ropivacaine.  Clin. Pharmacol. Ther. 70: 344-350.  Emanuelsson BM, Norsten-Hoog C, Sandberg R, and Sjovall J (1997) Ropivicaine and its 2H3-labelled analogue--bioanalysis and disposition in healthy volunteers.  Eur. J. Pharm. Sci. 5: 171-177.   Jokinen MJ, Neuvonen PJ, Lindgren L, Hoeckerstedt K, Sjoevall J, Breuer O, Askemark Y, Ahonen J, and Olkkola KT (2007) Pharmacokinetics of Ropivacaine in Patients with Chronic End-stage Liver Disease.  Anesthesiology 106: 43-55.  Naropin Product Label.",
545,Roquinimex,84088-42-6,84088-42-6,O=C(c1c(O)c2c(n(C)c1=O)cccc2)N(c1ccccc1)C,SGOOQMRIPALTEL-UHFFFAOYSA-N,0.21,"Strandgarden K, Hoglund P, Nordle O, Polacek J, Wannman H, and Gunnarsson PO.(1999) Dissolution rate-limited absorption and complete bioavailability of roquinimex in man.  Biopharm. Drug Dispos. 20: 347-354.",
546,Rosiglitazone,122320-73-4,122320-73-4,n1ccccc1N(C)CCOc1ccc(cc1)CC1C(=O)NC(=O)S1,YASAKCUCGLMORW-UHFFFAOYSA-N,0.20,"Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.  Drug Metab. Dispos. 28: 772-780.  Miller AK, DiCicco RA, and Freed MI (2002) The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.  Clin. Ther. 24: 1062-1071.  Avandia Product Label",
547,Rosuvastatin,287714-41-4,287714-41-4,C(=O)(C[C@H](CC(/C=C/c1c(nc(nc1c1ccc(cc1)F)N(C)S(=O)(=O)C)C(C)C)O)O)O,BPRHUIZQVSMCRT-RUEVOVDXSA-N,1.7,"Martin PD, Warwick MJ, Dane AL,  Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.  Clin. Ther. 25: 2553-2563.  Crestor Product Label.",
548,RPR 109881A,192573-38-9,192573-38-9,O1[C@H]2[C@](OC(=O)C)([C@@H]3[C@@]4([C@@H](C4)C2)C(=O)[C@H](OC(=O)C)C2=C([C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@H]3OC(=O)c3ccccc3)C2(C)C)C)C1.O.O,SEFGUGYLLVNFIJ-QDRLFVHASA-N,12,"Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, Semiond D, Perard D, Lebecq A, Besenval M, and Marty M (2002) Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.  Ann. Oncol. 13: 1140-1150.",
549,Saquinavir,127779-20-8,127779-20-8,C(=O)(N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](CN1[C@@H](C[C@H]2[C@@H](C1)CCCC2)C(=O)NC(C)(C)C)O)CC(=O)N)c1ccc2c(cccc2)n1,QWAXKHKRTORLEM-UGJKXSETSA-N,3.6,"Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, and Krahenbuhl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.  Br. J. Clin. Pharmacol. 45: 355-359.  Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, and Back DJ (2001) Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.  Drug Metab. Dispos.  29: 299-303.",
550,SarCNU,81965-43-7,81965-43-7,O=C(c1ccc(cc1)F)CC(=O)O,WSWKUJUQMXOEQK-UHFFFAOYSA-N,0.76,"Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Batist G, Patenaudr F, Bangash N, Panarello L, Alaoui-Jamali M, and Sausville E (2003) SarCNU, a nitosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.  J. Clin. Oncol. 21: 232-240.",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.
551,Sch34343,95415-91-1,95415-91-1,S1[C@H]2N(C(=O)[C@@H]2[C@H](O)C)C(=C1SCCOC(=O)N)C(=O)[O-].[Na+],DFRJGQBVJIXNJU-LAHZDFTNSA-M,0.30,"Lin CC, Lim J, Radwanski E, Kim, HK, Marco A, Lapiguera A, DiGiore C, and Symchowicz S (1987) Pharmacokinetics and metabolism of an intravenously administered penem (Sch 34343) in humans.  Antimic. Ag. Chemother.  31: 84-87.  Eliopoulos GM, Reiszner E, and Moellering RC (1985) In vitro activity of Sch 34343 against enterococci and other Gram-positive bacteria.  Antimic. Agents Chemother. 27: 28-32.",VDss calculated from digitized C vs t plot.
552,Scopolamine,51-34-3,51-34-3,[C@@H]12C[C@@H](C[C@@H]([C@@H]3[C@H]1O3)N2C)OC(=O)[C@H](CO)c1ccccc1,STECJAGHUSJQJN-FWXGHANASA-N,3.1,"Putcha L, Cintron NM, Tsui J, Vanderploeg JM and Kramer WG (1989) Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.  Pharm. Res. 6: 481-485.",VDss calculated from digitized C vs t plot.
553,Selegiline,2323-36-6,2323-36-6,c1ccccc1CC(C)N(C)CC#C,MEZLKOACVSPNER-UHFFFAOYSA-N,1.9,"Heinonen, EH, Anttila, MI, Lammintausta, RAS.(1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 56: 742-749.   De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004)  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet.  43: 157-185.  Emsam Product Label.  Zelapar Product Label.",
554,Sematilide,101526-83-4,101526-83-4,S(=O)(=O)(Nc1ccc(C(=O)NCCN(CC)CC)cc1)C,KHYPYQZQJSBPIX-UHFFFAOYSA-N,0.82,"Shi J, Ripley E, Gehr TWB, Sica DA, Dandekar KA, and Hinderling PH (1996) Pharmacokinetics of sematilide in renal failure.  J. Clin. Pharmacol. 36: 131-143.  Hinderling PH, Dilea C, Koziol T, and Millington G (1993) Comparative kinetics of sematilide in four species.  Drug Metab. Dispos. 21: 662-669.",
555,Sildenafil,139755-83-2,139755-83-2,c1(ccc(cc1c1nc2c(c(=O)[nH]1)n(nc2CCC)C)S(=O)(=O)N1CCN(CC1)C)OCC,BNRNXUUZRGQAQC-UHFFFAOYSA-N,1.4,"Nichols DJ, Muirhead GJ, and Harness JA (2002) Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality.  Br. J. Clin. Pharmacol. 53(Suppl. 1):  5S-12S.  Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, and Wright PA (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.  Xenobiotica  29: 297-310.",
556,Sisomicin,32385-11-8,32385-11-8,S(=O)(=O)(O)O.O([C@@H]1[C@@H](O)[C@H](O[C@H]2OC(=CC[C@H]2N)CN)[C@@H](N)C[C@H]1N)[C@H]1OC[C@](O)([C@H](NC)C1O)C,JVTNJDPXUPRGIE-KZSKFNJOSA-N,0.19,"Chung M, Schrogie JJ, and Symchowicz S (1981) Pharmacokinetic study of sisomicin in humans.  J. Pharmacokinet. Biopharm. 9: 535-551.  Lode H, Kemmerich B, and Koeppe P(1975)  Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin.  Antimic. Agents Chemother. 8: 396-401.  Pechere JC, Pechere MM, and Dugal R (1976) Clinical pharmacokinetics of sisomycin: two-compartment model analysis of serum data after I.V. and I.M. administration.  Eur. J. Clin. Pharmacol. 10: 251-256.  Ramirez-Ronda CH, Holmes RK, and Sanford JP (1975)  Effects of divalent cations on binding of aminoglycoside antibiotics to human serum proteins and to bacteria.  Antimic. Agents Chemother  7: 239-45. ",
557,Sitafloxacin,127254-12-0,127254-12-0,n1(c2c(c(=O)c(c1)C(=O)O)cc(c(N1CC3(CC3)[C@H](C1)N)c2Cl)F)C1C[C@H]1F,PNUZDKCDAWUEGK-VBUNGHGYSA-N,1.5,"O'Grady J, Briggs A, Atarashi S, Kobayashi H, Smith RL, Ward J, Ward C, and Milatovic D (2001) Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucsian subjects.  Xenobiotica 31: 811-822.  Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, and Tanaka M (1995) Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.  Antimic. Agents Chemother. 39: 170-174.",VDss calculated from CL and MRT reported in the reference.
558,Sitagliptin,486460-32-6,486460-32-6,OOP(=O)=O.Fc1c(F)cc(C[C@H](N)CC(=O)N2C([2H])([2H])C([2H])([2H])n3c(nnc3C(F)(F)F)C2)c(F)c1,MSUBASJQSBTRGJ-GLWFNPQESA-N,2.8,Januvia Product Label,"Intravenous clearance was calculated from oral dose, oral exposure, and absolute bioavailability reported in the product label for a 100 mg dose."
559,Solifenacin,242478-37-1,242478-37-1,O(C(=O)N1[C@H](c2c(CC1)cccc2)c1ccccc1)[C@@H]1C2CCN(C1)CC2,FBOUYBDGKBSUES-VXKWHMMOSA-N,8.2,"Kuipers ME, Krauwinkel WJJ, Mulder H, and Visser N (2004) Solifenacin demonstrates high absolute bioavailability in healthy men.  Drugs R D 5: 73-81.  Krauwinkel WJJ, Smulders RA, Mulder H, Swart PJ, and Taekema-Roelvink MEJ (2005) Effect of age on the pharmacokinetics of solifenacin in men and women.  Int. J. Clin. Pharmacol. Ther. 43: 227-238.",
560,Sotalol,3930-20-9,3930-20-9,S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C,ZBMZVLHSJCTVON-UHFFFAOYSA-N,1.3,"Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, and Cheymol G (1990) The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 579-582.  Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, and Slugg PH (1997) A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol. 37: 799-809.   Schnelle K, Klein G, and Schinz A (1979) Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. J. Clin. Pharmacol. 19: 516-522.  Fiset C, Philippon F, Gilbert M, and Turgeon J (1993) Stereoselective disposition of (+/-)-sotalol at steady-state conditions.  Br. J. Clin. Pharmacol. 36: 75-77.",
561,Sparfloxacin,110871-86-8,110871-86-8,c1(c(c(c2c(c1F)n(cc(c2=O)C(=O)O)C1CC1)N)F)N1CC(C)N[C@H](C1)C,DZZWHBIBMUVIIW-IENPIDJESA-N,3.9,Zagam Product Label.,
562,Spectinomycin,1695-77-8,1695-77-8,[Cl-].O1C2C([NH2+]C)C(O)C(NC)C(O)C2OC2OC(CC(=O)C12O)C,BIPVCOUVVAMJMZ-UHFFFAOYSA-N,0.13,"Wagner, JG, Novak, E, Leslie, LG, Metzler, CM (1968) Absorption, distribution and elimination of spectinomycin dihydrochloride in man.  Int. Zeit. Klin. Pharmakol. Ther. Toxikol. 1: 261-285. ",VDss calculated from C vs t data obtained by digitization of plots in the reference.
563,Squalamine,148717-90-2,148717-90-2,S(=O)(=O)(OC(CC[C@H]([C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4([C@@H](C[C@H]3O)C[C@@H](NCCCNCCCCN)CC4)C)CC2)CC1)C)C)C(C)C)O,UIRKNQLZZXALBI-OVOJGICBSA-N,0.23,"Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, and Rowinsky EK (2003) A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.  Clin. Canc. Res. 9: 2465-2471.",VDss calculated from C vs t data obtained by digitization of the representative plot provided in the report.
564,Stavudine,3056-17-5,3056-17-5,N1(C(=O)NC(=O)C(C1)C)[C@@H]1O[C@@H](C=C1)CO,ONAKHYDTKMSIOT-ZHFSPANRSA-N,0.67,"Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, and Mayer K (1992) Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.  J. Infec. Dis. 166: 480-485.  Horton CM, Dudley MN, Kaul S, Mayer KH, Squires K, Dunkle L, and Anderson R (1995) Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.  Antimic. Agents Chemother. 39: 2309-2315.  Zerit XR Product Label.",
565,Streptomycin,57-92-1,57-92-1,S(=O)(=O)(O)O.O([C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O)[C@@H]1O[C@H]([C@@](O)(C1O[C@@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1NC)CO)C=O)C,CFCMMYICHMLDCC-RVPLDQIASA-N,0.34,"Zhu M, Burman WJ, Jaresko GS, Berning SE, Jeliffe RW, and Peloquin CA (2001) Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.  Pharmacother. 21: 1037-1045.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",
566,Sufentanil,56030-54-7,56030-54-7,s1c(CCN2CCC(N(c3ccccc3)C(=O)CC)(CC2)COC)ccc1,GGCSSNBKKAUURC-UHFFFAOYSA-N,9.4,"Hudson RJ, Bergstrom RG, Thomson IR, Sabourin MA, Rosenbloom M, and Strunin L (1989) Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery.  Anesthesiol. 70: 426-431.  Scholz J, Bause H, Schulz M, Klotz U, Krishna DR, Pohl S, Schulte am Esch J (1994) Pharmacokinetics and effects on intracranial pressure of sulfentanil in head trauma patients.  Br. J. Clin. Pharmacol. 38: 369-372.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.  Arch. Int. Pharmacodyn. Ther. 257: 4-19.",
567,Sulbactam,68373-14-8,68373-14-8,P(OC)(OC)O.NCCCCCCCCC(C)(C)C,PYBLPERTFMJSMD-UHFFFAOYSA-N,0.32,"Foulds G, Stankewich JP, Marshall DC, O'Brien MM, Hayes SL, Weidler DJ, and McMahon FG (1983) Pharmacokinetics of sulbactam in human.  Antimic. Agents Chemother. 23: 692-699.  Rho JP, Castle S, Smith K, Bawdon RE, and Norman DC (1992) Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.  J. Antimic. Chemother. 29: 701-709.  Foulds G, Miller RD, Knirsch AK, and Thrupp LD (1985) Sulbactam kinetics and excretion into breast milk in postpartum women.  Clin. Pharmacol. Ther. 38: 692-696.  Blum RA, Kohli RK, Harrison NJ, and Schentag JJ (1989) Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.  Antimic. Agents Chemother.  (1989),  33: 1470-1476.  de la Pena A and Derendorf H (1999) Pharmacokinetic properties of beta-lactamase inhibitors.  Int. J. Clin. Pharmacol. Ther. 37: 63-75.",
568,Sulbenicillin,41744-40-5,41744-40-5,N12[C@@H]([C@@H](C1=O)NC(=O)[C@H](S(=O)(=O)O)c1ccccc1)SC([C@@H]2C(=O)O)(C)C,JETQIUPBHQNHNZ-NJBDSQKTSA-N,0.15,"Hansen I, Jacobsen E, and Wels J (1975) Pharmacokinetics of sulbenicillin, a new broad-spectrum semisynthetic penicillin.  Clin. Pharmacol. Ther.  17: 339-347.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",CL and VDss calculated from digitized plot.  Serum concentrations were detemined using bioassay.
569,Sulfadiazine,68-35-9,68-35-9,c1([S+](=O)(Nc2ncccn2)[O-])ccc(cc1)N,JNSIGQZDHNFJIB-UHFFFAOYSA-N,0.29,"Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu (1982) Coparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous administration.  J. Antimic. Chemother. 9: 461-470.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299.",VDss deteremined from Cvs t data obtained by digitization of plots in the reference.  
570,Sulfamethoxazole,723-46-6,723-46-6,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1noc(c1)C,VDGAVQMXNATRGM-UHFFFAOYSA-N,0.30,"Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299.",
571,Sulfinpyrazone,57-96-5,57-96-5,O=C1N(c2ccccc2)N(C(=O)C1CCS(=O)c1ccccc1)c1ccccc1,MBGGBVCUIVRRBF-UHFFFAOYSA-N,0.12,"Lecaillion JB, Souppart C, Schoeller JP, Humbert G, and Massias P (1979) Sulfinpyrazone kinetics after intravenous and oral administration.  Clin. Pharmacol. Ther. 26: 611-617.  Schlicht F, Staiger C, de Vries J, Gundert-Remy U, Hildebrandt R, Harenberg J, Wang NS, and Weber E (1985) Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.  Eur. J. Clin. Pharmacol. 28: 97-103.",VDss calculated from rate microconstants reported in the reference.
572,Sulfisoxazole,127-69-5,127-69-5,o1c(=S=O)[nH]cc1,ZKICZLXIRMBZFX-UHFFFAOYSA-N,0.17,"Kaplan SA, Weinfeld RE, Abruzzo CW, and Lewis M (1972) Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.  J. Pharm. Sci. 61; 773-778.  Oie S, Gambertoglio JG, and Fleckenstein L (1982) Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing.  J. Pharmacokinet. Biopharm. 10: 157-72.  Du Souich P, Calvo R, and Erill S (1990) Effects of cefotaxime on the serum protein binding of sulfisoxazole.  Biopharm. Drug Dispos. 11: 371-379.","Pharmacokinetic parameters were calculated from C vs t data provided in the reference by Kaplan, et al.."
573,Sumatriptan,103628-46-2,103628-46-2,CNS(=O)(=O)Cc1ccc2c(c1)c(CCN(C)C)c[nH]2,KQKPFRSPSRPDEB-UHFFFAOYSA-N,1.7,"Cosson VF, Fuseau E, Efthymiopoulos C, and Bye A (1997) Mixed effect modeling of sumatriptan pharmacokinetics during drug development.  I Interspecies allometric scaling.  J. Pharmacokinet. Biopharm. 25: 149-167.  Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. 27: 337-344.",
574,Suprofen,40828-46-4,40828-46-4,s1c(C(=O)c2ccc(C(C(=O)O)C)cc2)ccc1,MDKGKXOCJGEUJW-UHFFFAOYSA-N,0.040,"Zulliger HW and Fassolt A (1985) Pharmacokinetics and bioavailability of suprofen injection solution after intravenous application versus capsules on six healthy male volunteers. Arzneim.Forsch. 35: 976-980.  Chaikin P, Chasin M, Kennedy B, and Silverman BK (1983) Suprofen concentrations in human breast milk.  J. Clin. Pharmacol. 23: 385-390.  ",All parameters were calculated from C vs t data provided in the reference.
575,Suramin,145-63-1,145-63-1,S(=O)(=O)(O)c1c2c(c(S(=O)(=O)O)ccc2NC(=O)c2cc(NC(=O)c3cc(NC(=O)Nc4cc(C(=O)Nc5cc(C(=O)Nc6c7c(c(S(=O)(=O)O)cc6)cc(S(=O)(=O)O)cc7S(=O)(=O)O)ccc5C)ccc4)ccc3)c(cc2)C)cc(S(=O)(=O)O)c1,FIAFUQMPZJWCLV-UHFFFAOYSA-N,0.54,"Collins, JM, Klecker, RW, Yarchoan, R, Lane, HC, Fauci, AS, Redfield, RR, Broder, S, Myers, CE (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 26: 22-26.",
576,Tacrine,321-64-2,321-64-2,Nc1c2CCCCc2nc2c1cccc2,YLJREFDVOIBQDA-UHFFFAOYSA-N,11,"Lou G, Montgomery PR, and Sitar DS (1996) Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.  J. Psych. Neurosci.  21: 334-339.  Makela PM, Truman CA, Ford JM, and Roberts CJC (1994) Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease. Eur. J. Clin. Pharmacol. 47:  151-155.",
577,Tacrolimus,104987-11-3,104987-11-3,O1[C@@]2(O)C(=O)C(=O)N3[C@H](C(=O)O[C@@H]([C@@H]([C@@H](O)CC(=O)[C@@H](/C=C(/C[C@@H](C[C@H](OC)[C@@H]1[C@@H](OC)C[C@H]2C)C)\C)CC=C)C)/C(=C/[C@H]1C[C@@H](OC)[C@H](O)CC1)/C)CCCC3,QJJXYPPXXYFBGM-LFZNUXCKSA-N,1.2,"Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, and Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.  Clin. Pharmacol. Ther. 69: 24-31.  Iwasaki K, Miyazaki Y, Teramura Y, Kawamura A, Tozuka Z, Hata T, and Undre N (1996) Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid.  Res. Comm. Molec. Path. Pharmacol. 94: 251-257.",
578,Talinolol,57460-41-0,57460-41-0,O(c1ccc(NC(=O)NC2CCCCC2)cc1)CC(O)CNC(C)(C)C,MXFWWQICDIZSOA-UHFFFAOYSA-N,3.3,"Trausch B, Oertel R, Richter K, and Gramatte T (1995) Disposition and bioavailability of the beta1-adrenoreceptor antagonist talinolol in man.  Biopharm. Drug Dispos. 16: 403-414.  Trausch B, Oertel R, Richter K, and Gramatte T (1995) Die proteinbindung von talinolol.  Pharmazie   50: 72.",
579,Tamsulosin,106133-20-4,106133-20-4,CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C,DRHKJLXJIQTDTD-OAHLLOKOSA-N,0.21,"van Hoogdalem E, Soeishi Y, Matsushima H, and Higuchi S (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling.  J. Pharm. Sci.  86: 1156-1161.  Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, and Tsunoo M (1998) Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans.  Drug Metab. Dispos. 26: 240-245.",
580,Tegaserod,145158-71-0,145158-71-0,N=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)NCCCCC,IKBKZGMPCYNSLU-RGVLZGJSSA-N,5.3,"Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, and Legangneux E (1999) Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.  Br. J. Clin. Pharmacol.  47: 483-491.  Appel-Dingemanse S (2002) Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity.  Clin. Pharmacokinet. 41: 1021-1042.",
581,Teicoplanin A2-1,61036-64-4,61036-64-4,Clc1cc2C(OC3OC(C(O)C(O)C3NC(=O)C)CO)C3NC(=O)C(NC(=O)C4NC(=O)C5NC(=O)C(NC(=O)C(N)c6cc(Oc7cc5cc(O)c7C)c(O)cc6)C(O)c5cc(Cl)c(Oc6c(OC7OC(C(O)C(O)C7NC(=O)CC/C=C/CCCCC)CO)c(Oc1cc2)cc4c6)cc5)c1cc(c2c(C(NC3=O)C(=O)OC)cc(O)cc2OC2OC(C(O)C(O)C2O)CO)c(O)cc1,LCTCUBQFWLTHNS-MDZDMXLPSA-N,1.5,"Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, and Thompson GA (1991) Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans.  J. Pharm. Sci.  80:  605-607. Bonati M, Traina GL, Villa G, Salvadeo A, Gentile MG, Fellin G, Rosina R, Cavenaghi L, and Buniva G (1987) Teicoplanin pharmacokinetics in patients with chronic renal failure.  Clin. Pharmacokin. 12: 292-301.  Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",
582,Telavancin,372151-71-8,372151-71-8,CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2Oc3c4cc5cc3Oc6ccc(cc6Cl)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7c8ccc(c(c8)-c9c(cc(c(c9O)CNCP(=O)(O)O)O)[C@H](NC(=O)[C@H]([C@@H](c1ccc(c(c1)Cl)O4)O)NC7=O)C(=O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)CO)O)O)C,ONUMZHGUFYIKPM-MXNFEBESSA-N,0.11,"Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, and Nicolau DP (2006) Tissue penetration of telavancin after intravenous administration in healthy subjects.  Antimicr. Agents Chemother. 50: 788-790.  Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, and Barriere S (2005) Pharmacokinetics, serum inhibitory and bacteriocidal activity, and safety of telavancin in healthy subjects.  Anitmic. Agents Chemother. 49: 195-201.",
583,Telithromycin,191114-48-4,191114-48-4,O1[C@]2([C@H](N(C1=O)CCCCn1cc(nc1)c1cccnc1)[C@H](C(=O)[C@@H](C[C@@](OC)([C@H](O[C@@H]1O[C@@H](C[C@H](N(C)C)[C@H]1O)C)[C@H](C(=O)[C@H](C(=O)O[C@@H]2CC)C)C)C)C)C)C,LJVAJPDWBABPEJ-PNUFFHFMSA-N,3.0,"Perret C, Lenfant B, Weinling E, Wessels DH, Scholtz HE, Montay G, and Sultan E (2002) Pharmacokinetics and Absolute Oral Bioavailability of an 800-mg Oral Dose of Telithromycin in Healthy Young and Elderly Volunteers.  Chemotherapy 48: 217-223.  Yamazaki H, Lamy S, Ducelier C, Bonnat C, and Lenfant B (2003) Study of binding of telithromycin to human serum proteins. Nippon Kagaku Ryoho Gakkai Zasshi  51: 206-209. ",
584,Telmisartan,144701-48-4,144701-48-4,O=C(c1ccccc1c1ccc(Cn2c3cc(c4nc5ccccc5n4C)cc(C)c3nc2CCC)cc1)O,RMMXLENWKUUMAY-UHFFFAOYSA-N,5.3,"Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PAM, van Marle SP, Tamminga WJ, Sollie FAE, and Jonkman JHG (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.  J. Clin. Pharmacol. 40: 1312-1322.",
585,Temozolomide,85622-93-1,85622-93-1,O=c1n(C)nnc2n1cnc2C(=O)N,BPEGJWRSRHCHSN-UHFFFAOYSA-N,0.50,"Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, and Lejeune F (1998)  Pharmacokinetics of temozolamide in association with fitemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.  Canc. Chemother. Pharmacol.  42: 433-440. ",VDss calculated from digitized C vs t plot provided in the report. 
586,Temsirolimus,162635-04-3,162635-04-3,O1[C@@]2(O)C(=O)C(=O)N3[C@H](C(=O)O[C@H]([C@@H](C[C@H]4C[C@@H](OC)[C@H](OC(=O)C(CO)(CO)C)CC4)C)CC(=O)[C@@H](/C=C(/[C@@H](O)[C@@H](OC)C(=O)[C@@H](C[C@@H](/C=C/C=C/C=C(/[C@@H](OC)C[C@@H]1CC[C@H]2C)\C)C)C)\C)C)CCCC3,CBPNZQVSJQDFBE-FUXHJELOSA-N,3.0,"Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, and Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.  J. Clin. Oncol. 12: 2336-2347.",
587,Teniposide,29767-20-2,29767-20-2,c1c2c(cc3c1[C@H]([C@@H]1[C@@H]([C@@H]3O[C@H]3[C@@H]([C@@H](O)[C@H]4[C@H](O3)COC(O4)c3sccc3)O)COC1=O)c1cc(c(c(c1)OC)O)OC)OCO2,NRUKOCRGYNPUPR-PSZSYXFXSA-N,0.41,"Holthuis JJM, de Vries LGE, Postmus PE, van Oort WWJ, Verleun H, Hulshoff A, Sleijfer DT, and Mulder NH (1987) Pharmacokinetics of high-dose teniposide. Canc. Treatm. Rep. 71: 599-603.  Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, and Evans WE (1992) Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.  Pharmacother. 12: 273-277.",
588,Tenofovir,147127-20-6,147127-20-6,Nc1ncnc2c1ncn2C[C@H](OCP(=O)(O)O)C,SGOIRFVFHAKUTI-ZCFIWIBFSA-N,0.83,"Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellman NS, Safrin S, and Kahn JO (1998) Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.  Antimic. Agents Chemother. 42: 2380-2384.  Fung HB, Stone EA, and Piacenti FJ (2002) Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.  Clin. Ther. 24: 1515-1548",Averaged data from two dose levels.
589,Tenoxicam,59804-37-4,59804-37-4,S1(=O)(=O)N(C(C(=O)c2sccc12)C(=O)Nc1ncccc1)C,OTGJPAOGHQFBMI-UHFFFAOYSA-N,0.19,"Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, and Jeunet FS (1984) Pharmacokinetics of tenoxicam in healthy human volunteers. Eur. J. Rheum. Inflam. 7: 33-44.  Nilsen OG, Aasarod K, Wideroe TE, and Guentert TW (2001) Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.  Pharmacol. Toxicol. 89: 265-272.","VDss calculated from reported micro rate constants in Heintz, et al.."
590,Terazosin,63590-64-7,63590-64-7,n1c(nc2c(c1N)cc(c(c2)OC)OC)N1CCN(CC1)C(=O)C1CCCO1.O.[Cl-].O,NZMOFYDMGFQZLS-UHFFFAOYSA-M,0.98,Patterson SE (1985) Terazosin kinetics after oral and intravenous doses.  Clin. Pharmacol. Ther. 38: 423-427.  Sonders RC (1986) Pharmacokinetics of terazosin.  Am. J. Med. 80: 20-24.,VDss calculated from reported micro rate constants.
591,Terbutaline,23031-25-6,23031-25-6,OC(c1cc(O)cc(c1)O)CNC(C)(C)C,XWTYSIMOBUGWOL-UHFFFAOYSA-N,1.5,"Borgstrom L, Nyberg L, Jonsson S, Lindberg C, and Paulson J (1989) Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.  Br. J. Clin. Pharmacol. 27: 49-56.  Nyberg L (1984) Pharmacokinetic parameters of terbutaline in healthy man.  An overview.  Eur. J. Resp. Dis. 65(Suppl 134) 149-160.  Leferink JG, van den Berg W, Wagemaker-Engels I, Kreukniet J, and Maes RAA (1982) Pharmacokinetics of terbutaline, a beta2-sympathomimetic, in healthy volunteers and asthmatic patients.  Arz. Forsch. 32: 159-164.",Cited terminal phase t1/2.  Data are for the racemate.
592,Terodiline,15793-40-5,15793-40-5,N(C(CC(c1ccccc1)c1ccccc1)C)C(C)(C)C,UISARWKNNNHPGI-UHFFFAOYSA-N,5.1,"Hallen B, Gabrielsson J, Palmer L, and Ekstrom B (1993) Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers.  Pharmacol. Toxicol.  73: 153-158.  Hallen B, Gabrielsson J, Nyambati S, Johansson A, Larsson E, and Guilbaud O (1995) Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites.    Pharmacol. Toxicol.  76: 171-177.",
593,Tesaglitazar,251565-85-2,251565-85-2,O=C(O)[C@@H](OCC)Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1,CXGTZJYQWSUFET-IBGZPJMESA-N,0.13,"Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.  Drug Metab. Dispos.  32: 923-929.",
594,Tetracycline,60-54-8,60-54-8,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(c2c1cccc2O)O)O)O)C(=O)N)N(C)C)O,NWXMGUDVXFXRIG-UHFFFAOYSA-N,1.2,"Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest.  38:  1950-1963.",calculated from digitized plots 
595,"Tetrahydrocannabinol, D9-",1972-08-3,1972-08-3,O1C([C@H]2[C@H](c3c1cc(cc3O)CCCCC)C=C(CC2)C)(C)C,CYQFCXCEBYINGO-IAGOWNOFSA-N,8.9,"Wall ME, Sadler BM, Brine D, Taylor H, and Perez-Reyes M (1983)  Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.  Clin. Pharmacol. Ther. 34: 352-363.  Busto U, Bendayan R, and Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs.  Clin. Pharmacokinet. 16: 1-26.",VDss was calculated using C vs t data  provided in the reference.
596,Tezosentan,180384-57-0,180384-57-0,O=S(=O)(c1ncc(C(C)C)cc1)Nc1nc(c2cc(c3n[nH]nn3)ncc2)nc(OCCO)c1Oc1ccccc1OC,TUYWTLTWNJOZNY-UHFFFAOYSA-N,0.28,"Dingemanse J, Clozel M, and Giersbergen PLM (2002) Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.  Br. J. Clin. Pharmacol. 53: 355-362.  Treiber A, Van Giersbergen PLM, and Dingemanse J (2003) In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.  Xenobiotica 33: 399-414.",
597,Thalidomide,50-35-1,50-35-1,Cl.O([C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)c(OC)ccc2)C(=O)C)[C@@H]1O[C@H]([C@@H](O)[C@@H](N)C1)C,GUGHGUXZJWAIAS-QQYBVWGSSA-N,0.95,"Eriksson T, Bjorkman S, Roth B, and Hoglund P (2000) Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.  J. Pharm. Pharmacol. 52: 807-817.  Eriksson T, Bjorkman S, and Hoglund P (2001) Clinical pharmacology of thalidomide.  Eur. J. Clin. Pharmacol. 57: 365-376.  ","Values represent the average for bioth stereoisomers, which interconvert."
598,Theophylline,58-55-9,58-55-9,Cn1c2nc[nH]c2c(=O)n(C)c1=O,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,0.51,"Kraan J, Borgstrom L, Koeter GH, Laseur M, Jonkman JHG, and deNoord OE (1988) Creation of four consecutive intantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with expoonentially decreasing delivery rates. Eur. J. Clin. Pharmacol. 35: 657-661.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res.  20: 1015-1021.  Lombardi TP, Bertino JS, Goldberg A, Middleton E, and Slaughter RL (1987) The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance.    J. Clin. Pharmacol. 27: 523-529.",
599,Thionylan (Methapyrilene),91-80-5,91-80-5,c1cccc(n1)N(Cc1sccc1)CCN(C)C.Cl,BONORRGKLJBGRV-UHFFFAOYSA-N,3.3,"Calandre EP, Alferez N, Hassanein K, and Azarnoff DL (1981) Methapyrilene kinetics and dynamics.  Clin. Pharmacol. Ther. 29: 527-532. ",VDss calculated from C vs t data obtained by digitization of the plot included in the reference.
600,Thiopental,76-75-5,76-75-5,[Na+].N1C(=NC(=O)C(C1=O)(CC)CC(CCC)C)[S-],ZAKOUHUVJQTRPI-UHFFFAOYSA-M,1.2,"Cordato DJ, Gross AS, Herkes GK, and Mather LE (1997) Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone.  Br. J. Clin. Pharmacol. 43: 355-362.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",Data from individual stereoisomers were combined.  Half-life was estimated from the C vs t plot provided in the reference.
601,Thiotepa,52-24-4,52-24-4,S=P(N1CC1)(N1CC1)N1CC1,FOCVUCIESVLUNU-UHFFFAOYSA-N,1.6,"Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, and Bitran JD (1988) Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.  J. Clin. Oncol. 6: 1192-1196.  Hagen B and Nilsen OG (1987) The binding of thio-TEPA in human serum and to isolated serum protein fractions.  Cancer Chemother. Pharmacol. 20: 319-323.",
602,Tiagabine,115103-54-3,115103-54-3,N=C1NC(=O)/C(=C/c2ccnc3ccccc23)/S1,MBHBIJDGRZJPJU-XFFZJAGNSA-N,1.1,"Jansen JA, Oliver S, Dirach J, and Mengel HB (1995)  Absolute bioavailability of tiagabine. Epilepsia  36(Suppl. 3): s159",
603,Tiazofurin,60084-10-8,60084-10-8,s1c(nc(c1)C(=O)N)[C@@H]1O[C@@H]([C@@H](O)[C@H]1O)CO,FVRDYQYEVDDKCR-DBRKOABJSA-N,1.1,"Jayaram HN, Lapis E, Tricot G, Kneebone P, Paulik E, Zhen W, Engeler GP, Hoffmann R, and Weber G (1992) Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.  Int. J. Canc. 51: 182-188.  Roberts JD, Stewart JA, McCormish JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, and Young JA (1987) Phase 1 trail of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation.  Canc. Treatm. Rep. 71: 141-149.",
604,Ticarcillin,34787-01-4,34787-01-4,S1[C@H]2N([C@H](C1(C)C)C(=O)O)C(=O)[C@H]2NC(=O)C(c1ccsc1)C(=O)O,OHKOGUYZJXTSFX-IRHHVTTKSA-N,0.16,"Watanabe K, Koyama M, Iijima F, Nakazawa H, and Nakahira K (1986) Phase I studies on BRL 28500 (clavulanic acid-ticarcillin).  Chemotherapy 34: 247.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.  Libke RD, Clarke JT, Ralph ED, Luthy RP, and Kirby WMM (1975) Ticarcillin vs carbenicillin: clinical pharmacokinetics.  Clin. Pharmacol. Ther.  17: 441-446.",Combined data from Watanabe and Libke papers
605,Tigecycline,220620-09-7,220620-09-7,O[C@@]12[C@H]([C@H](N(C)C)C(=C(C2=O)C(=O)N)O)C[C@H]2C(=C1O)C(=O)c1c(C2)c(N(C)C)cc(NC(=O)CNC(C)(C)C)c1O,FPZLLRFZJZRHSY-HJYUBDRYSA-N,12,"Muralidharan G, Micalizzi M, Speth J, Raible D, and Trpy S (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.  Antimic. Agents Chemother.  49: 220-229.  Doan TL, Fung HB, Mehta D, and Riska PF (2006) Tigecycline: a glycylcycline antimicrobial agent.  Clin. Ther. 28: 1079-1106.",
606,Tilidine,51931-66-9,51931-66-9,O(C(=O)C1([C@H](N(C)C)C=CCC1)c1ccccc1)CC,WDEFBBTXULIOBB-LDCVWXEPSA-N,4.0,"Vollmer KO, Thomann P, and Hengy H (1989) Pharmacokinetics of tilidine and metabolites in man.  Arz. Forsch. 39: 1283-1288.  Janicke UA and Gundert-Remy U (1985) Stereoselective protein binding of (+/-)-cis and (+/-) trans tilidine.  Arch. Pharmacol. 329: R101.",
607,Timolol,26839-75-8,26839-75-8,c1(c(OC[C@H](CNC(C)(C)C)O)nsn1)N1CCOCC1,BLJRIMJGRPQVNF-JTQLQIEISA-N,1.5,"Vermeij P, el Sherbini-Schepers M, and van Zweiten PA (1978) The disposition of timolol in man.  J. Pharm. Pharmacol. 30: 53-55.  Meier J (1982) Pharmacokinetic comparison of pindolol with other beta adrenoceptor blocking agents.  Am. Heart J. 104: 364-373.",Parameters were calculated from C vs t data obtained by digitization of plots in the reference.
608,Tinidazole,19387-91-8,19387-91-8,CCS(=O)(=O)CCn1c(C)ncc1[N+](=O)[O-],HJLSLZFTEKNLFI-UHFFFAOYSA-N,0.59,"Vinge E, Andersson KE, Ando G, and Lunell E (1983) Biological availability and pharmacokinetics of tinidazole after single and repeated doses.  Scand. J. Infect. Dis.  15: 391-397.  Sawyer PR, Brogden RN, Pinder RM, Speight TM, and Avery GS (1976) Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.  Drugs 11: 423-440.",VDss calculated from digitized C vs t plot.
609,Tirapazamine,27314-97-2,27314-97-2,Nc1n[n+]([O-])c2c([n+]1[O-])cccc2,ORYDPOVDJJZGHQ-UHFFFAOYSA-N,0.56,"Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, and Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.  Clin. Cancer Res. 3: 31-38.  Robin H, Senan S, Workman P, and Graham MA (1995) development and validation of a sensitive solid-phase extraction and high performance liquid chromatoigraphy assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose selection.  Canc. Chemother. Pharmacol. 36: 266-270.",
610,Tirofiban,142373-60-2,142373-60-2,Cl.S(=O)(=O)(NC(Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O)CCCC,KPKFFYOMPGOQRP-UHFFFAOYSA-N,0.99,"Barrett JS, Murphy G, Peerlinck K, De Lepeliere I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, and Arnout J (1994) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycprotein-IIb/IIIa receptor antagonist, in healthy men.  Cin. Pharmacol. Ther. 56: 377-388.  Kondo K and Umemura K (2002) Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: Comparison with the monoclonal antibody abciximab. Clin. Pharmacokinet. 41: 187-195.",
611,Tizanidine,51322-75-9,51322-75-9,Clc1ccc2c(c1NC1=NCCN1)nsn2,XFYDIVBRZNQMJC-UHFFFAOYSA-N,2.4,"Zanaflex Product Label.  Granfors MT, Backman JT, Laitila J, and Neuvonen PJ (2004) Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro.  Br. J. Clin. Pharmacol. 57: 349-353.","Clearance value cited in Granfors, et al."
612,Tobramycin,32986-56-4,32986-56-4,CN.NCC1OC(OC2CCC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)CC1O,RYRDYRHNMCOISV-UHFFFAOYSA-N,0.23,"Bourget P, Fernandez H, Delouis C, abd Taburet AM (1991) Pharmacokinetics of tobramycin in pregnant women, safety and efficacy of a once-daily dose regimen.  J. Clin. Pharm. Ther.  16: 167-176.  Champoux N, Du Souich P, Ravaoarinoro M, Phaneuf D, Latour J, and Cusson JR (1996) Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers.  Br. J. Clin. Pharmacol. 42: 325-331.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",Data from Champeaux et al was digitized to calculate parameters.  
613,Tocainide,41708-72-9,41708-72-9,O=C(Nc1c(cccc1C)C)C(N)C,BUJAGSGYPOAWEI-UHFFFAOYSA-N,1.8,"Lalka D, Meyer MB, Duce BR, and Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.  Clin. Pharmacol. Ther. 19: 757-766.  Thomson AH, Murdoch G, Pottage A, Kelman AW, Whiting B, and Hillis WS (1986) The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.  Br. J. Clin. Pharmacol. 21: 149-154,  Sedman AJ, Bloedow DC, and Gal J (1982) Serum binding of tocainide and its enantiomers in human subjects.  Res. Comm. Chem Path. Pharmacol. 38: 165-168.",Combined data from individual enantiomers.
614,Tolamolol,38103-61-6,38103-61-6,O(c1c(cccc1)C)CC(O)CNCCOc1ccc(cc1)C(=O)N,SKQDKFOTIPJUSV-UHFFFAOYSA-N,4.0,"Faulkner JK, Stopher DA, Walden R, Singleton W, and Taylor SH (1975) Pharmacokinetic and pharmacological studies with tolamolol in man.  Br. J. Clin. Pharmacol. 2: 423-428.",VDss calculated from reported micro rate constants.
615,Tolbutamide,64-77-7,64-77-7,O=C(NS(=O)(=O)c1ccc(C)cc1)NCCCC,JLRGJRBPOGGCBT-UHFFFAOYSA-N,0.12,"Zilly W, Breimer DD, and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.  Eur. J. Clin. Pharmacol. 9: 219-227.  Ayanoglu G, Uihlein M, and Grigoleit HG (1986) A new aspect of serum protein binding of tolbutamide.  Int. J. Clin. Pharmacol. Ther. Toxicol. 24: 65-68.",Concentration-dependent protein binding reported; free fraction value is cited that was collected at relevant circulating concentrations.
616,Tolcapone,134308-13-7,134308-13-7,O(c1cc2c(C(C(=NN=C2c2cc(OC)c(OC)cc2)C)CC)cc1OC)C,RUJBDQSFYCKFAA-UHFFFAOYSA-N,0.12,"Jorga KM, Kroodsma JM, Fotteler B, Heizmann P, Meyer J, Rasch MC, and van Hattum J (1998) Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.  Clin. Pharmacol. Ther. 63: 646-654. ",
617,Toloxatone,29218-27-7,29218-27-7,OCC1OC(=O)N(C1)c1cccc(c1)C,MXUNKHLAEDCYJL-UHFFFAOYSA-N,1.5,"Strolin Benedetti M, Rovei V, Dencker SJ, Nagy A, and Johansson R (1982) Pharmacokinetics of toloxatone in man following intravenous and oral administrations.  Arz. Forsch. 32: 276-280.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
618,Tolterodine,124937-51-5,124937-51-5,Oc1c([C@@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(cc1)C,OOGJQPCLVADCPB-FQEVSTJZSA-N,1.5,"Brynne N, Stahl MMS, Hallen B, Edlund PO, Palmer L, Hoglund P, and Gabrielsson J (1997) Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.  Int. J. Clin. Pharmacol. Ther. 35: 287-295.  Brynne N, Dalen P, Alvan G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine.  Clin. Pharmacol. Ther. 63: 529-539.  Pahlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species.  Biopharm. Drug Dispos. 20: 91-99.",Data from CYP2D6 EM subjects included.
619,Tomopenem,222400-20-6,222400-20-6,N12C(=C([C@@H]([C@@H]2[C@H](C1=O)[C@H](O)C)C)S[C@H]1C[C@@H](C(=O)N2[C@@H](NC(=O)CNC(=N)N)CCC2)N(C1)C)C(=O)O,HXSRKROQMFKEAR-ORPMZVJSSA-N,0.23,"Shibayama T, Matsushita Y, Hirota T, Ikeda T, and Kuwahara S (2006) Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.  Antimicr. Agents Chemother. 50: 4186-4188.  Shibayama T, Matsushita Y, Kawai K, Hirota T, Ikeda T, and Kuwahara S (2007) Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals   Antimic. Agents Chemother. 51: 257-263.  ",
620,Topixantrone,156090-18-5,156090-18-5,O=c1c2c3c(nn(c3ccc2NCCN(C)C)CCNCCO)c2c1ccnc2,ZHAKYGFJVGCOAE-UHFFFAOYSA-N,57,"Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, and Bernareggi A (2004) Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthropyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase 1 study group trial of the Central European Society of Anticancer Drug Research (CESAR).  Anti-Cancer Drugs 15: 15-22.",
621,Topotecan,123948-87-8,123948-87-8,[Cl-].O1Cc2c(C(O)(CC)C1=O)cc1n(Cc3c1[nH+]c1c(c3)c(CN(C)C)c(O)cc1)c2=O,DGHHQBMTXTWTJV-UHFFFAOYSA-N,1.8,"Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.  Br. J. Canc. 73: 1268-1271.  van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, Maes RAA, and Beijnen JH (1995) Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.  Canc. Chemother. Pharmacol. 35: 237-245.  Masubuchi N, May RD, and Atsumi R (2004) A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay.  Clin. Cancer Res. 10: 6722-6731.",
622,Torsemide,56211-40-6,56211-40-6,S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(ccc2)C)ccnc1,NGBFQHCMQULJNZ-UHFFFAOYSA-N,0.21,"Spahn H, Knauf H, and Mutschler E (1990) Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.  Eur. J. Clin. Pharmacol. 39: 345-348.  Knauf H and Mutschler E (1998) Clinical pharmacokinetics and pharmacodynamics of torasemide.  Clin. Pharmacokinet. 34: 1-24.",VDss calculated from reported MRT.
623,Trabectedin,114899-77-3,114899-77-3,CC(=O)Oc1c2c(c3OCOc3c1C)[C@@H]1COC(=O)[C@@]3(NCCc4cc(O)c(OC)cc34)CCS[C@H]2[C@@H]2N1[C@@H](O)[C@@H]1Cc3cc(C)c(OC)c(O)c3[C@H]2N1C,AXYPHJWOKPNXAX-IZQXKXCFSA-N,25,"Lau L, Supko JG, Blaney S, Harshon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, and Baruchel S (2005) A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors.  A children's oncology group study.  Clin. Canc. Res.  11: 672-677.",Note: Pharmacokinetic data were from children.
624,Tramadol,27203-92-5,27203-92-5,[C@@]1(c2cc(ccc2)OC)([C@@H](CCCC1)CN(C)C)O,TVYLLZQTGLZFBW-GOEBONIOSA-N,2.8,"Lintz W, Barth H, Osterloh G, and Schmidt-Boethelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd communication. Suppositories.  Arz. Forsch. 48: 889-899.  Grond S and Sablotzki A (2004) Clinical pharmacology of tramadol.  Clin. Pharmacokinet. 43: 879-923.","Parameters calculated from data reported in a table in Lintz, et al."
625,Tranexamic acid,1197-18-8,1197-18-8,O=C(O)[C@@H]1CC[C@H](CC1)CN,GYDJEQRTZSCIOI-LJGSYFOKSA-N,0.38,"Puigdellivol E, Carral ME, Moreno J, Pla-Delfina JM, and Jane F (1985) Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man.  Int. J. Clin. Pharmacol. Ther. Toxicol.  23: 298-301.",PK parameters were calculated from reported C vs t data.  Data table in the report has incorrect units.
626,Traxoprodil,134234-12-1,134234-12-1,OC1(CCN(CC1)C(C(O)c1ccc(O)cc1)C)c1ccccc1,QEMSVZNTSXPFJA-UHFFFAOYSA-N,4.4,"Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, and Gibbs MA (2006) Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolizers.  Clin. Pharmacokin. 45: 989-1001.  Protein binding from in-house data, Pfizer, Inc.",Data from CYP2D6 extensive metabolizers.
627,Trazodone,19794-93-5,19794-93-5,Clc1cc(N2CCN(CCCn3nc4n(c3=O)cccc4)CC2)ccc1,PHLBKPHSAVXXEF-UHFFFAOYSA-N,0.52,Nilsen OG and Dale O (1992) Single dose pharmacokinetics of trazodone in healthy subjects.  Pharmacol. Toxicol. 71: 150-153.,VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
628,Triamcinolone Acetonide,76-25-5,76-25-5,CC1(C)O[C@@H]2CC3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)C4(F)[C@@H](O)C[C@]3(C)C2(O1)C(=O)CO,YNDXUCZADRHECN-ISLBBTSASA-N,1.4,"Argenti D, Shah B, Heald D (1999) A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration.  J. Clin. Pharmacol. 39: 695-702.  Mager DE and Jusko WJ (2002) Quantitative structure pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.  J. Pharm. Sci. 91: 2441-2451.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
629,Triamterene,396-01-0,396-01-0,Nc1nc(N)c2nc(c3ccccc3)c(N)nc2n1,FNYLWPVRPXGIIP-UHFFFAOYSA-N,13,"Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, and Volger KD (1983) Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.  Eur. J. Clin. Pharmacol. 25: 237-241.  Hasegawa J, Lin ET, Williams RL, Sorgel F, and Benet LZ  (1982) Pharmacokinetics of triamterene and its metabolite in man.  J. Pharmacokinet. Biopharm. 10: 507-523.",
630,Triazolam,28911-01-5,28911-01-5,Clc1cc2c(n3c(nnc3C)CN=C2c2c(Cl)cccc2)cc1,JOFWLTCLBGQGBO-UHFFFAOYSA-N,0.58,"Vanderveen RP, Jirak JL, Peters GR, Cox SR, and Bombardt PA (1991) Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin. Pharm. 10: 539-543.  Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, and Juhl RP (1984) Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration.  Clin. Pharmacol. Ther. 36: 379-383.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
631,Trimazosin,35795-16-5,35795-16-5,O(c1c2nc(nc(N)c2cc(OC)c1OC)N1CCN(CC1)C(=O)OCC(O)(C)C)C,YNZXWQJZEDLQEG-UHFFFAOYSA-N,0.18,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  ",
632,Trimethoprim,738-70-5,738-70-5,CCCC[N+](CCCC)(CCCC)CCCC.O.[Cl-],FODWRUPJCKASBN-UHFFFAOYSA-M,1.5,"Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu U (1982) Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion.  J. Antimic. Chemother.  9: 461-470.   Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration.  J. Pharm. Biomed. Anal. 1:  293-299.",VDss calculated from C vs t data obtained by digitization of the plot showing the 200 mg dose.
633,Trimetrexate,52128-35-5,52128-35-5,c1(cc(cc(c1OC)OC)NCc1c(c2c(cc1)nc(nc2N)N)C)OC.Cl.Cl.Cl,ZNJRHEVYOYMEHR-UHFFFAOYSA-N,0.77,Neutrexin Product Label,
634,Trimipramine,739-71-9,739-71-9,O=C(O)/C=C\C(=O)O.N1(c2c(CCc3c1cccc3)cccc2)CC(CN(C)C)C,YDGHCKHAXOUQOS-BTJKTKAUSA-N,16,"Abernethy DR, Greenblatt DJ, and Shader RI (1984) Trimipramine kinetics and absolute bioavailability:  use of gas-liquid chromatography with nitrogen-phosphorus detection.  Clin. Pharmacol. Ther. 35: 348-353.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.
635,Tropisetron,89565-68-4,89565-68-4,O([C@@H]1C[C@H]2N([C@@H](C1)CC2)C)C(=O)c1c2c([nH]c1)cccc2,ZNRGQMMCGHDTEI-ITGUQSILSA-N,9.7,"Kees F, Farber L, Bucher M, Mair G, Morike K, and Grobecker H (2001) Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.    Br. J. Clin. Pharmacol. 52: 705-707.",
636,Trospectomycin,88669-04-9,88669-04-9,O1[C@H]2[C@H](O[C@@H]3O[C@@H](CC(=O)[C@]13O)CCCC)[C@@H](O)[C@H](NC)[C@H](O)[C@@H]2NC,KHAUBYTYGDOYRU-IRXASZMISA-N,0.70,"Nichols DJ, Bye A, and Novak E (1991) Pharmacokinetics of trosectomycin sulphate in healthy subjects after single intravenous and intramuscular doses.  Br. J. Clin. Pharmacol.  32: 255-257.",Averaged data from all dose levels.
637,Trovafloxacin,147059-72-1,147059-72-1,Fc1c(N2C[C@H]3[C@H](C3N)C2)nc2n(cc(c(=O)c2c1)C(=O)O)c1c(F)cc(F)cc1,WVPSKSLAZQPAKQ-SOSAQKQKSA-N,1.3,"Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, and Friedman HL (1997) Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrovafloxacin.  J. Antimic. Chemother. 39(Suppl B): 75-80.  Teng R, Liston TE, Harris SC (1996) Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.  J. Antimic. Chemother.  37: 955-963.",Dosed as alatrovafloxacin prodrug which is very rapidly converted to trovafloxacin.
638,Troxacitabine,145918-75-8,145918-75-8,C1(=NC(=O)C(C=N1)[C@H]1CO[C@@H](O1)CO)N,QQOMBQDLZWTWPU-UVCATTPVSA-N,1.0,"Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, and Kantarjian HM. (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.  J. Clin. Oncol. 19: 762-771.",
639,Tubocurarine,57-94-3,57-94-3,C1Cc2c3[C@H]([N+]1(C)C)Cc1cc(c(cc1)O)Oc1c(cc4CC[NH+](C(Cc5ccc(cc5)Oc3c(c(c2)OC)O)c4c1)C)OC.[Cl-].[Cl-],GXFZCDMWGMFGFL-LQRXZVNRSA-N,0.45,"Razman IM, Shanks CA, and Triggs EJ (1978) Studies of d-tubocurarine pharmacokinetics in humans and dogs.  Anaesth. Intens. Care 6: 30-35.  Ghoneim MM, Kramer SE, Bannow R, Pandya H, and Routh JI (1973) Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease.  Anesthesiol.  39: 410-415.",Pharmacokinetic parameters determined from reported two-compartment model parameters.
640,UK-240455,178908-09-3,178908-09-3,CS(=O)(=O)N(CCO)C1=C2C(=CC(=C1Cl)Cl)NC(=O)C(=O)N2,BGJHUMNCODFLCH-UHFFFAOYSA-N,0.80,"Webster R, Cole S, Gedge J, Roffey S, Walker D, and Wild W (2003) Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs, and man.  Xenobiotica 33: 541-560.",
641,Urapidil,34661-75-1,34661-75-1,c1(=O)n(c(cc(=O)n1C)NCCCN1CCN(c2c(ccc(c2)C)OC)CC1)C,RAWLZBUZFGOUJJ-UHFFFAOYSA-N,0.75,"Zech K, Steinijans VW, and Radtke HW (1986) Pharmacokinetics of urapidil in normal subjects. In Amery (Ed) Treatment of Hypertension with Urapidil: Preclinical and Clinical Update. 29-38, ICSS 101, RSM Services Ltd, London.",VDss calculated using C vs t data obtained from a digitized plot.
642,Valproic Acd,99-66-1,99-66-1,Clc1c([C@@]2(O[C@H](CO2)COc2ccc(N3CCN(CC3)C(=O)C)cc2)Cn2ccnc2)ccc(Cl)c1.OC(=O)C(CCC)CCC,UFYDFVLTTTVZRX-MHUAFMOUSA-N,0.14,"Bryson SM, Verma N, Scott PJW, and Rubin PC (1983) Pharmacokinetics of valproic acid in young and elderly subjects.  Br. J. Clin. Pharmacol. 16: 104-105.  Hussein Z, Patterson KJ, Lamm JE, Cavanaugh JH, and Granneman GR (1993) Effect of infusion duration on valproate pharmacokinetics.  Biopharm. Drug Dispos. 14: 389-399.  Gugler R and Meuller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.  Br. J. Clin. Pharmacol. 5: 441-446.",
643,Valsartan,137862-53-4,137862-53-4,O=C(N([C@H](C(=O)O)C(C)C)Cc1ccc(c2c(c3nnn[nH]3)cccc2)cc1)CCCC,ACWBQPMHZXGDFX-QFIPXVFZSA-N,0.22,"Flesch G, Muller P, and Lloyd P (1997) Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 52: 115-120.  Colussi DM, Parisot C, Rossolino ML, Brunner LA, and Lefevre GY (1997) Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.  J. Clin. Pharmacol. 37: 214-221.",
644,Valspodar,121584-18-7,121584-18-7,O=C1N([C@@H](C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H]1C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C)C(=O)[C@@H](C/C=C/C)C)C,YJDYDFNKCBANTM-QCWCSKBGSA-N,1.8,"Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, and Figg WD (1997) Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.  J. Clin. Pharmacol. 37: 123-128.  Simon N, Dailly E, Combes O,  Malaurie E,  Lemaire M, Tillement JP, and Urien S (1998) Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br. J. Clin. Pharmacol. 45: 173-175.",
645,Vancomycin,1404-90-6,1404-90-6,[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)Oc1c2cc3cc1Oc1c(cc(cc1)[C@H](C(NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@H](C(=O)NC3C(=O)NC1C(=O)NC(C(=O)N[C@H](c3c(c4cc1ccc4O)c(cc(c3)O)O)C(=O)O)[C@@H](c1ccc(O2)c(c1)Cl)O)CC(=O)N)O)Cl)(N)C,MYPYJXKWCTUITO-XUEPVZEFSA-N,0.54,"Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, and Riff LJ (1988) Vancomycin pharmacokinetics in patients with various degrees of renal function.  Antimic. Agents Chemother. 32: 848-852.  Matzke GR, McGory RW, Halstenson CE, and Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimic. Agents Chemother. 25: 433-437.  Cutler NR, Narang PK, Lesko LJ, Ninos M, and Power M (1984) Vancomycin disposition: the importance of age.  Clin. Pharmacol. Ther. 36: 803-810.  Nakashima M, Katagiri K, Oguma T (1992) Phase 1 studies for vancomycin hydrochloride for injection.  Chemotherapy 40: 210-224.",
646,Vardenafil,224785-90-4,224785-90-4,n12[nH]c(nc(=O)c1c(nc2CCC)C)c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC1)CC.O.O.O.Br,OABMWWSCRREQGZ-UHFFFAOYSA-N,3.0,Levitra Product Label,
647,Vecuronium Bromide,50700-72-6,50700-72-6,[Br-].CC(=O)OC1C(CC2C3CCC4=CC(OC(=O)C)C(CC4C3CCC12C)N1CCCCC1)[N+]1(C)CCCCC1,FNTCGIIKSXQCIN-UHFFFAOYSA-M,0.30,"Arden JR, Lynam DP, Castagnoli KP, Canfell PC, Cannon JC, and Miller RD (1988) Vercuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis.  Anesthesiology  68: 771-776.  Cameron M, Donati F, and Varin F (1995) In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients.  Anesth. Analg 81: 1019-1025.  Bencini AF, Scaf AH, Sohn YJ, Meistelman C, Lienhart A, Kersten UW, Schwarz S, and Agoston S (1986) Disposition and urinary excretion of vecuronium bromide in anethetised patients with normal renal function or renal failure.  Anesth. Analg. 65: 245-251. ",
648,Venlafaxine,93413-69-5,93413-69-5,COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1,PNVNVHUZROJLTJ-UHFFFAOYSA-N,4.4,"Patat A, Troy S, Burke J, Trocherie S, Danjou P, LeCoz F, Allain H, and Gandon JM (1998) Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects.  J. Clin. Pharmacol. 38: 256-267.  Effexor Product Label.",
649,Verapamil,52-53-9,52-53-9,COc1ccc(cc1OC)CCN(CCCC(c1ccc(c(c1)OC)OC)(C(C)C)C#N)C,SGTNSNPWRIOYBX-UHFFFAOYSA-N,3.7,"Abernethy DR, Wainer IW, Longstreth JA, and Andrawis NS (1993) Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration.  J. Pharmacol. Exp. Ther. 266: 904-911.  Zachariah PK, Moyer TP, Theobald HM, Frantz RP, Kurtz SB, McCarthy JT, and Smith RL (1991) The pharmacokinetics of racemic verapamil in patients with impaired renal function.  J. Clin. Pharmacol. 31: 45-53.  Eichelbaum M, Mikus G, and Vogelgesang B (1984) Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after ntravenous administration.  Br. J. Clin. Pharmacol. 17: 453-458.  Eichelbaum M, Somogyi A, von Unruh GE, and Dengler HJ (1981) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isoyope-labelled verapamil.  Eur. J. Clin. Pharmacol. 19: 133-137.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",Values for indivudual enantiomers were averaged.
650,Verlukast,120443-16-5,120443-16-5,O=C(O)CCS[C@H](c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1)SCCC(=O)N(C)C,AXUZQJFHDNNPFG-LHAVAQOQSA-N,0.11,"Depre M, Margolskee DJ, Hseih JYK, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, and De Schepper PJ (1992) Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 43: 427-430.  Cheng H, Schwartz JI, Lin C, Amin RD, Seibold JR, Lasseter KC, Ebel DL, Tocco DJ, and Rogers JD (1994) The bioavailability and nonlinear pharmacokinetics of MK-679 in humans. Biopharm. Drug Dispos. 15: 409-418.","Parameters were determined using C vs t data obtained by digitization of the plots in the reference by Depre, et al."
651,Viloxazine,46817-91-8,46817-91-8,CCOc1ccccc1OCC1CNCCO1,YWPHCCPCQOJSGZ-UHFFFAOYSA-N,0.73,"Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, Trio R, and Perucca E (1986) Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.  Psychopharmacol.  90: 295-298.",VDss calculated from data obtained by digitization of the C vs t plot in the report.
652,Vinblastine,865-21-4,865-21-4,C123[C@H]4N(CC1)CC=C[C@@]4(CC)[C@@H]([C@]([C@@H]2N(c1c3cc(c(c1)OC)[C@@]1(c2[nH]c3ccccc3c2CCN2C[C@](C[C@@H](C1)C2)(O)CC)C(=O)OC)C=O)(O)C(=O)OC)OC(=O)C,OGWKCGZFUXNPDA-HAVDPRAOSA-N,28,"Lu K, Yap HY, and Loo TL (1983) Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.  Canc. Res. 43: 1405-1408.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm.Res. 20: 1015-1021.",Highly variable; used the median value.
653,Vincristine,57-22-7,57-22-7,O[C@]1([C@@H]2N(c3c([C@@]42[C@H]2N(CC4)CC=C[C@]2([C@H]1OC(=O)C)CC)cc(c(OC)c3)[C@@]1(c2[nH]c3c(c2CCN2C[C@@H](C1)C[C@](O)(C2)CC)cccc3)C(=O)OC)C=O)C(=O)OC,OGWKCGZFUXNPDA-XQKSVPLYSA-N,2.4,"Sethi VS, Jackson DV, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, and Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients.  Cancer Res. 41: 3551-3555.  Abdel-Rahman M, Wosch F, Harder S, and Woodcock BG (1992) Interaction between verapamil and vincristine binding to plasma proteins. Int. J. Clin. Pharmacol. Ther. Toxicol. 30:536",
654,Vindesine,53643-48-4,53643-48-4,O[C@]1([C@@H]2N(c3c([C@@]42[C@H]2N(CC4)CC=C[C@]2([C@H]1O)CC)cc(c(OC)c3)[C@]1(C[C@H]2C[C@](O)(CN(C2)CCC2C1=Nc1c2cccc1)CC)C(=O)OC)C)C(=O)N,RJHLHHANMLUOBE-YOQHIDJQSA-N,5.0,"Ohnuma T, Norton L, Andrejczuk A, and Holland JF (1995) Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans. Cancer Res. 45: 464-469.  ",VDss calculated using micro rate constants provided in the reference.
655,Vinorelbine,71486-22-1,71486-22-1,O([C@@H]1[C@]2([C@@H]3N(CC[C@@]43[C@@H](N(c3c4cc(c(OC)c3)[C@]3(CC4CN(Cc5c3[nH]c3c5cccc3)CC(=C4)CC)C(=O)OC)C)[C@@]1(O)C(=O)OC)CC=C2)CC)C(=O)C,GBABOYUKABKIAF-BXZSYHTRSA-N,23,"Sorio R, Robieux I, Galligioni E, Freschi, A, Colussi AM, Crivellari D, Saracchini S, and Monfardini S (1997) Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.  Eur. J. Cancer  33: 301-303.   Gebbia V and Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile.  Exp. Op. Drug Safety 4: 915-928. ",
656,Voriconazole,137234-62-9,137234-62-9,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,BCEHBSKCWLPMDN-MGPLVRAMSA-N,2.2,"Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, and Nichols D (2003) The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.  Br. J. Clin. Pharmacol. 56(Suppl. 1):  2-9.   Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.  Drug Metab. Dispos. 31: 731-741.",
657,Vorinostat,149647-78-9,149647-78-9,c1ccccc1NC(=O)CCCCCCC(=O)NO,WAEXFXRVDQXREF-UHFFFAOYSA-N,0.50,"Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.  Clin. Cancer Res.  9: 3578-3588.  Zolinza Product Label.",VDss calculated from digitized C vs t plot.
658,Warfarin,81-81-2,81-81-2,c1(c(c2c(oc1=O)cccc2)O)[C@H](CC(=O)C)c1ccccc1,PJVWKTKQMONHTI-OAHLLOKOSA-N,0.13,"Bjornsson TD, Meffin PJ, Swezey S, and Blaschke TF (1979) Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.  J. Pharmacol. Exp. Ther. 210: 316-321.",
659,Xamoterol,81801-12-9,81801-12-9,O(c1ccc(O)cc1)CC(O)CNCCNC(=O)N1CCOCC1,DXPOSRCHIDYWHW-UHFFFAOYSA-N,0.64,"Bastain W, Boyce MJ, Stafford LE, Morton PB, Clarke DA, and Marlow HF (1988) Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur. J. Clin. Pharmacol. 34: 469-473.  ",
660,Zalcitabine,7481-89-2,7481-89-2,O1C(n2ccc(nc2=O)N)CC[C@H]1CO,WREGKURFCTUGRC-UUEFVBAFSA-N,0.54,"Klecker RW, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S, and Myers CE (1988) Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.  J. Clin. Pharmacol. 28: 837-842.",
661,Zaleplon,151319-34-5,151319-34-5,O=C(N(c1cc(c2n3ncc(c3ncc2)C#N)ccc1)CC)C,HUNXMJYCHXQEGX-UHFFFAOYSA-N,1.3,"Rosen AS, Fournie P, Darwish M, Danjou P, and Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability.  Biopharm. Drug Dispos. 20: 171-175.   Sonata Product Label.",
662,Zanamivir,139110-80-8,139110-80-8,O.CC(=O)NC1C(NC(=N)N)C=C(OC1C(O)C(O)CO)C(=O)O,OELRRAURPSTFEX-UHFFFAOYSA-N,0.23,"Cass LMR, Efthymiopoulos C, and Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.  Clin. Pharmacokinet. 36(Suppl. 1): 1-11.  Daniel MJ, Barnett JM, and Pearson BA (1999) The low potential for drug interactions with zanamivir.  Clin. Pharmacokinet. 36(Suppl. 1): 41-50.",
663,Zidovudine,30516-87-1,30516-87-1,O1[C@@H](n2c(=O)[nH]c(=O)c(c2)C)C[C@H](N=[N+]=[N-])[C@H]1CO,HBOMLICNUCNMMY-XLPZGREQSA-N,1.8,"Aweeka FT, Mak M, Al-Uzri A, Peter K, Dett C, Franco J, Affrime M, Guerciolini R, Cutler DL, et al.(1995)  Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor.  J. Clin. Pharmacol. 35: 856-864.  Blum MR, Liao SHT, Good SS, and deMiranda P (1988) Pharmacokinetics and bioavailability of zidovudine in human.  Am. J. Med. 85(Suppl 2A): 189-194.  Morse GD, Shelton MJ, and O'Donnell AM (1993) Comparative pharmacokinetics of antiviral nucleoside analogues.  Clin. Pharmacokinet. 24: 101-123.  ",
664,Ziprasidone,146939-27-7,146939-27-7,Clc1c(cc2c(NC(=O)C2)c1)CCN1CCN(c2nsc3c2cccc3)CC1,MVWVFYHBGMAFLY-UHFFFAOYSA-N,1.0,"Miceli JJ, Wilner KD, Swan SK, and Tensfeldt TG (2005) Pharmacokinetics, safety, and tolerability of intramuscular Ziprasidone in healthy volunteers. J.Clin. Pharmacol.  45:  620-630.   Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, and Turncliff RZ (2000)  The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.  Br. J. Clin. Pharmacol. 49(Suppl 1): 27s-33s. 

",
665,Zoledronic Acid,118072-93-8,118072-93-8,O=P(C(O)(P(=O)(O)O)Cn1ccnc1)(O)O,XRASPMIURGNCCH-UHFFFAOYSA-N,0.60,"Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Ravera C, Schran H, Seaman J, and Waldmeier F (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.  J. Clin. Pharmacol. 43: 154-162.  Reclast Product Label.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.
666,Zolmitriptan,139264-17-8,139264-17-8,O=C1OC[C@H](Cc2cc3c([nH]cc3CCN(C)C)cc2)N1,ULSDMUVEXKOYBU-ZDUSSCGKSA-N,1.8,"Seaber EJ, Peck RW, Smith DA, Allanson J, Hefting NR, Van Lier JJm Sollie FAE, Wemer J, and Jonkman JHG (1998) The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. J. Clin. Pharmacol. 46: 433-439.   Dixon R and Warrander A  (1997) The clinical pharmacokinetics of zolmitriptan.  Cephalalgia 17(Suppl 18): 15-20.",
667,Zolpidem,82626-48-0,82626-48-0,c1c(cn2c(c1)nc(c2CC(=O)N(C)C)c1ccc(cc1)C)C,ZAFYATHCZYHLPB-UHFFFAOYSA-N,0.54,"Thenot JP, Hermann P, Durand A, Burke JT, Allen J, Garrigou D, Vajta S, Albin H, Thebault JJ, Olive G, and Warrington SJ (1988) Pharmacokinetics and metabolism of zolpidem in various animal species and humans.  In Imidazopyridines in Sleep Disorders (ed Sauvanet JP, Langer SZ, and Morselli PL).  Raven Press, New York, pp 139-153.",
668,Zonampanel,210245-80-0,210245-80-0,O=c1n(c2c([nH]c1=O)cc([N+](=O)[O-])c(n1ccnc1)c2)CC(=O)O.O,OBHWTRBRRFQGRJ-UHFFFAOYSA-N,0.19,"Minematsu T, Sohida KY, Hashimoto T, Imai H, Usui T, and Kamimura H (2005) Identification of metabolites of [14C]zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.  Xenobiotica  35: 359-371.",
669,Zopiclone,43200-80-2,43200-80-2,Clc1cnc(N2C(OC(=O)N3CCN(CC3)C)c3nccnc3C2=O)cc1,GBBSUAFBMRNDJC-UHFFFAOYSA-N,1.3,"Gaillot J, Heusse D, Hougton GW, Marc Aurele J, Dreyfus JF (1983) Pharmacokinetics and metabolism of zopiclone.  Pharmacology 27(suppl. 2): 76-91.  Fernandez C, Gimenez F, Thuillier A, and Farinotti R (1999) Stereoselective binding of zopiclone to human plasma proteins.  Chirality 11: 129-132.",
670,Zotarolimus,221877-54-9,221877-54-9,[C@]12(C(=O)C(=O)N3[C@H](C(=O)O[C@@H](CC(=O)[C@@H](/C=C(/[C@H](C(C(=O)C(CC(/C=C/C=C/C=C(/[C@H](C[C@@H](O1)CC[C@H]2C)OC)\C)C)C)OC)O)\C)C)[C@@H](C[C@H]1CC(OC)[C@H](n2nnnc2)CC1)C)CCCC3)O,CGTADGCBEXYWNE-RKLMHPEASA-N,1.3,"Palaparthy R, Pradhan R, Chan J, Wang Q, Ji Q, Achari R, Chira T, Schwartz LB, O'Dea R (2005) Pharmacokinetics and safety of ABT-578, a sirolimus (rapamycin) analogue, after single intravenous bolus injection in healthy male volunteers.  Clin. Drug. Invest. 25: 491-498.  ",